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Summary 
 
 Heart failure (HF) is a major health concern affecting 15 million people in Europe 
and around 900 000 people in the U.K. HF predominantly affects the elderly, with the 
mean age of patients with a diagnosis of HF between 70 and 80 years. Most previous HF 
studies have accordingly focused on older patients. Although HF is less common in 
younger adults (<65 years), 15% to 20% of patients hospitalised with HF are younger than 
60 years of age. Very few studies have described the characteristics of younger adults with 
HF and its outcome. 
 
 The aims of this thesis are to describe the clinical characteristics of younger adults 
with HF, explore the epidemiology of HF in younger adults and determine their short- and 
long-term outcomes. This was made possible by access multiple databases consisting of 
large patient cohorts with HF. The first chapter is a systematic literature review of younger 
adults with HF.  Gaps in the current literature were identified and the thesis focused on 
some of these.  
 
 The CHARM study allows detail characterisations of younger adults with HF. It 
recorded characteristics of patients with HF, including symptoms and signs of HF, 
electrocardiographic changes, chest radiographic findings, and also left ventricular ejection 
fraction. HF hospitalisations and its precipitating factors were also recorded systematically. 
Younger adults were more likely to have a third heart sound and hepatomegaly, but less 
likely to have pulmonary crackles and peripheral oedema. Similarly, radiological findings 
in younger adults were less likely to show interstitial pulmonary oedema or pleural 
effusion. Interestingly, younger adults aged <40 years not only have similar HF 
hospitalisation rate to older patients, however during their presentation with 
decompensated HF, they were less likely to have clinical pulmonary oedema and 
radiological signs of HF. Physicians managing younger adults with HF need to be aware of 
this. Younger adults were also less compliant with medications and lifestyle restriction 
resulting in hospitalisation with decompensated HF. Fortunately, despite these challenges, 
mortality rates in younger adults with HF were lower compared to older patients. 
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 To further substantiate the findings from the CHARM study, the MAGGIC study, a 
meta-analysis consists of over 40 000 patients with HF from large observational studies 
and randomised controlled trials, was examined. In both databases, the commonest 
aetiology of HF in younger adults was dilated cardiomyopathy. The ejection fraction was 
the lowest in younger adults. Similar to the CHARM study, mortality rates in younger 
adults were lower compared to older patients. However, in the MAGGIC study, by 
stratifying mortality into patients with preserved ejection fraction and with reduced 
ejection fraction, younger patients with preserved ejection fraction have a much lower 
mortality rate compared to patients with reduced ejection fraction.  
 
 Findings from clinical trials are not always reflective of the real life clinical 
practice. The U.K. Clinical Practice Research Datalink (CPRD), a large and well-validated 
primary care database with 654 practices contributing information into the database 
representing approximated 8% of the U.K. population, is a rich dataset offering a unique 
opportunity to examine the characteristics, treatments, and outcomes of younger adults 
with HF in the community. In contrast to the CHARM and MAGGIC studies, younger 
adults aged <40 years were stratified into 20-29 and 30-39 years in the CPRD analysis. 
This is possible due to the larger number of younger adults with HF. Further stratifying the 
younger age groups demonstrated heterogeneity among younger adults with HF. In 
contrast to previous data showing younger adults have lower comorbidities, the proportions 
of depression, chronic kidney disease, asthma, and any connective tissue disease were high 
among patients aged 20-29 years in the analysis from the CPRD. Surprisingly, the 
treatment rates for angiotensin converting enzyme (ACE) inhibitor, and aldosterone 
antagonist were the lowest in patients aged 20-29 years. With the exception of patients 
aged ≥80 years, treatment rate with beta-blocker was also the lowest in patients aged 20-29 
years. With over two decades of follow up, long-term mortality rates in younger adults 
with HF can be determined. The mortality rates continued to decline from 1988 to 2011. 
Physicians managing younger adults with HF can now use this contemporary data to 
provide prognostic information to patients and their family.  
 
 A hospital administrative database is the logical next platform to explore younger 
adults with HF. The Alberta Ministry of Health database links an outpatient database to a 
hospitalisation database providing ample data to examine the relationship between 
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outpatient clinic visits and hospital admissions in younger adults with HF. Following a 
diagnosis of HF in the outpatient setting, younger adults were admitted to the hospital with 
decompensated HF much sooner than older patients. Younger adults also presented to 
emergency department more frequently following their first hospitalisation for HF.  
 
 In conclusion, this thesis presented the characteristics and outcomes of younger 
adults with HF, and helped to extend our current understanding on this important topic. I 
hope the data presented here will benefit not only physicians looking after younger adults 
with HF, but also patients and their family.  
 
 
  
 
 
 
Chapter 1 
 
Introduction 
A review of the epidemiology, and characteristics of young 
adults with heart failure 
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1.1 Background 
 
Heart failure (HF) affects around 900,000 people in the UK and 15 million people 
in Europe.(1;2) Approximately 20% of hospitalised patients with HF are less than 65 years 
of age.(3) Most studies have focussed on the elderly. Little attention has been given to 
young adults with HF until recently. An improved understanding of the epidemiology, 
outcomes, and aetiology of young adults with HF may help managing these patients. I 
conducted a literature review to evaluate the current understanding of HF in young adults.  
 
1.1.1 Definition of HF 
 
The U.K. National Institute for Health and Care Excellence defines HF as a 
complex clinical syndrome of symptoms and signs that suggest the efficiency of the heart 
as a pump is impaired. It is caused by structural or functional abnormalities of the heart.(4) 
Similarly, the European Society of Cardiology defines HF as an abnormality of cardiac 
structure or function leading to failure of the heart to deliver oxygen at a rate 
commensurate with the requirements of the metabolising tissues, despite normal filling 
pressures or in the expense of increased filling pressure.(5)  
 
 Prior to these authoritative definitions, HF was broadly defined as an inability of 
the heart to pump blood around the body to meet its metabolic demands resulting in a 
clinical syndrome characterised by a constellation of symptoms and signs.(6)  
 
1.1.2 Definition of young 
 
In the U.K. cardiac transplant is rarely performed in patients aged 65 years and 
above with end-stage HF.(7) Young is, therefore, pragmatically defined as adults less than 
65 year of age. Patients aged <40 years are arbitrary defined as very young adults.  
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1.2 Search strategy 
 
English language publications in Pubmed, EMBASE and Cochrane Library from 
1966 to January 2014 were searched. The search combined terms related to HF: ‘heart 
failure’, ‘ventricular dysfunction’, ‘systolic dysfunction’, ‘myocardial failure’ and ‘cardiac 
failure’ with generic terms ‘epidemiology’, ‘incidence’, ‘prevalence’, ‘mortality’, 
‘hospitalisation’, ‘aetiology’, ‘etiology’, ‘young’ and ‘age’ using Boolean operators. A 
hand search of references identified from articles was conducted. The search was 
performed by myself and another researcher independently. Data from studies meeting the 
search criteria were entered into pre-defined tables independently. Only studies defined 
young as less than 65 years of age or younger were selected. For studies reporting 
mortality in patients with HF, I have only selected studies reporting mortality rates from 
year 2000 onwards.  
 
1.3 Epidemiology 
 
1.3.1 Incidence of HF in young adults with HF 
 
The incidence of HF in young and very young adults is low. In Europe and the US 
incidence of HF in those aged < 65 years is 0.40 per 1000 population per year in 
comparison to 5.80 to 7.30 per 1000 population per year in those aged ≥65 years (Table 
1.1).(8;9) Only one study has been performed outside Europe or North America in Taiwan. 
There are limited data on incidence of HF in very young adults (two from the UK, two 
from France, and one from Taiwan). The incidence of HF (per 1000 population per year) in 
the UK ranges from 0.00 to 0.02 in 25 to 34 years, 0.00 to 0.20 in 35-44 years, 0.08-0.38 in 
45-54 years, and 0.64 to 1.70 in 55-64 years.(8;9) This is similar to other studies performed 
in Europe and Taiwan: 0.02 per 1000 population in age group 20 to 30 years and 0.26 per 
1000 population in age group 20 to 44 years, respectively.(10;11)  
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The studies from the UK are over a decade ago and those from France or Taiwan 
were based on hospitalisation data. More contemporary study examining incidence of HF 
in primary care and secondary care is needed. 
 
1.3.2 Trends in incidence of HF in young adults with HF 
 
The incidence of HF in young adults with HF remains static in the last three 
decades.  
 
Data from Western Australia (1990 to 2005) and the UK (1984 to 1992 and 1993 to 
2001) demonstrated that the incidence HF hospitalisation in younger adults (<65 years) has 
not change significantly since the mid 80’s (Table 1.2).(12-14) The relative percentage 
change (2002-2005 vs. 1990-1993) of the age standardised rates of index hospitalisation 
for HF in patients aged <65 years was +1.70% (27.47 per 100000 vs. 27.00 per 100000) in 
men and -11.50% (14.93 per 100000 vs. 16.87 per 100000) in women.(12) A recent 
Swedish study included all patients with a primary or secondary diagnosis of HF from the 
Stockholm regional health care data which contains all consultations in primary and 
secondary (defined as specialist outpatient care) care, and all hospitalisations showed 
incidence of HF between 2006 and 2010 remains static in age groups 40-49 and 50-59 
years while the incidence in those aged >60 years decreases.(15) Similarly, a study from 
Australia reporting index admission for HF by age group demonstrated little change in the 
rates of index admission for HF between 2002-2003 and 2006-2007 in patients <65 years 
compared to those aged ≥65 years which index admission rates have been decreasing over 
time.(16)  
 
Another study from Sweden included patients with first-ever HF diagnosis code in 
any position from the national hospital discharge registry reported the incidence of HF 
from 1987 to 2006 increased by 50% (2.5 per 100000 in 1987-1991 to 3.7 per 100000 in 
2002-2006) and 43% (10.2 per 100000 in 1987-1991 to 14.6 per 100000 in 2002-2006) 
among individuals aged 18-34 and 35-44 years, respectively.(17) 
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Among these studies, only two studies (one from the Sweden, and one from 
Scotland) included very young adults with HF showing conflicting trends of incidence of 
HF. More studies in the very young adults and also from other countries would help to 
confirm these results.  
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Table 1.1: Incidence of HF by country, and gender in young adults with HF 
 
Location Year  Type of study Number Incidence (per 1000/year) 
U.K.     
Scotland(18) 1999 to 
2000 
Retrospective, primary care 
cohort study 
307741  Men Women Total 
45-64 1.40 1.30 1.30 
65-74 6.00 6.10 6.10 
75-84 20.20 13.50 16.00 
≥85 24.80 21.60 22.40 
Total 1.80 2.20 2.00 
 
Bromley, South 
London(8) 
 Population cohort study 292000  Men Women 
25-34 0.00 0.00 
35-44 0.04 0.00 
45-54 0.38 0.08 
55-64 1.71 0.64 
65-74 3.30 1.74 
75-84 8.10 5.45 
≥85 10.44 5.99 
>24 1.40 1.10 
 
UK GPRD(19) 1996 Retrospective, primary care 
cohort study 
689467  Men Women 
40-44 0.24 0.16 
45-49 0.72 0.11 
50-54 0.70 0.32 
55-59 2.13 0.85 
60-64 4.47 2.43 
65-69 6.38 4.59 
70-74 11.28 7.86 
75-79 19.24 15.48 
80-84 31.17 22.09 
 
Hillingdon(9)  
 
1995 to 
1996 
Population cohort study 151000  Men Women Total 
25-34 0.00 0.04 0.02 
35-44 0.20 0.20 0.20 
45-54 0.30 0.10 0.20 
55-64 1.70 0.70 1.20 
65-74 3.90 2.30 3.00 
75-84 9.80 5.90 7.40 
85+ 16.80 9.60 11.60 
 
UK GPRD(20) 1991 to 
1994 
Retrospective, primary care 
cohort study 
696884 55-64 3.40 
75-84 25.50 
 
UK GP(21) 1991 to 
1992 
Retrospective national 
database 
-  Men Women Total 
45-64 1.40 1.00 1.00 
65-74 9.30 7.40 8.30 
75-84 22.70 16.20 18.60 
85+ 29.10 32.90 32.00 
Overall   2.30 
 
Other European countries 
France (110) 2009 Retrospective, hospitalised 
cohort study 
69958  Men Women Total 
20-39 - - - 
40-49 <1.00 <1.00 <1.00 
50-54 1.00 <1.00 <1.00 
55-59 1.00 <1.00 1.00 
60-64 2.00 1.00 1.00 
65-69 3.00 2.00 2.00 
70-74 5.00 3.00 4.00 
75-79 9.00 6.00 7.00 
80-84 16.00 11.00 12.00 
85-89 26.00 19.00 21.00 
90-94 34.00 28.00 30.00 
95+ 37.00 33.00 34.00 
 
Goteborg(22) 1970 to 
1996 
Population cohort study 7495  Men 
55-64 2.10 
65-74 9.10 
75-79 11.50 
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Groningen(23) 1993 to 
1998 
Population cohort study 5279  Men Women 
57-60 2.50 2.50 
61-69 6.40 4.10 
70-79 20.00 15.40 
80+ 28.20 22.40 
 
Lorraine, 
France(11) 
1994 Prospective, hospitalised with 
advanced heart failure, cohort 
study 
499  Men Women Total 
20-30 0.02 0.01 0.02 
30-40 0.02 0.02 0.02 
40-50 0.16 0.02 0.09 
50-60 0.47 0.07 0.27 
60-70 0.98 0.28 0.60 
70-80 1.48 0.58 0.94 
 
Rotterdam(24) 1989 to 
1993 
Population cohort study 7983 55-59 1.40 
60-64 3.10 
65-69 5.40 
70-74 11.70 
75-79 17.00 
80-84 30.10 
85-89 41.90 
≥90 47.40 
 
Eastern 
Finland(25) 
1986 to 
1988 
Prospective, community 
cohort study 
11000  Men Women 
Boston criteria 
45-54 1.90 -- 
55-64 3.10 1.50 
65-74 8.20 2.00 
45-74 3.60 1.10 
Framingham criteria 
45-54 2.30 0.20 
55-64 3.30 2.20 
65-74 7.70 2.90 
45-74 3.80 1.70 
 
U.S.     
Forsyth County, 
Jackson, suburbs 
of Minneapolis, 
Washington 
County(26) 
1987 to 
2002 
Population cohort study 15792  Men Women 
Caucasian   
45-49 2.40 1.70 
50-54 5.60 3.10 
55-59 8.40 4.40 
60-64 14.30 7.70 
African American  
45-49 5.20 3.80 
50-54 7.20 7.60 
55-59 14.00 10.10 
60-64 13.40 17.40 
 
Worcester(27) 2000 Retrospective, hospitalised 
cohort study 
2604 <55 0.31 
55-64 1.81 
65-74 4.23 
75-84 11.00 
≥85 18.20 
 
Framingham(28) 40 
years 
follow 
up 
Population cohort study -  Men Women 
45-54 2.00 1.00 
55-64 5.00 3.00 
65-74 10.00 8.00 
75-84 19.00 14.00 
85-94 28.00 26.00 
 
Rochester(29) 1981 to 
1982 
Retrospective, population 
cohort study 
-  Men Women 
45-49 1.00 0.00 
50-54 1.00 0.00 
55-59 3.00 1.00 
60-64 6.00 2.00 
65-69 16.00 5.00 
70-74 9.00 10.00 
0-74 1.60 0.70 
 
Others     
Taiwan(10) 2005 Retrospective, hospitalised 
cohort study 
1 million  Men Women Total 
20-44 0.39 0.15 0.26 
45-54 1.57 0.96 1.27 
55-64 4.28 2.74 3.49 
65-74 13.10 11.24 12.15 
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≥75 33.14 38.09 35.52 
20-64 1.14 0.64 0.88 
≥65 21.70 21.92 21.81 
All 3.91 3.37 3.63 
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Table 1.2: Trends of incidence of HF by country, gender, and year in young adults with HF 
 
Location Year  Type of study Number Incidence (per 1000 population/year) 
Sweden(15) 2006-
2010 
Cross sectional study 2.1 
million 
 Men Women 
2006   
40-49 0.60 0.30 
50-59 2.40 1.10 
60-69 7.00 3.50 
70-79 19.10 14.40 
80-89 43.40 35.20 
≥90 71.70 57.40 
2007   
40-49 0.60 0.30 
50-59 2.20 1.20 
60-69 5.80 3.40 
70-79 17.50 14.20 
80-89 41.10 34.80 
≥90 62.60 52.90 
2008   
40-49 0.60 0.30 
50-59                 2.10 1.00  0.22 0.01 
60-69 5.70 3.10  
70-79 16.80 12.60 
80-89 42.60 35.00 
≥90 60.30 49.60 
2009   
40-49 0.60 0.20 
50-59                 2.20 0.80 
60-69 4.80 2.90 
70-79 14.90 12.00 
80-89 39.50 34.60 
≥90 56.40 51.40 
2010   
40-49 0.50 0.20 
50-59 2.10 1.00 
60-69 5.20 2.30 
70-79 13.20 10.70 
80-89 38.20 31.00 
≥90 51.50 42.50 
   
 
Australia(16) 2000-
2007 
Retrospective, hospitalised 
cohort study (first index HF 
hospitalisation) 
 age Men Women 
2002-2003 
45-49 0.19 0.10 
50-54 0.34 0.19 
55-59 0.71 0.38 
60-64 1.33 0.76 
65-69 2.36 1.52 
70-74 4.14 3.12 
75-79 6.92 4.94 
80-84 11.65 8.87 
85+ 19.50 14.31 
2003-2004 
45-49 0.16 0.10 
50-54 0.37 0.26 
55-59 0.65 0.37 
60-64 1.56 0.79 
65-69 2.26 1.48 
70-74 4.33 2.72 
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75-79 6.78 4.86 
80-84 10.93 8.00 
85+ 18.65 16.03 
2004-2005 
45-49 0.15 0.08 
50-54 0.31 0.17 
55-59 0.65 0.31 
60-64 1.32 0.65 
65-69 2.38 1.40 
70-74 3.92 2.50 
75-79 6.20 4.66 
80-84 10.27 7.93 
85+ 17.81 13.94 
2005-2006 
45-49 0.28 0.09 
50-54 0.41 0.17 
55-59 0.63 0.34 
60-64 1.37 0.61 
65-69 2.12 1.16 
70-74 3.58 2.47 
75-79 6.87 4.42 
80-84 10.58 7.29 
85+ 18.71 14.94 
2006-2007 
45-49 0.21 0.12 
50-54 0.39 0.16 
55-59 0.67 0.35 
60-64 1.31 0.62 
65-69 1.90 1.19 
70-74 3.46 2.67 
75-79 6.53 4.20 
80-84 11.33 7.75 
85+ 17.85 14.96 
 
Sweden(17) 1987 to 
2006 
Population cohort study 443995  Men Women 
1987-91   
18-34 0.03 0.02 
35-44 0.13 0.07 
45-54 0.63 0.29 
55-84 9.47 5.22 
1992-96   
18-34 0.03 0.02 
35-44 0.17 0.10 
45-54 0.80 0.39 
55-84 10.98 6.31 
1997-2001   
18-34 0.03 0.03 
35-44 0.16 0.09 
45-54 0.78 0.33 
55-84 8.96 4.99 
2002-06   
18-34 0.04 0.03 
35-44 0.19 0.10 
45-54 0.74 0.31 
55-84 7.77 4.36 
 
Georgia(30) 2000 to 
2005 
Retrospective, hospitalised 
and outpatient cohort study 
359947  Men Women 
2000   
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18-54 1.36 0.97 
55-64 6.76 7.29 
65-74 27.24 22.23 
≥75 55.25 56.40 
2001   
18-54 1.48 1.18 
55-64 10.47 7.53 
65-74 24.56 20.14 
≥75 56.07 56.34 
2002   
18-54 1.56 1.33 
55-64 11.83 6.91 
65-74 24.79 22.98 
≥75 49.01 52.81 
2003   
18-54 1.34 1.32 
55-64 9.21 5.86 
65-74 25.15 18.21 
≥75 57.13 44.19 
2004   
18-54 1.55 1.11 
55-64 8.78 6.54 
65-74 26.09 16.36 
≥75 40.40 42.14 
2005   
18-54 1.22 0.91 
55-64 8.95 5.48 
65-74 18.49 15.57 
≥75 57.83 41.39 
 
Western 
Australia(12) 
1990 to 
2005 
Retrospective, hospitalised 
cohort study 
19342  Men Women 
1990-1993   
<65 0.27 0.17 
65-74 4.26 2.85 
≥75 12.87 10.38 
1994-1997   
 <65 0.27 0.15 
65-74 3.44 2.31 
≥75 10.11 8.18 
1998-2001   
<65 0.24 0.15 
65-74 2.84 1.94 
≥75 8.66 7.05 
2002-2005   
<65 0.28 0.15 
65-74 2.38 1.52 
≥75 7.80 6.32 
Relative % change 
<65 +1.7 -11.5 
65-74 -44.1 -46.5 
≥75 -39.4 -39.0 
 
Scotland(14) 1984, 
1988, and 
1992 
Retrospective, hospitalised 
cohort study 
5.1 
million 
 Men Women 
1984   
<25 0.02 0.01 
25-54 0.34 0.17 
55-64 3.17 1.78 
65-74 8.12 5.15 
>75 18.08 14.51 
1988   
<25 0.03 0.02 
25-54 0.32 0.17 
55-64 3.33 1.90 
65-74 8.04 5.27 
>75 18.43 15.00 
1992   
<25 0.03 0.03 
25-54 0.40 0.20 
55-64 3.92 2.15 
65-74 9.99 6.36 
>75 22.08 18.86 
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1.3.3 Prevalence of HF in young adults with HF 
 
The prevalence of HF in very young adults (<40 years) is low ranging from 0.01-
0.30% (Table 1.3).(31-33) In adults aged 45-54 years and 55-64 years, the prevalence of 
HF range from 0.13-1.30% and 0.52-5.50%, respectively.(34-36) Between 1980 and 1998, 
some studies reported similar prevalence of HF in younger adults over two decades 
(approximately 0.01%) in young adults aged 0-34 years and 25-44 years.(37;38) Another 
study utilised the electronic medical record system of Kaiser Permanente reported 
prevalence of HF in patients aged 18-54 years and 55-64 years increased by about a third 
from 2000 to 2005 (men vs. women: 18-54 years: 0.41% vs. 0.34% in 2000 and 0.60% vs. 
0.52% in 2005; 55-64 years: 3.35% vs. 2.41% in 2000 and 4.64% vs. 3.17% in 2005).(30) 
Between 2006 and 2010, the prevalence of HF remained unchanged.(15) Very little is 
known about the prevalence of HF in the rest of the world.  
 
1.3.4 Prevalence of left ventricular systolic dysfunction (LVSD) in young adults with 
HF 
 
The definition of LVSD varies between studies limiting inter-study comparison. 
The Framingham Study defined LVSD as ≤50%(39); a Scotland study as ≤30%(40); the 
Echocardiographic Heart of England screening study as <40%(34), and the Harrow Heart 
Failure Watch Study as <45%(41).  
 
The prevalence of asymptomatic LVSD in young adults is 0.0% in 25-34 years, 
0.35% in 35-44 years, 2.8% in 45-54 years and 1.6% in 55-64 years.(40) 
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Table 1.3. Prevalence of heart failure by country, and gender in young adults with HF  
 
Location Year  Type of study Number Prevalence (%) 
U.K.     
Kent, Surrey 
and Sussex(33) 
2002 to 
2003 
Population-based cohort 
study 
256188  Men Women Total 
0-34 0.02 0.01 0.02 
35-44 0.02 0.03 0.03 
45-54 0.11 0.06 0.09 
55-64 0.56 0.33 0.44 
65-74 2.37 1.52 1.92 
75-84 6.82 6.09 6.38 
85+ 12.57 12.47 12.5 
All age 0.71 0.95 0.83 
 
Harrow(41) 2000 to 
2001 
Population-based cohort 
study 
734 Prevalence of LVSD <45%  
 Men Women Total 
45-54 2.50 0.00 1.10 
55-64 3.30 1.60 2.30 
65-74 10.80 0.00 6.30 
75-84 11.40 2.90 7.10 
≥75 13.20 7.10 10.00 
 
Scotland(18) 1999 to 
2000 
Retrospective, primary care-
based cohort study 
307741  Men Women Total 
45-64 0.43 0.32 0.38 
65-74 2.57 2.07 2.30 
75-84 6.39 5.31 5.73 
≥85 10.39 8.52 9.01 
Total 0.64 0.78 0.71 
 
West 
Midland(34) 
1995 to 
1999 
Population-based cohort 
study 
3960  Men Women Total 
Definite HF according to ESC criteria 
45-54 0.30 0.00 0.20 
55-64 2.70 0.90 1.80 
65-74 4.20 1.70 2.90 
75-84 7.30 6.60 6.90 
≥85 21.70 11.60 15.20 
Total 3.00 1.70 2.30 
LVEF <40% 
45-54 0.60 0.00 0.30 
55-64 3.00 0.50 1.80 
65-74 4.80 1.10 2.90 
75-84 4.90 2.60 3.70 
≥85 8.70 0.00 3.00 
Total 3.00 0.70 1.80 
LVEF 40-50% 
45-54 1.30 1.30 1.30 
55-64 4.00 3.00 3.50 
65-74 6.70 2.80 4.70 
75-84 6.30 5.70 6.00 
≥85 13.00 14.00 13.60 
Total  4.10 4.10 3.50 
 
England and 
Wales(37) 
1994 to 
1998 
Retrospective, primary care-
based cohort study 
1.4 
million 
 Men Women 
1994   
0-34 0.01 0.01 
35-44 0.04 0.04 
45-54 0.24 0.17 
55-64 1.45 0.96 
65-74 4.67 3.77 
75-84 11.42 10.56 
85+ 18.41 20.23 
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1995   
0-34 0.01 0.01 
35-44 0.04 0.03 
45-54 0.26 0.16 
55-64 1.46 0.97 
65-74 4.57 3.69 
75-84 11.20 10.25 
85+ 18.41 19.72 
1996   
0-34 0.01 0.01 
35-44 0.05 0.03 
45-54 0.28 0.17 
55-64 1.49 0.98 
65-74 4.48 3.67 
75-84 10.90 10.09 
85+ 18.36 19.16 
1997   
0-34 0.01 0.01 
35-44 0.04 0.03 
45-54 0.26 0.17 
55-64 1.44 0.94 
65-74 4.59 3.64 
75-84 11.01 10.05 
85+ 18.29 18.59 
1998   
0-34 0.01 0.01 
35-44 0.04 0.03 
45-54 0.27 0.18 
55-64 1.39 0.92 
65-74 4.49 3.58 
75-84 10.86 9.86 
85+ 19.07 18.88 
 
West 
London(42) 
1997 to 
1998 
Retrospective, primary care-
based cohort study 
- <65 0.10 
65+ 4.50 
 
Liverpool(43) 
 
1994 Retrospective, primary care-
based cohort study 
151000  Men Women 
35-44 0.00 0.10 
45-54 0.50 0.60 
55-64 2.20 1.10 
65-74 3.90 4.50 
75+ 4.10 9.60 
 
Scotland(40) 1992 Cross sectional survey 1640  Men Women 
Symptomatic HF with EF≤30% 
25-34 0.00 0.00 
35-44 0.00 0.00 
45-54 1.40 1.20 
55-64 2.50 2.00 
65-74 3.20 3.60 
Asymptomatic HF with EF≤30% 
25-34 0.00 0.00 
35-44 0.70 0.00 
45-54 4.40 1.20 
55-64 3.20 0.00 
65-74 3.20 1.30 
 
Nottingham(44) 1991 to 
1992 
Retrospective, primary care-
based cohort study 
22117 30-39 0.10 
40-49 0.15 
50-59 0.55 
60-69 1.72 
70-79 4.18 
80-89 4.69 
90+ 5.45 
 
Scotland(38) 1980 to 
1990 
Retrospective, hospitalised-
based cohort study 
5.1 
million 
 Men Women 
1980   
25-44 0.01 0.01 
45-64 0.15 0.09 
65-74 0.61 0.37 
75+ 1.28 1.07 
Total 0.13 0.13 
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1990   
25-44 0.02 0.01 
45-64 0.26 0.13 
65-74 0.88 0.54 
75+ 1.91 1.53 
Total 0.21 0.21 
 
North west 
London, 
Middlesex(45) 
1988 Cross-sectional, primary 
care-based study 
30204 <65 0.06 
65+ 2.77 
 
Other European countries 
Sweden(15) 2006-
2010 
Cross sectional study 2.1 
million 
 Men Women 
2006   
40-49 0.30 0.10 
50-59 1.10 0.50 
60-69 3.60 1.60 
70-79 10.00 6.40 
80-89 21.40 17.93 
≥90 36.90 33.00 
2007   
40-49 0.30 0.10 
50-59 1.10 0.50 
60-69 3.40 1.50 
70-79 9.60 6.40 
80-89 21.20 17.90 
≥90 34.30 32.70 
2008   
40-49 0.30 0.20 
50-59                 1.20  0.50 0.22 0.01 
60-69 3.30  1.50 
70-79 9.20 6.20 
80-89 21.50 18.30 
≥90 32.70 30.90 
2009   
40-49 0.30 0.20 
50-59                 1.20 0.50 
60-69 3.10 1.50 
70-79 8.70 6.00 
80-89 21.60 18.20 
≥90 33.00 31.80 
2010   
40-49 0.30 0.20 
50-59 1.20 0.50 
60-69 3.10 1.40 
70-79 8.20 5.80 
80-89 21.60 18.20 
≥90 30.30 29.40 
 
Madrid(32) 2007 Cross-sectional, observational 
study 
198670  Men Women Total 
<40 0.03 0.03 0.03 
40-49 0.06 0.08 0.07 
50-59 0.33 0.25 0.29 
60-69 0.99 0.70 0.83 
70-79 2.97 2.70 2.81 
>80 8.21 7.19 7.51 
ALL 0.59 0.79 0.69 
 
Spain(35) 2004 to 
2005 
Population-based cohort 
study 
1776  Men Women Total 
45-54 1.30 1.20 1.30 
55-64 7.40 3.60 5.50 
65-74 7.00 8.80 8.00 
>75 15.60 16.40 16.10 
Total 6.50 7.00 6.80 
 
Dutch(36) 2001 National Survey in General 
Practice 
374000  Men Women Total 
0-24 <0.01 <0.01 <0.01 
25-44 0.02 0.02 0.02 
45-54 0.14 0.12 0.13 
55-64 0.75 0.31 0.52 
65-74 2.63 1.77 2.17 
75+ 9.67 8.56 9.17 
ALL 0.67 0.81 0.74 
 
Madeira(46) 2000 to Prospective, cross-sectional, 686 25-49 1.24 
	 38	
2001 observational study 50-59 6.17 
60-69 7.62 
70-79 13.32 
80+ 14.34 
 
Rotterdam(24) 1989 to 
2000 
Population-based cohort 
study 
7983 55-64 0.90 
65-74 4.00 
75-84 9.70 
85+ 17.40 
 
Copenhagen(47
) 
1997 to 
2000 
Population-based cohort 
study 
764  Men Women 
50-59 1.80 0.80 
60-69 2.00 1.00 
70-79 6.30 3.60 
80-89 13.90 4.30 
Total 4.20 2.30 
 
Portugal(48) 1998 Cross-sectional observational 
study 
5434 25-49 1.36 
50-59 2.93 
60-69 7.63 
70-79 12.67 
80+ 16.14 
 
Copenhagen(49
) 
1993 to 
1995 
Cross-sectional primary care-
based study 
2158 40-49 0.50 
50-59 1.50 
60-69 4.80 
70-79 9.30 
80+ 11.70 
 
Asturias, 
Spain(50) 
1995 to 
1999 
Cross-sectional study 391 40-49 <1.00 
50-59 2.00 
60-69 5.00 
70-79 13.00 
80+ 18.00 
 
Goteborg(22) 1970 to 
1996 
Population-based cohort 
study 
7495  Men 
55-64 0.60 
65-74 2.80 
75-79 6.20 
 
Rotterdam(51) 1990 to 
1993 
Population-based cohort 
study 
5540  Men Women Total 
Prevalence of HF 
55-64 0.70 0.60 0.70 
65-74 3.70 1.60 2.70 
75-84 14.40 12.10 13.00 
85-94 5.90 14.00 11.70 
Total 3.10 3.00 3.00 
Prevalence of LVSD FS≤25% 
55-64 3.70 1.20 2.30 
65-74 7.60 3.10 5.30 
75-84 6.90 3.30 4.80 
85-94 10.00 10.50 10.30 
Total 5.50 2.20 3.70 
 
Goteborg(52) 1963 to 
1980 
Population-based cohort 
study 
973 Prevalence of manifest HF (men) 
50 2.10 
54 2.40 
60 4.30 
67 13.00 
 
U.S.     
Georgia(30) 2000 to 
2005 
Retrospective, hospitalised 
and outpatient-based cohort 
study 
359947  Men Women 
2000   
18-54 0.41 0.34 
55-64 3.35 2.41 
65-74 8.05 5.87 
≥75 17.00 15.68 
2001   
18-54 0.47 0.41 
55-64 3.53 2.67 
65-74 8.03 6.07 
≥75 15.62 15.78 
2002   
18-54 0.53 0.47 
55-64 4.13 2.89 
65-74 8.54 7.11 
≥75 17.01 17.19 
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2003   
18-54 0.57 0.51 
55-64 4.25 3.07 
65-74 9.68 7.29 
≥75 18.61 17.17 
2004   
18-54 0.60 0.54 
55-64 4.42 3.22 
65-74 10.48 7.63 
≥75 18.37 17.74 
2005   
18-54 0.60 0.52 
55-64 4.64 3.17 
65-74 10.14 7.68 
≥75 19.75 17.67 
 
 US (104) 
 
2003-
2006 
National statistics -  Men Women 
20-39 0.30 0.20 
40-59 1.90 1.40 
60-79 9.10 4.90 
≥80 14.7 12.80 
 
Heart Disease 
and Stroke 
Statistics 
2007(31) 
1999 to 
2004 
National statistic 5.2 
million 
 Men Women 
20-39 0.30 0.20 
40-59 2.00 1.50 
60-79 7.20 5.20 
80+ 11.60 12.40 
 
Cleveland(53) 1998 to 
2000 
Prospective, hospitalisation-
based cohort study 
481 Prevalence of asymptomatic 
LVEF≤45% 
60-64 7.80 
65-69 5.90 
70-74 10.50 
75+ 7.70 
 
Rochester(54) 1997 to 
2000 
Population-based cohort 
study 
2042 45-54 0.70 
55-64 1.30 
65-74 1.50 
75+ 8.40 
 
Rochester(54) 1997 to 
2000 
Population-based cohort 
study 
2042  Men Women Total 
Prevalence of LVEF≤50% 
45-54 5.10 1.00 3.00 
55-64 7.40 2.20 4.80 
65-74 10.60 3.80 7.10 
75+ 22.80 6.60 12.90 
Prevalence of LVEF≤40% 
45-54 1.70 0.00 0.80 
55-64 1.90 0.60 1.30 
65-74 4.70 0.80 2.70 
75+ 7.90 2.20 4.40 
 
National Health 
Interview 
Survey(55) 
1999 Cross-sectional study 30801  Men Women Total 
18-39 0.04 0.10 0.10 
40-64 1.20 1.10 1.10 
65-74 4.50 2.90 3.60 
75+ 5.70 5.30 5.30 
 
Third National 
Health and 
Nutrition 
Examination 
Survey(56) 
1988 to 
1994 
Population-based, cross-
sectional surveys 
5549  Men Women Total 
40-49 0.20 0.20 0.30 
50-59 3.90 2.00 2.90 
60-69 6.30 5.60 5.80 
70-79 10.80 5.90 8.10 
≥80 6.10 8.70 7.80 
 
Framingham(39
) 
1987 to 
1990 
(original 
cohort) 
1991 to 
1995 
(offspring 
cohort) 
Population-based cohort 
study 
4257  Men Women 
Prevalence of asymptomatic LVEF≤50% 
40-59 2.10 0.50 
60-69 7.20 0.80 
70-79 11.30 1.00 
80+ 14.30 1.90 
All 6.00 0.80 
 
Framingham(28
) 
40 years 
follow up 
Population-based cohort 
study 
  Men Women 
50-59 0.80 0.80 
80-89 6.60 7.90 
 
Framingham(57 34 years Population-based cohort  50-59 0.80 
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) follow up study 60-69 2.30 
70-79 4.90 
80-89 9.10 
 
Rochester(58) 
 
1986 Cross-sectional study 2122  Men Women Total 
35-54 0.00 0.20 0.10 
55-64 0.50 0.50 0.50 
65-74 2.30 0.00 1.20 
75+ 6.90 8.00 7.60 
35+ 1.76 2.09 1.93 
 
Rochester(29)  
 
1981 to 
1982 
Cross-sectional study -  Men Women 
45-49 0.10 0.10 
50-54 0.10 0.20 
55-59 0.70 0.30 
60-64 1.20 0.70 
65-69 2.60 1.10 
70-74 2.80 2.70 
0-74 0.33 0.21 
 
National Health 
and Nutrition 
Examination 
Survey I(59) 
1971 to 
1975 
Population-based cohort 
study 
14407  Men Women Total 
Self reported HF 
25-54 0.40 0.30 0.40 
55-64 2.20 2.00 2.10 
65-74 3.70 3.20 3.40 
25-74 1.10 1.00 1.10 
HF diagnosed using clinical score 
25-54 0.80 1.30 1.10 
55-64 4.50 3.00 3.70 
65-74 4.80 4.30 4.50 
25-74 1.90 2.00 2.00 
 
Others     
Canberra, 
Australia(60) 
2002 to 
2003 
Cross-sectional survey 1275  Men Women Total 
60-64 3.60 2.60 3.10 
65-69 7.30 2.00 4.80 
70-74 5.20 4.80 5.00 
75-79 17.80 7.80 12.40 
80-86 15.70 10.40 13.60 
Total 8.20 4.40 6.30 
 
Arab(61) 
 
1992 to 
1994 
Prospective, hospitalisation-
based cohort study 
225000 <45 0.11 
45-64 1.57 
≥65 2.52 
Overall 0.52 
 
Taiwan(62) 
 
1991 to 
1993 
 2660  Men Women Total 
Prevalence of LVEF<55% 
35-44 12.10 8.00 9.60 
45-54 11.10 9.20 10.00 
55-64 12.70 11.80 12.30 
65-74 11.60 9.80 10.70 
>75 14.30 4.30 9.30 
All 12.00 9.30 10.50 
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1.3.5 Mortality in young adults with HF 
 
Table 1.4 summarises the in-hospital, thirty-day, one-, two-, three-year, and five-
year mortality rates in young adults with HF. I have only included studies reporting 
mortality rate from year 2000 onwards. 
 
The in-hospital mortality in young adults with HF is low from 1.2% to 3.5%.(63-
65) Similarly, the 30 days mortality in young adults is also low 2.6% to 3.7%.(12;66) One 
Scottish study included patients from 1986 to 2003 reported higher 30 days mortality of 
9.6% compared to the previous two studies which included patients from 2002-2005 and 
2009, respectively.(67) Younger adults have lower 1 year mortality and increases with 
age.(12;17;67) In Scotland 5 year survival rates were 39.5% and 56.4% in those aged <55 
and 55-64 years, respectively.(67) Contemporary study reporting long-term mortality in 
young adults with HF is lacking.  
 
In Sweden the mortality rate has improved between 1987 and 2003. Younger 
patients aged 35-64 years had the best improvement in 3 year mortality rate after first 
hospitalisation with a diagnosis of HF compared to patients aged 65-84 years (Period 
1999-2001 vs. 1987-1989: Men aged 35-64 years 17% vs. 39%; Women aged 35-64 years 
19% vs. 31%; Men aged 65-84 years 41% vs. 57%; Women aged 65-84 years 36% vs. 
50%; all p<0.0001).(68) An updated analysis of this database stratified the younger 
patients (<55 years) into 18-34, 35-44, and 45-54 years demonstrated marked improvement 
in 1 year mortality in all age groups from 1987-1991 to 1997-2001 with no further 
improvement after 2001 compared to those aged 55-84 years which mortality continues to 
improve.(17)  
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Table 1.4. Mortality of HF in young adults with HF 
 
Study Year of study Number of patients Mortality 
In-hospital    
Qatar(64) 
 
1991-2010 7066 99-02 
<50 9.2% 
51-70 10..4% 
>70 13.9% 
03-06 
<50 8.4% 
51-70 6.5% 
>70 9.4% 
07-10 
<50 3.5% 
51-70 4.2% 
>70 7.0% 
 
US(63) 2001-2009 1 686 089 2001 
18-44 1.7% 
45-54 1.6% 
55-64 2.7% 
65-74 3.6% 
≥75 6% 
2002 
18-44 1.6% 
45-54 1.7% 
55-64 2.4% 
65-74 3.5% 
≥75 5.8% 
2003 
18-44 1.6% 
45-54 1.7% 
55-64 2.3% 
65-74 3.3% 
≥75 5.6% 
2004 
18-44 1.7% 
45-54 1.7% 
55-64 2.4% 
65-74 3.2% 
≥75 5.4% 
2005 
18-44 1.2% 
45-54 1.6% 
55-64 1.9% 
65-74 2.9% 
≥75 5.2% 
2006 
18-44 1.4% 
45-54 1.3% 
55-64 1.9% 
65-74 2.8% 
≥75 4.9% 
2007 
18-44 1.4% 
45-54 1.3% 
55-64 1.7% 
65-74 2.5% 
≥75 4.6% 
2008 
18-44 1.4% 
45-54 1.3% 
55-64 1.6% 
65-74 2.5% 
≥75 4.5% 
2009 
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18-44 1.5% 
45-54 1.3% 
55-64 1.7% 
65-74 2.5% 
≥75 4.5% 
 
France(66) 2009 69968 <55 2.0% 
55-69 2.9% 
70-79 4.3% 
80-89 7.6% 
≥90 12.8% 
 
US(65) 
 
2007-2008 430665  Men Women 
20-24 2.7% 2.5% 
25-29 1.7% 1.6% 
30-34 1.5% 1.3% 
35-39 0.9% 0.9% 
40-44 1.0% 1.2% 
45-49 1.3% 0.9% 
50-54  1.3% 1.0% 
55-59 1.3% 1.3% 
60-64 2.0% 1.5% 
65-69 2.2% 1.9% 
70-74 2.9% 2.4% 
75-79 3.2% 2.9% 
80-84  4.3% 3.8% 
85-89 5.2% 4.4% 
90-94 6.9% 6.0% 
≥95 8.7% 7.1% 
 
GWTG-HF(69) 
 
2005 to 2007 57937 ≤65 1.6% 
66-77 3.1% 
76-85 3.8% 
≥85 5.3% 
 
NHS HF 
survey(70) 
2005 to 2006 9387 <55 <3% 
>85 23% 
 
Taiwan(10) 
 
2005 2692 20-64 2.7% 
≥65 4.2% 
All 3.9% 
 
Worcester(71) 
 
2000 2604 <55 1.7% 
55-64 2.6% 
65-74 2.5% 
75-84 7.0% 
≥85 6.1% 
 
30 days mortality    
France(66) 2009 69968 <55 3.7% 
55-69 5.1% 
70-79 7.3% 
80-89 12.7% 
≥90 21.6% 
 
Western 
Australia(12) 
 
1990 to 2005 27105 1990-1993 
<65 6.5% 
65-74 10.6% 
≥75 13.7% 
1994-1997 
<65 4.3% 
65-74 8.1% 
≥75 11.2% 
 
1998-2001 
<65 3.8% 
65-74 6.7% 
≥75 11.4% 
 
2002-2005 
<65 2.6% 
65-74 6.3% 
≥75 10.9% 
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Scotland(67) 1986 to 2003 116556 <55 9.6% 
55-64 12.4% 
65-74 16.8% 
75-84 21.4% 
≥85 25.6% 
 
1 year mortality    
Sweden(17) 1987 to 2006 443995 1987-1991 
18-34 28.3% 
35-44 25.1% 
45-54 25.4% 
55-84 39.1% 
1992-1996 
18-34 19.9% 
35-44 18.1% 
45-54 17.2% 
55-84 30.4% 
1997-2001 
18-34 12.3% 
35-44 12.6% 
45-54 13.7% 
55-84 27.8% 
2002-2006 
18-34 12.2% 
35-44 10.6% 
45-54 12.2% 
55-84 26.6% 
 
Western 
Australia(12) 
 
1990 to 2005 27105 Overall 
<65 13.4% 
65-74 22.4% 
≥75 33.0% 
1990-1993 
<65 18% 
65-74 25.8% 
≥75 36.4%% 
1994-1997 
<65 15.3% 
65-74 22.8% 
≥75 33.9% 
1998-2001 
<65 12.0% 
65-74 21.3% 
≥75 31.7% 
2002-2005 
<65 8.9% 
65-74 18.2% 
≥75 29.8% 
 
Japan(72) 2004 to 2005 2685 Managed in cardiology 
clinic 
15-39 11.1% 
40-49 1.9% 
50-59 3.0% 
60-69 3.4% 
70-79 6.6% 
80-89 10.5% 
90-101 13.2% 
Managed by GP 
15-39 0% 
40-49 0.0% 
50-59 0.0% 
60-69 1.5% 
70-79 3.8% 
80-89 8.3% 
90-101 18.5% 
 
Scotland(67) 1986 to 2003 116556 <55 22.0% 
55-64 30.4% 
65-74 40.0% 
75-84 48.6% 
>84 57.2% 
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3 year mortality    
Sweden(68)  1987 to 2003 179753  Men Women 
Aged 35-64 years   
87-89 39.0% 31.0% 
90-92 34.0% 27.0% 
93-95 24.0% 22.0% 
97-99 22.0% 21.0% 
99-01 17.0% 19.0% 
Aged 65-84 years   
87-89 57.0% 50.0% 
90-92 52.0% 46.0% 
93-95 46.0% 39.0% 
97-99 43.0% 38.0% 
99-01 41.0% 36.0% 
 
5 year mortality    
Scotland(67) 1986 to 2003 116556 <55 39.4% 
55-64 56.4% 
65-74 69.4% 
75-84 80.7% 
>84 89.3% 
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1.3.6 Cause of death in young adults with HF 
 
The only study I found reporting cause of death in young adults is the Amiodarone 
Trialists’ meta-analysis.(73) The study included 6252 patients stratified into ≤50, 51-60, 61 
to 70, 71 to 80, and >80 years demonstrated that younger patients were more likely to die 
suddenly compared to their older counterparts (≈50% of all death in patient ≤50 years was 
sudden death vs. 26% of all death in patient >80 years).(73) 
 
1.3.7 HF Hospitalisations in young adults with HF 
 
Table 1.5 summarises HF hospitalisation rate in young adults with HF. The 
hospitalisation rate in young adults with HF is lower compared to older patients with men 
displaying higher hospitalisation rates. However, very young adults with HF have not 
experienced the same decline in HF hospitalisation as their older counterpart.  
 
In the US National Inpatient Sample dataset, young adults aged 20-24 years have 
the lowest HF hospitalisation rate (12.5 per 100000) and increases with age consistent with 
other studies.(3;12;65) An updated analysis from the same dataset examined trend of HF 
hospitalisation from 2001 to 2009 reported no significant decline in HF hospitalisation in 
patients aged 18-44 and 45-54 years similar other studies which suggest the largest decline 
in HF hospitalisations are in the older patients.(12;63;74) 
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Table 1.5. HF hospitalisation rate in young adults with HF 
 
Study Year of 
study 
Number of 
patients 
Hospitalisation (per 100,000) 
US(63) 2001-2009 1 686 089 Primary diagnosis 
 
18-44 45-54 55-64 66-74 75+ 
2001 44.00 247.00 704.00 1709.00 4272.00 
2002 45.00 254.00 653.00 1608.00 3894.00 
2003 45.00 245.00 649.00 1552.00 3827.00 
2004 48.00 259.00 640.00 1541.00 3868.00 
2005 48.00 248.00 593.00 1487.00 3861.00 
2006 49.00 257.00 563.00 1372.00 3624.00 
2007 47.00 241.00 526.00 1266.00 3373.00 
2008 41.00 207.00 462.00 1089.00 3102.00 
2009 38.00 207.00 447.00 1070.00 3064.00 
Δ (%) -12.80 -16.20 -36.50 -37.40 -28.30 
P 0.570 0.036 <0.001 <0.001 <0.001 
 
US(74) 2001-2009    18-49 50-64 65-74 75-84 85+ 
Primary diagnosis 
2001- 
2003 59.00 456.00 1415.00 2899.00 5235.00 
2004– 
2006 65.00 431.00 1293.00 2681.00 5002.00 
2007-
2009 61.00 384.00 1095.00 2373.00 4521.00 
Secondary diagnosis 
2001- 
2003 108.00 983.00 3462.00 7601.00 14784.00 
2004– 
2006 131.00 1071.00 3641.00 7906.00 14991.00 
2007-
2009 134.00 1045.00 3376.00 7303.00 13499.00 
 
US(65) 
 
2007-2008 430665 Primary diagnosis 
 Men Women 
20-24 15.00 10.00 
25-29 24.00 17.00 
30-34 43.00 28.00 
35-39 74.00 40.00 
40-44 124.00 74.00 
45-49 193.00 116.00 
50-54  302.00 200.00 
55-59 431.00 301.00 
60-64 667.00 476.00 
65-69 1076.00 773.00 
70-74 1582.00 1220.00 
75-79 2323.00 1782.00 
80-84  3434.00 2701.00 
≥85 5340.00 4407.00 
 
Tennessee, 
US(75) 
 
2006-2008 20222 (2006); 
16889 (2008) 
Primary diagnosis 
 Men Women 
2006 
20-34 22.00 14.00 
35-44 95.00 64.00 
45-54 243.00 190.00 
55-64 561.00 424.00 
65-74 1216.00 1038.00 
75-84 2474.00 2066.00 
≥80 4310.00 3769.00 
	 48	
2008 
20-34 19.00 11.00 
35-44 85.00 52.00 
45-54 207.00 146.00 
55-64 454.00 333.00 
65-74 1049.00 819.00 
75-84 2088.00 1651.00 
≥80 3741.00 3246.00 
 
US(76) 1997 and 
2006 
15614 (1997) 
20459 (2006) 
Primary diagnosis 
 Men Women 
1997   
25-34 12.00 10.00 
35-44 51.00 52.00 
45-54  169.00 149.00 
55-64 512.00 409.00 
65-74 1169.00 959.00 
75-84 2321.00 1950.00 
≥85 3867.00 3667.00 
2006   
25-34 22.00 14.00 
35-44 97.00 64.00 
45-54  248.00 190.00 
55-64 569.00 424.00 
65-74 1234.00 1046.00 
75-84 2498.00 2086.00 
≥85 4337.00 3812.00 
 
Switzerland(77) 
 
2005 8120  Men Women 
25-34 2.20 1.80 
35-44 6.90 2.90 
45-54  25.70 8.20 
55-64 80.80 31.50 
65-74 269.70 132.70 
75-84 836.40 491.30 
≥85 1821.70 1228.40 
 
Western 
Australia(12) 
1990 to 
2005 
19342 Primary diagnosis 
 Men Women 
Aged <65 years   
90-93 71.78 37.07 
94-97 65.37 34.68 
98-01 58.38 37.49 
02-05 59.23 33.68 
Aged 65-74 years   
90-93 852.36 595.39 
94-97 908.88 571.28 
98-01 751.90 504.15 
02-05 626.00 352.96 
Aged ≥75 years   
90-93 2435.62 2136.97 
94-97 2696.71 2136.07 
98-01 2645.28 2110.67 
02-05 2122.86 1724.85 
Overall   
<65 63.03 35.78 
65-74 757.29 488.36 
≥75 2410.40 1974.77 
 
U.S. National 
Hospital 
Discharge 
Survey(3) 
1979 to 
2004 
 HF as principal diagnosis 
 Men Women 
Aged <65 years   
1979 50.90 39.30 
2004 134.00 98.20 
RPC +163.2% +149.7% 
Aged 65-74 years   
1979 865.60 667.90 
2004 1469.70 1161.10 
RPC +69.8% +67.1% 
Aged ≥75 years   
1979 2288.80 1976.70 
2004 3788.90 3402.40 
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RPC +65.5% +72.1% 
 
Spain(78) 1996 1069 Principal or any diagnosis and fulfilled criteria 
 Men  Women Total 
15-39 4.60 1.50 3.10 
40-64 120.00 84.00 100.00 
65-79 680.00 580.00 620.00 
≥80 1890.00 2080.00 2020.00 
All 170.00 220.00 200.00 
 
France(79) 1992 to 
1996 
138543 Primary diagnosis 
White 
15-44 90.00 
45-64 670.00 
65-74 1980.00 
75-84 4100.00 
≥85 6530.00 
 
Minnesota(80) 1995 5503 All discharges 
 Men Women 
35-44 36.00 20.00 
45-54 144.00 103.00 
55-64 560.00 403.00 
65-74 1691.00 1181.00 
75-84 4055.00 2703.00 
Overall 549.00 486.00 
 
Spain(81) 
 
1980 to 
1993 
42961 (1980); 
73442 (1993) 
Primary diagnosis 
 Men  Women Total 
Aged 45-64 years 
1980 275.15 168.70 219.98 
1993 266.36 162.61 212.82 
Change  -3.30% -3.61 -3.25% 
Aged >65 years 
1980 732.06 508.29 599.49 
1993 1014.59 932.65 954.85 
Change 38.9% 83.49% 59.28% 
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1.4 Aetiology of HF in young adults with HF 
 
The majority of HF in very young adults is caused by conditions other than 
coronary heart disease (Table 1.6).  The younger the patient the more likely they are to 
have a non-ischaemic aetiology. Reporting of aetiology will not represent exhaustive 
investigation. Few have investigated sub-groups of dilated cardiomyopathy. How many of 
these patients labelled with dilated cardiomyopathy have adult congenital heart disease or 
other causes of HF beyond the most common causes is unknown. In the CARE-HF trial, 
among all the patients with investigators reported dilated cardiomyopathy, only 40% of 
them were truly idiopathic after excluding patients without any previous coronary 
angiography, patients with coronary artery disease or diabetes or hypertension or 
combination of these.(82)  
 
 
 
 
 
 
Table 1.6. Aetiology of HF in young adults with HF 
 
Study Aetiology (%) 
Clinical trials  
Pooled analysis of 5 
randomised controlled 
trials(83) 
N=11642 
 Male Female 
 Ischaemic Nonischaemic Ischaemic Nonischaemic 
N 5021 3770 1134 1717 
<65 43 65 38 60 
65-74 41 25 40 28 
75+ 16 9 22 12 
 
HF ACTION study(84) 
N=2331 
 
 <60 60-69 ≥70 
N 1214 640 477 
Ischaemic 37.6 61.9 72.3 
p<0.001    
 
CARE HF(82) 
N=813 
 
Age <60 60-70 >70 
N 219 315 277 
Ischaemic 25 38 49 
Hypertension 6 10 10 
DCM 58 45 36 
Alcohol related 5 2 0 
Valve 3 2 2 
Other 3 2 3 
 
MERIT-HF(85) 
N=3991 
 
 <65  ≥65  
 Placebo Metoprolol 
CR/XL 
Placebo Metoprolol 
CR/XL 
N 1009 1000 992 990 
Ischaemic 56 55 75 75 
p<0.0001     
 
LVAD(86) 
N=222 
 
 ≤44 45-53 53-59 ≥60 
N 55 55 56 56 
Ischaemic 15 60 65 54 
p<0.01     
 
DIG Study(87) 
N= 7788 
 
 <50 50-59 60-69 70-79 ≥80 
N 841 1545 2885 2092 425 
Ischemic 50 67.5 72.5 73 68.5 
Non-ischemic 50 32.5 27.5 27 31.5 
 
Arab(61) 
N=1164 
 
 13-24 25-34 35-44 45-54 55-64 ≥65 
N 18 43 120 194 435 353 
Ischaemic 0 9 43 41 56 64 
Hypertensive 0 16 18 26 30 23 
Idiopathic 28 23 17 12 6 3 
Valvular 33 37 14 4 0 0 
 
PRIME-II study(88) 
N=311 
 
 38-62 63-69 70-73 74-80 
N 76 77 67 91 
Coronary artery disease 68 83 72 78 
DCM 25 12 18 14 
Hypertension 3 4 3 8 
Other 4 1 7 0 
 
AREA IN-CHF study(89) 
N=467  
 <64 ≥64 
N 232 235 
Ischaemic 51 52 
Idiopathic  33 27 
Hypertensive 7 13 
Valvular heart disease 3 5 
Other 4 1 
p not significant   
 
North American 
centers(90) 
N=546 
 <65 ≥65 
N 328 218 
Ischaemic 38 73 
Hypertensive 9 6 
Idiopathic 40 17 
Others 13 4 
p<0.001   
 
Val-HeFT(91) 
N= 5010 
 <65 ≥65 
N 2660 2350 
Ischaemic 49.3 66.1 
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p<0.001   
 
BEST study(92) 
N= 270 
 <65 ≥65 
N 1616 1092 
Ischaemic 49 73 
p<0.001   
 
Registry/ Prospective cohort 
Get With the Guidelines-
HF(69) 
N=57937 
 
 ≤65 66-77 76-85 >85 
N 16245 12488 18398 10806 
Ischaemic HF 31.9 44.9 42.5 32.5 
p<0.0001     
 
IMPROVE HF(93) 
N= 15381 
 
 ≤64 65-76 >76 
N 5307 5176 4791 
Ischaemic 53 71 73 
Non-ischaemic 25 12 10 
Valvular 2 2 2 
Other 13 8 7 
p<0.001    
 
IMPROVEMENT of 
HF survey(94) 
N=8256 
 
 <65 65-74 75-84 ≥85 All 
N 2574 2549 2243 890 8256 
Coronary 
heart disease 
46 47 43 34 44* 
Hypertension 23 25 26 22 24* 
Valvular 8 8 9 9 9 
Idiopathic 6 3 2 2 4* 
Other 17 17 20 33 19* 
*statistically significant, p<0.001 
 
The Carvedilol Heart 
Failure Registry(95) 
N=4280 
 
 <55 55-64 65-75 >75 
N 806 922 1363 1188 
Ischaemic 34 55 62 63 
Hypertensive 18 16 14 16 
Idiopathic 31 19 14 11 
Other 16 9 10 10 
p<0.001     
 
Italian Network on 
Congestive Heart Failure 
Registry(96) 
N= 8178 
 ≤65 66-75 ≥75 
 AF No AF AF No AF AF No AF 
N 683 3578 638 2013 412 854 
Ischaemic 18 37 28 52 33 49 
Valvular 22 6 27 8 20 12 
Hypertensive 12 9 17 14 23 20 
Idiopathic 39 42 23 23 17 15 
Other 9 6 5 3 8 4 
 
AF=atrial fibrillation; AREA IN-CHF= AntiREmodelling Effect of Aldosterone Receptors Blockade with Canrenone IN 
Mild Chronic Heart Failure) study; BEST=Beta-Blocker Evaluation in Survival Trial; CARE-HF= the Cardiac 
Resynchronization-Heart Failure study; DIG=Digitalist Investigation Group; IMPROVE-HF=The Registry to Improve 
the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; LVAD=left ventricular assist device; 
MERIT-HF=The Metoprolol CR/XL Randomised Intervention Trial in Chronic Heart Failure; PRIME-II=Second 
Prospective Randomised Study of Ibopamine on Mortality and Efficacy. 
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1.5 Co-morbidities in young adults with HF 
 
Table 1.7 illustrates the co-morbidities in young adults with HF. Young adults (<65 
years) have a lower prevalence of hypertension, prior myocardial infarction, atrial 
fibrillation, hyperlipidaemia, chronic kidney disease, stroke or transient ischaemic attack, 
peripheral artery disease and malignancy.(10;69;93-95;97-99). The prevalence of diabetes 
in young adults with heart failure are conflicting with some suggesting it is higher and 
some lower comparing to older patients.(10;33;69;87;93;94;97-99).  
 
Comparing to older patients, younger adults were more likely to have depression 
(<65 years: 10.4% vs. ≥65 years: 8%),(93) and misuse alcohol (≤65 years: 2.6%, 66-77 
years: 0.9%, 76-85 years: 0.4% and >85 years: 0.1%; p<0.0001).(69) Cigarette smoking is 
also more common in young adults <65 years.(69;98)  
 
All these studies have defined young as <50-65 years. None has further stratified 
them into smaller age group. The trends of comorbidities in young adults are yet to be 
investigated.  
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Table 1.7. Co-morbidities in young adults with HF 
 
Study Co-morbidities (%) Age 
SHIFT trial(100) 
N=6505 
 
 <53 53- <60 60- <69 ≥69 
N 1522 1521 1750 1712 
Ischaemic HF 48 69 73 79 
AF/ flutter 5 6 8 12 
MI 42 59 60 63 
Hypertension 52 68 70 75 
Stroke 4 7 10 10 
Diabetes 21 35 34 32 
Renal failure 3 4 6 12 
All p<0.0001     
 
IMPROVE HF(93) 
N= 15381 
 
 ≤64 65-76 >76 
N 5307 5176 4791 
Atrial fibrillation 20 32 41 
Diabetes 35 38 29 
Hypertension 58 64 64 
Prior MI 34 43 42 
COPD 13 20 17 
CABG 22 37 35 
PVD 8 14 13 
Depression 10 8 8 
All p<0.001    
 
GWTG-HF(69) 
N=57937 
 
 ≤65 66-77 76-85 >85 
N 16245 12488 18398 10806 
HF 24 24 23 23 
CAD/IHD 32 45 44 36* 
Hypertension 59 60 58 56* 
AF 13 24 31 32* 
Hyperlipidaemia 28 36 32 21* 
CRI 14 18 17 14* 
Anaemia 10 13 15 16* 
Pulmonary 
disease 
23 27 24 18* 
DM(no insulin) 19 19 12 6* 
DM (insulin) 19 24 20 13* 
Alcohol abuse 3 1 0 0* 
Tobacco 33 16 7 2* 
*p<0.0001     
 
HF ACTION 
study(84) 
N=2331 
 
 <60 60-69 ≥70 
N 1214 640 477 
Diabetes mellitus  29 38 32* 
COPD 7 13 15* 
PAD 4 9 12* 
*p<0.001    
 
InSync/InSync ICD 
Italian Registry(97) 
N= 1787 
 
 <65 65-74 ≥75 
N 571 740 476 
COPD 5 7 6 
Diabetes Mellitus 8 9 6 
Hypertension 13 18 20* 
Renal failure 3 8 4* 
≥3 co-morbidities 4 9 7* 
CAD 39 50 50* 
Permanent AF 11 18 21* 
*statistically significant 
 
Taiwan(10) 
N=2692 
 
 20-64 ≥65 All 
N 567 2125 2692 
Diabetes mellitus 36 26 28* 
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Hypertension 41 38 39 
COPD 9 22 19* 
Stroke 6 10 9* 
Nephropathy 18 11 13* 
Cancer 4 5 5 
Infection 23 32 30* 
Digestive disease 19 23 22 
IHD 30 32 32 
PAD 4 2 1* 
*statistically significant 
 
Kent, Surrey and 
Sussex Primary 
Care Research 
Network(33) 
N= 2129 
 
 45-54 55-64 65-74 75-84 85+ 
 M W M W M W M W M W 
Atrial fibrillation 15 0 31 15 33 23 33 27 26 28 
Diabetes 20 18 28 21 22 22 15 15 10 9 
Hypertension 35 36 42 40 42 48 41 50 35 42 
Coronary artery 
disease 
50 27 55 29 57 43 45 38 40 35 
 
MERIT-HF(85) 
N=3991 
 
 <65  ≥65  
 Placebo Metoprolol 
CR/XL 
Placebo Metoprolol 
CR/XL 
N 1009 1000 992 990 
Previous MI 42 40 55 56* 
Hypertension 42 44 46 44 
DM 23 25 26 25 
AF 13 12 20 19* 
*p<0.0001     
 
DIAMOND study 
and ECHOS(101)  
N= 8507 
 
 <65 65-74 75-84 ≥85 All 
N 1865 2769 3048 825 8507 
Cardiovascular comorbidities 
IHD 48 56 53 42 52 
Hypertension 24 27 26 20 25 
Diabetes 16 17 16 12 16 
Stroke/TIA 6 11 11 11 10* 
Previous MI 35 38 34 22 34* 
Atrial fibrillation 16 24 25 20 22* 
PAD 6 8 6 4 6 
Associated comorbidities 
COPD 22 26 23 14 23* 
Anaemia 2 3 4 5 3* 
Depression 2 2 1 2 2 
Severe dementia 0 0 0 1 0* 
Renal 
insufficiency 
2 6 17 35 11* 
Myxoedema 1 2 3 3 2* 
Hyperthyroidism 1 1 2 2 2* 
Cancer history 2 4 5 6 4* 
Arthritis urica 5 6 5 5 5 
Rheumatic 
arthritis 
1 2 2 2 2* 
Polymyalgia 
rheumatic 
0 1 2 2 1* 
Colitis ulcerosa 0 0 0 0 0 
Gastro intestinal 
ulcer 
4 6 5 5 5 
Total of ≥3 20 32 33 26 29* 
Cardiovascular ≥2 32 43 41 30 39 
*statistically significant 
 
IMPROVEMENT 
of HF survey(94) 
N=8256 
 
 <65 65-74 75-84 ≥85 All 
N 2574 2549 2243 890 8256 
CAD 46 43 37 23 40* 
Cerebrovasc
ular disease 
9 16 19 21 16* 
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PVD 16 21 21 18 19* 
Hypertensio
n 
61 67 64 62 64 
Diabetes 19 23 19 13 20* 
Pulmonary 
disease 
27 35 32 28 31 
Renal 
dysfunction 
10 19 25 32 19* 
AF 16 25 31 36 25* 
*statistically significant 
 
DIAMOND 
study(98) 
N= 5419 
 
 <61 61-70 71-80 >80 
N 718 1481 2203 1089 
IHD 51 60 59 51* 
Previous MI 35 42 39 28* 
Hypertension 22 26 26 20* 
Valvular disease 3 4 4 3 
COPD 20 24 25 17* 
Diabetes  13 19 17 15* 
Atrial fibrillation 16 23 27 27* 
Current Smoking 52 41 31 19* 
*statistically significant 
 
DIG study(87) 
N= 7788 
 
 <50 50-59 60-69 70-79 ≥80 
 D P D P D P D P D P 
N 437 404 748 797 1465 1420 1013 1079 226 199 
MI 45 50 64 63 67 67 66 64 56 59 
HTN 43 44 43 45 48 47 50 51 48 49 
DM 19 22 29 30 32 31 28 30 17 19 
D=digoxin; P=placebo 
 
The Carvedilol 
Heart Failure 
Registry(95) 
N=4280 
 
 <55 55-64 65-75 >75 
N 806 922 1363 1188 
Prior MI 28 43 47 41 
Hypertension 51 58 60 61 
Diabetes 30 39 34 25 
Angina 21 26 30 29 
All p<0.001     
 
CHARM study(99) 
N=7599 
 
 <50 50-59 60-69 70-79 >80 
N 605 1474 2351 2474 695 
Diabetes 22.1 29.8 31.5 28.6 20.4* 
Hypertension 43.3 51.9 55.8 58.0 59.1* 
Atrial fibrillation 12.4 19.2 24.6 34.2 43.3* 
*p<0.001      
 
North American 
centers(90) 
N=546 
 <65 ≥65 
N 328 218 
Prior MI 33 51* 
Prior PCI 14 13 
Prior CABG 18 42* 
Peripheral arterial disease 4 11* 
Stroke 8 10 
Hypertension 52 63* 
Hyperlipidaemia 43 56* 
Ventricular arrhythmia 21 22 
Atrial fibrillation/ flutter 25 37* 
Pacemaker 9 25* 
Implantable defibrillator 14 15 
Diabetes 31 37 
COPD or Asthma 15 24* 
Depression requiring 
treatment 
13 11 
Arthritis 7 13* 
Malignancy 4 11* 
Renal failure 4 9* 
Current Alcohol use 52 50 
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Alcohol abuse history 22 11* 
Smoking (any) 62 57* 
Current/recent Tobacco use 28 13* 
Illicit drug use 9 2* 
*Statistically significant   
 
AREA IN-CHF 
study(89) 
N=467  
 <64 ≥64 
N 232 235 
Previous admission for HF 47 47 
Previous MI 48 51 
Previous revascularisation 36 35 
Stroke 1 3 
Chronic AF 5 11 
Hypertension 42 49 
Diabetes 14 27 
Current smoker 18 10 
Ex-smoker 44 46 
 
V-HeFT I and 
II(102) 
N= 1446 
 
 ≤55 56-60 51-65 >65 
V-HeFT I     
N 185 182 170 105 
Coronary artery disease 35 47 52 41 
Hypertension 30 45 46 37 
V-HeFT II     
N 175 173 231 225 
Coronary artery disease 41 57 55 58 
Hypertension 40 57 55 58 
 
AF=atrial fibrillation; CABG=coronary artery bypass grafting; CAD=coronary artery disease; COPD=chronic obstructive 
pulmonary disease; CRI=chronic renal impairment; DM=diabetes mellitus; HF=heart failure; HTN=hypertension; 
IHD=ischaemic heart disease; MI=myocardial infarction; PCI=percutaneous coronary intervention; PAD=peripheral 
artery disease; PVD=peripheral vascular disease; TIA=transient ischaemic attack.  
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1.6 Symptoms and signs of HF in young adults with HF 
 
1.6.1 Symptoms 
 
There are limited data on symptoms of HF by age categories (Table 1.8). Younger 
adults have better NYHA functional class. The DIG trial dichotomised age at 65 years of 
age reported no difference in proportions in dyspnoea at rest and on exertion.(103) No 
other trials or studies have examined the differences in symptoms of HF in detail in young 
adults with HF.  
 
1.6.2 Signs 
 
From the limited data that has been published, younger adults with HF have 
different signs of HF (Table 1.8). Younger patients are less likely to have pulmonary 
rales,(82;85;103) and less likely to have peripheral oedema.(82;85;103) Further studies are 
needed to examine the differences in signs of HF in young adults with HF.  
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Table 1.8. Symptoms, signs, and NYHA functional classes in young adults with HF 
 
Study Symptoms and signs & NYHA functional classes (%) 
Clinical trials  
SHIFT(100)  
N=6505 
 <53 53- <60 60- <69 ≥69 
NYHA n=1522 n=1521 n=1750 n=1712 
II 55 48 51 41 
III 43 51 47 56 
IV 2 1 2 3 
All p<0.0001     
 
CARE HF(82) 
N=813 
 
 <60 60-70 >71 
N 219 315 277 
Pulmonary rales 5 12 17 
Peripheral oedema 13 19 22 
3rd heart sound 16 20 22 
JVP elevated  14 18 21 
 
HF ACTION 
study(84) 
N=2331 
 
 <60 60-69 ≥70 
N 1214 640 477 
NYHA    
II 66.6 61.4 57.9 
III 32.9 37.7 40.0 
IV 0.6 0.9 2.1 
p<0.001    
 
CHARM study(99) 
N=7599 
 <50 50-59 60-69 70-79 >80 
N 605 1474 2351 2474 695 
NYHA class      
II 49 49 45 43 37 
III 49 49 52 54 58 
IV 2 2 3 3 5 
p<0.001      
 
MERIT-HF(85) 
N=3991 
 
 <65  ≥65  
 Placebo Metoprolol 
CR/XL 
Placebo Metoprolol 
CR/XL 
N 1009 1000 992 990 
Peripheral oedema 14 16 15 15* 
Jugular venous 
distension 
14 14 13 13* 
Pulmonary rales 10 10 12 12* 
Third heart sound 22 24 24 23* 
*not statistically significant 
NYHA     
II 46 45 37 36 
III 51 52 59 60 
IV 3.3 3.0 4.3 3.9 
P<0.0001     
 
DIG study(87) 
N= 7788 
 
 <50 50-59 60-69 70-79 ≥80 
 D P D P D P D P D P 
N 437 404 748 797 1465 1420 1013 1079 226 199 
NYHA           
I-II 75 75 72 72 69 69 65 66 57 55 
III-IV 25 25 28 28 31 31 35 34 43 45 
 
Val-HeFT(91) 
N= 5010 
 <65 ≥65 
N 2660 2350 
NYHA class III & IV 34 43 
NYHA IV 2 2 
p<0.001   
 
BEST(92) 
N= 2708 
 
 <65  ≥65  
 Bucindolol Placebo Bucindolol Placebo 
N 821 795 533 559 
NYHA III 93 93 89 89 
NYHA IV 7 7 11 11 
p=0.015     
 
DIG trial (103) 
N=7788 
 <65 ≥65 p 
N 3752 4036  
Symptoms and signs of HF    
Dyspnoea at rest  22 22 0.565 
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Dyspnoea on exertion 74 77 0.001 
Jugular venous distension 12 14 0.031 
Third heart sound 25 23 0.104 
Pulmonary rales 13 20 <0.0001 
Lower extremity oedema 20 22 0.010 
NYHA functional class    
I 16 13 <0.0001 
II 56 53  
III 27 32  
IV 2 2*  
 
North American 
centers(90) 
N=546 
 <65 ≥65 
N 328 218 
NYHA   
I 13 8* 
II 45 37* 
III 38 50* 
IV 5 6* 
*statistically significant   
 
PRIME-II study(88) 
N=311 
 38-62 63-69 70-73 74-80 
N 76 77 67 91 
NYHA     
III 78 68 72 63 
III/IV 21 29 28 33 
IV 1 3 0 4 
 
Registry  
The Carvedilol Heart 
Failure Registry(95) 
N=4280 
 <55 55-64 65-75 >75 
N 806 922 1363 1188 
NYHA III/IV 34 36 38 42 
p<0.001     
 
IMPROVEMENT of 
HF survey(94) 
N=8256 
 
 <65 65-74 75-84 ≥85 All 
N 2574 2549 2243 890 8256 
NYHA class      
II 52 46 41 39 46 
III 38 41 42 44 41 
IV 11 13 17 17 14 
p<0.001      
 
IMPROVE HF(93) 
N= 15381 
 ≤64 65-76 >76 
N 5307 5176 4791 
NYHA class    
I 21 21 18 
II 28 25 26 
III 18 17 18 
IV 2 3 3 
p=0.022    
 
Italian Network on 
Congestive Heart 
Failure Registry(96) 
N=8178 
 ≤65 66-75 ≥75 
 AF No AF AF No AF AF No AF 
N 683 3578 638 2013 412 854 
Third heart sound 21 28 18 21 18 17 
NYHA class III-IV 37 26 43 29 41 35 
 
  
D=Digoxin; NYHA=New York Heart Association functional class; P= placebo; 
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1.7 Investigations in young adults with heart failure 
 
1.7.1 Electrocardiogram (ECG) 
 
Younger adults with HF are more likely to be in sinus rhythm and less likely to be 
in atrial fibrillation or flutter.(88) 
 
1.7.2 Chest Radiography 
 
The Digitalis Investigation Group (DIG) and the Italian Network on Congestive 
Heart Failure, both reported lower proportions of cardiomegaly and pulmonary congestion 
in young adults aged <65 years compared to older patients.(87;96;103)  
 
1.7.3 Echocardiogram 
 
Younger adults (<50-65 years) have the lowest left ventricular ejection fraction and 
increases with age (Table 1.9). Mean left ventricular cavity size is greater in younger 
adults; left ventricular end diastolic diameter was 52mm in younger patients <61 years in 
comparison to 35mm in older patients >80 years.(98) Similar findings were also found in 
young black men <60 years.(104)  
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Table 1.9. Echocardiographic parameters in young adults with HF 
 
Study Age 
SHIFT(100) 
N=6505 
Mean (SD) <53 53- <60 60- <69 ≥69 
N 1522 1521 1750 1712 
EF, % 28.4 (5.4) 29.1 (5.0) 28.9 (5.2) 29.6 (5.0) 
All p<0.0001     
 
DIAMOND study 
and ECHOS(101)  
N= 8507 
 
% or mean <65 65-74 75-84 ≥85 P 
N 1865 2769 3048 825  
Wall motion index 1.1 1.3 1.4 1.5 <0.001 
LVEF>45% 36 45 49 53 <0.001 
 
DIG study(87) 
N= 7788 
 
Mean <50 50-59 60-69 70-79 ≥80 
 D P D P D P D P D P 
N 437 404 748 797 1465 1420 1013 1079 226 199 
EF,% 30.5 29.4 30.5 29.4 31.8 31.8 33.1 33.6 36.6 33.8 
 
The Carvedilol Heart 
Failure Registry(95) 
N=4280 
Mean (SD) <55 55-64 65-75 >75 
N 806 922 1363 1188 
EF, % 30 (12) 30 (12) 31 (12) 33 (13) 
P<0.001     
 
DIAMOND 
study(98) 
N= 5419 
 
% or median (5-
95% percentile) 
<61 61-70 71-80 >80 
N 718 1481 2203 1089 
WMI≤ 1.2 52 45 39 33 
WMI 1.1 (0.5-1.9) 1.2 (0.9-2.0) 1.4 (1.0-2.0) 1.5 (1.0-2.0) 
LVEDD (mm) 52 (35-67) 50 (35-66) 47 (35-63) 35 (32-60) 
p<0.001     
 
French hospital 
survey(105) 
N=1058 
 
% 27-68 68-78 78-86 86-100 
Echocardiography 87 83 74 64 
Ejection fraction     
<30% 32 26 11 12 
30-39% 22 23 25 25 
40-44% 18 13 16 15 
>45% 28 38 48 48 
p=0.001     
 
CHARM study(99) 
N=7599 
Mean (SD) <50 50-59 60-69 70-79 >80 
EF, % 36 (14) 38 (14) 38 (15) 40 (15) 43 (16) 
p<0.0001      
 
Val-HeFT(91) 
N= 5010 
Mean <65 ≥65 
N 2660 2350 
LVIDd/BSA, cm/m2 3.6 3.7^ 
*p=0.062; ^p<0.001   
 
V-HeFT I and 
II(102) 
N= 1446 
 
Mean ≤55 56-60 51-65 >65 
V-HeFT I     
N 185 182 170 105 
EF, % 28 32 31 30* 
V-HeFT II     
N 175 173 231 225 
EF, % 26 29 30 31* 
*p≤0.02     
 
GWTG-HF(69) 
N=57937 
 
 ≤65, 66-77 76-85 >85 
N 16245 12488 18398 10806 
EF (%), median (IQR) 30 (20-50) 36 (25-55) 40 (28-55) 45 (30-60)* 
EF<40% (% total cohort) 56 46 39 29* 
Proportion with LV function 
documented 
93.8 93.1 92.8 89.4* 
*p<0.0001     
 
Italian Network on 
Congestive Heart 
Failure Registry(96) 
% ≤65 66-75 ≥75 
 AF No AF AF No AF AF No AF 
N 683 3578 638 2013 412 854 
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N=8178 EF       
>40% 27 21 35 23 41 34 
30-40% 37 40 42 46 43 44 
<30% 36 39 24 31 16 22 
 
AREA IN-CHF 
study(89) 
N=467  
Median (IQR) <64 ≥64 
N 232 235 
LVEF, % 40 (33-46) 41 (34-45) 
LVEDV (ml/m2) 80 (64-107) 77 (63-100) 
LVESV (ml/m2) 47 (36-67) 47 (37-61) 
LV mass (g) 135 (106-163) 145 (118-167)* 
E/A ratio 0.95 (0.75-1.20) 0.83 (0.67-1.22*) 
Deceleration time (ms) 179 (134-228) 197 (141-257)^ 
*p<0.05; ^p<0.01   
 
Brooklyn heart 
failure clinic(104) 
N=108 
Mean (SD) <60 ≥60 
 Black men Black women Black men Black women 
EF, % 19.8 (1.2) 25.5 (2.0) 26.2 (2.4) 25.2 (2.2) 
LVEDD, cm 7.2 (0.1) 6.2 (0.3) 6.4 (0.2) 6.4 (0.2) 
 
BSA=body surface area; D=Digoxin, EF=ejection fraction; LVEDD=left ventricular end diastolic diameter; LVEDV=left 
ventricular end diastolic volume; LVESV=left ventricular end systolic volume; LViDd=left ventricle internal diameter at 
diastole; LV=left ventricle; P= placebo; SD=standard deviation; WMI=wall motion index.  
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1.8 Renal function, haematological parameters and serum biomarkers in young 
adults with HF 
 
Young adults with HF have lower serum creatinine(14;82;87-
89;91;93;99;103;106;107), urea(14;82;91;93;108), brain natriuretic 
peptide(69;88;89;93;109), but higher haemoglobin,(69;82;99;106;107;109) and glomerular 
filtration rate (Table 1.10).(82;106) No significant different in mean serum sodium and 
potassium across age groups has been documented.(82;93) BNP and NT-pro BNP are 
lower in young adults (<65 years) compared to older patients.(69;88;89) There is no 
significant different in aldosterone level between young and older patients (dichotomised 
at 64 year of age).(89)  
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Table 1.10. Renal function, haematological parameters and serum biomarkers in 
young adults with HF 
 
Study Laboratory results Age 
SHIFT(100)  
N=6505 
Mean (SD) <53 53- <60 60- <69 ≥69 
 n=1522 n=1521 n=1750 n=1712 
Creatinine 
clearance 
(mL/min/1.73kg/
m2) 
87.4 (24.0) 79.0 (21.2) 71.0 (20.4) 63.3 (19.1) 
p<0.0001     
 
DIG study(87) 
N= 7788 
 
% <50 50-59 60-69 70-79 ≥80 
 D P D P D P D P D P 
N 437 404 748 797 1465 1420 1013 1079 226 199 
Cr≥1.7 
mg/dl 
4 6 6 5 13 12 20 20 25 33 
 
CARE HF(82) 
N=813 
 
Median (IQR) <60 60-70 >71 
Haemoglobin (g/dl) 14.0 (13.1 to 15.1) 13.6 (12.6 to 14.8) 13.0 (11.9 to 14.2) 
White blood cell 
count (x 109/L) 
7.5 (6.3 to 9.2) 7.6 (6.3 to 9.0) 7.5 (6.1 to 9.1) 
C reactive protein 
(mg/l) 
6 (1 to 13) 6 (1 to 13) 8 (1 to 17) 
Sodium (mmol/l) 138 (136 to 140) 138 (136 to 141) 139 (137 to 141) 
Potassium (mmol/l) 4.2 (3.9 to 4.6) 4.4 (4.1 to 4.7) 4.5 (4.1 to 4.8) 
Urea (mmol/l) 8.4 (5.9 to 15.0) 11.7 (7.4 to 19.3) 11.8 (8.4 to 18.9) 
Creatinine (µmol/l) 94 (80 to 111) 106 (90 to 133) 118 (99 to 147) 
Glomerular filtration 
rate (ml/min/1.73m2) 
72 (59 to 87) 60 (48 to 71) 49 (40 to 62) 
 
MERIT-HF(85) 
N=3991 
 
Mean (SD) <65 ≥65 
 Placebo Metoprolol 
CR/XL 
Placebo Metoprolol 
CR/XL 
Serum Creatinine, 
ug/L 
100 (28) 100 (27) 113 (37) 115 (37) 
 
CHARM study(99) 
N=7599 
Mean (SD) <50 50-59 60-69 70-79 >80 
Kalaemia (mmol/L) 4.3 (0.5) 4.3 (0.4) 4.4 (0.5) 4.4 (0.5) 4.4 (0.5) 
Haemoglobin (mmol/L) 14.2 (1.5) 13.9 (1.5) 13.6 (1.6) 13.3 (1.6) 13.2 (1.7) 
Creatininemia (mg/dL) 1.1 (1.5) 1.1 (0.4) 1.2 (0.4) 1.3 (0.7) 1.3 (0.5) 
 
IMPROVE HF(93) 
N= 15381 
 
Median (IQR) ≤64 65-76 >76 
Sodium, mEq/L 139 (137-141) 140 (137-142) 140 (138-142) 
BUN, mg/dL 18 (14-25) 22 (17-31) 26 (19-35) 
Creatinine, mg/dL 1.1 (0.9-1.4) 1.2 (1.0-1.6) 1.3 (1.1-1.7) 
BNP, pg/ml 254 (91.3-668.5) 383 (168-871) 546.5 (261-1080) 
All p<0.001    
 
Val-HeFT(91) 
N= 5010 
Mean <65 ≥65 
N 2660 2350 
Serum Creatinine, mg/dL,  1.2 1.4 
Blood urea nitrogen, mg/dL 19.6 24.7 
 
DIG trial (103) 
N=7788 
Mean (SD) <65 ≥65 
N 3752 4036 
Serum Creatinine (mg/dl) 1.2(0.3) 1.4(0.4) 
Serum potassium (mEq/l) 4.3(0.4) 4.4(0.4) 
 
GWTG-HF(69) 
N=57937 
 
Median, IQR ≤65, % 66-77, % 76-85, % >85, % 
Cr (mg/dL) 1.3 (1.0-1.9) 1.4 (1.0-2.0) 1.4 (1.0-1.9) 1.3 (1.0-1.8) 
Hb (g/dL) 12.5 (10.9-
14.1) 
12.0 (10.6-
13.5) 
11.9 (10.5-
13.2) 
11.8 (10.5-
13.1) 
BNP (pg/ml) 814 (384-
1690) 
815 (398-
1650) 
849 (453-
1646) 
872 (468-
1648) 
Troponin (ng/ml) 0.05 (0.03-
0.10) 
0.05 (0.03-
0.11) 
0.05 (0.03-
0.11) 
0.06 (0.03-
0.12) 
 
Italian Network on 
Congestive Heart 
Failure Registry(96) 
N=8178 
% ≤65 66-75 ≥75 
 AF No AF AF No AF AF No AF 
N 683 3578 638 2013 412 854 
Potassium <3.5mEq/l 2.4 1.6 3.7 2.0 4.2 1.4 
Creatinine>2.5mg/dl 1.4 2.1 2.3 3.6 1.8 5.4 
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AREA IN-CHF 
study(89) 
N=467  
Median (IQR) <64 ≥64 
Creatinine (mg/dl) 1.00 (0.90-1.15) 1.10 (0.90-1.30)* 
Creatinine clearance (ml/min) 88 (77-109) 65 (54-81)^ 
Potassium (mmom/l) 4.4 (4.1-4.6) 4.4 (4.1-4.7) 
BNP (pg/ml) 52 (23-129) 116 (62-216)^ 
Aldosterone (pg/ml) 124 (80-191) 113 (70-167) 
*p<0.001; ^p<0.0001   
 
PRIME-II study(88) 
N=311 
 38-62 63-69 70-73 74-80 
Creatinine (µmol/l), 
mean (SD) 
107 (31) 114 (33) 120 (32) 130 (50) 
Natriuretic peptide 
(median [min-max]) 
    
ANP (pmol/l) 88 (12-597) 103 (19-508) 115 (18-720) 105 (28-815) 
NT-ANP (pmol/l) 689 (129-3414) 1066 (256-
3081) 
1151 (239-
4210) 
1148 (344-
3760) 
BNP (pmol/l) 33 (0.6-352) 47 (3-322) 79 (1.4-502) 65 (7.6-373) 
NT-proBNP (pmol/l) 372 (3-2928) 527 (5-3380) 711 (3-5295) 715 (14-4820) 
 
ANP= Atrial Natriuretic Peptide; BNP=B-type Natriuretic Peptide; BUN=blood urea nitrogen; D=Digoxin, 
IQR=interquartile range; NT-ANP=N-terminal Atrial Natriuretic Peptide; NT-proBNP= N-terminal pro B-type 
Natriuretic Peptide; P= placebo; SD=standard deviation; 
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1.9 Baseline medications in young adults with HF 
 
Young adults (<65 years) with HF are more likely to be on a beta-blocker, ACE 
inhibitor or ARB, and aldosterone antagonist (Table 1.11). They are also prescribed higher 
doses of beta-blocker and aldosterone antagonist.(82;100) Younger adults require less 
diuretics and in smaller doses.(33;82;100) The use of digitalis in younger adults is 
conflicting with some older studies reported lower prescription rate,(33;94) but more 
contemporary series reported higher use of digoxin in younger adults.(82;100) 
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Table 1.11. Baseline medications in young adults with HF 
 
Study Medications (%) Age 
SHIFT(100)  
N=6505 
 <53 53- <60 60- <69 ≥69 
N 1522 1521 1750 1712 
Beta blocker (all) 93 92 89 85 
At least half 
target dose 
53 54 48 41 
At target dose 27 26 22 18 
ACE inhibitors 78 81 79 77 
ARB 14 12 15 16 
Diuretics 82 81 84 86 
Antialdosterone 
agents 
68 62 59 54 
Cardiac 
glycosides 
30 23 18 17 
all statistical significant 
 
IMPROVE HF(93) 
N= 15381 
 
 ≤64 65-76 >76 
N 5307 5176 4791 
ACEi/ARB 84 80 73* 
B-blocker 90 86 81* 
Aldosterone 
antagonist 
46 34 27* 
Anticoagulation 71 71 68 
*p<0.001    
 
GWTG-HF(69) 
N=57937 
 
 ≤65, % 66-77, % 76-85, % >85, % 
N 16245 12488 18398 10806 
ACEi/ARB 89 84 82 79* 
Beta-blocker 91 88 88 83* 
Aldosterone 
antagonist 
29 25 21 18* 
*p<0.0001     
 
HF ACTION 
study(84) 
N=2331 
 
 <60 60-69 ≥70 
N 1214 640 477 
ACEi/ARB 96 94 92* 
B-blocker 96 94 91^ 
*p=0.01;^p<0.001    
 
InSync/InSync ICD 
Italian Registry(97) 
N= 1787 
 
 <65 65-74 ≥75 
N 571 740 476 
ACEi/ARB 79 71 70* 
Beta-blocker 60 45 37* 
Digoxin 43 43 45 
Diuretics 87 89 88 
Nitrates 17 23 26* 
Class III 
antiarrhythmic drug 
34 38 34 
*Statistically significant  
 
Taiwan(10) 
N= 2692 
 
 20-64 ≥65 All 
N  567 2125 2692 
ACEi and/or ARB 58 49* 51 
CCB 29 29 29 
Beta blocker 35 23* 25 
Diuretic 74 77 76 
Aspirin 39 42 41 
Clopidogrel 12 13 13 
Digoxin 29 33 32 
Warfarin 7 5* 5 
*Statistically significant  
 
CARE HF(82) 
N=813 
 
 <60 60-70 >71 
N 219 315 277 
Diuretic All 99 99 99 
Loop diuretics 90 95 97 
Proportion taking ≥80mg of furosemide 
or equivalent 
37 46 46 
Thiazide (or related) diuretic 16 18 11 
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Proportion on loop/thiazide 
combination 
11 14 9 
Spironolactone 63 57 50 
Spironolactone at least 25mg daily 60 49 43 
Other diuretics 6 7 4 
ACE inhibitor 85 81 74 
ACE inhibitor at least half target dose 50 38 28 
ARB 13 18 18 
ACEi or ARB 97 96 92 
Beta blockers 84 71 64 
Beta blocker at least half target dose 53 36 34 
Digitalis 49 47 33 
Amiodarone 12 19 19 
Other antiarrhythmic agents 1 0 0 
Nitrate 20 33 40 
Calcium channel blocker 4 4 8 
Insulin 8 14 9 
Oral hypoglycaemic 9 14 9 
Insulin + oral hypoglycaemic 1 2 1 
Statins 39 41 39 
Other lipid lowering 9 6 8 
Anticoagulants 41 36 27 
Aspirin 33 42 55 
Other antiplatelet 4 8 8 
Other NSAIDS 1 2 4 
Allopurinol 16 20 18 
 
Kent, Surrey and 
Sussex Primary Care 
Research 
Network(33) 
N= 2129 
 
 45-54 55-64 65-74 75-84 85+ 
 M W M W M W M W M W 
ACEi 90 82 86 69 82 72 78 75 63 61 
Loop diuretics 65 64 71 71 76 84 84 82 83 83 
Thiazide diuretics 25 27 51 46 51 49 52 57 54 57 
Spironolactone 10 9 21 17 21 17 15 13 14 12 
Digoxin 15 0 37 21 31 25 39 32 31 39 
Aspirin 80 55 72 42 68 60 64 60 68 60 
Lipid lowering 
agents 
55 27 62 33 51 44 29 28 4 7 
 
Spanish national 
survey(110) 
N= 2145 
 
 <65 65-80 >80 
N 226 1038 881 
on admission    
Diuretics 66 69 68 
Spironolactone 18 18 12 
ACEis, low dose 31 32 28 
ACEis, appropriate 
dose 
10 13 9 
Beta-blockers 16 10 5 
Digoxin 28 33 32 
Nitrates 18 26 33 
ARAII 7 7 4 
Anticoagulants 32 31 12 
Amiodarone 5 8 7 
Amlodipine 6 9 6 
on discharge    
Diuretics 86 86 84 
Spironolactone 38 32 25 
ACEis, low dose 36 40 42 
ACEis, appropriate 
dose 
28 23 17 
Beta-blockers 18 8 6 
Digoxin 35 40 38 
Nitrates 27 33 40 
ARAII 7 7 5 
Anticoagulants 41 36 17 
Amiodarone 8 9 8 
Amlodipine 10 9 7 
 
MERIT-HF(85) 
N=3991 
 
 <65  ≥65  
 Placebo Metoprolol 
CR/XL 
Placebo Metoprolol 
CR/XL 
N 1009 1000 992 990 
Diuretics 89 89 91 93 
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ACE inhibitors 91 91 87 87* 
ACE inhibitors 
or AII blocker 
97 97 95 94* 
Digitalis 66 64 62 63 
Aspirin 43 43 49 48* 
Statin 25 24 23 21* 
*Statistically significant 
 
DIAMOND study 
and ECHOS(101)  
N= 8507 
 
 <65 65-74 75-84 ≥85 All 
N 1865 2769 3048 825 8507 
ACEi 64 55 48 38 53 
Beta-blocker 42 35 33 29 35 
Diuretics 85 88 90 89 88 
Digoxin 44 49 48 46 47 
All statistically significant 
 
IMPROVEMENT of 
HF survey(94) 
N=8256 
 
 <65 65-74 75-84 ≥85 All 
 M F M F M F M F M F 
ACEi/ ARB 69 68 72 71 67 68 57 65 69* 69 
Β-blocker 44 35 31 31 23 23 14 12 33* 27* 
ACEi/ ARB and B-
blocker 
30 25 22 23 15 15 8 8 22* 19* 
Loop or thiazides 
diuretics 
61 70 72 79 81 83 88 86 71* 79* 
Spironolactone 11 13 13 13 15 17 16 15 13* 15* 
Digitalis 33 39 41 45 41 48 49 50 38* 45* 
Antiplatelet drug 68 56 64 56 56 54 62 55 63* 56 
Oral anticoagulant 19 16 24 18 23 16 14 7 21 15* 
*Statistically significant 
 
French hospital 
survey(105) 
N=1058 
 
 27-68 68-78 78-86 86-100 
ACE inhibitors 82 67 60 49* 
Diuretics 91 93 92 88^ 
Digitalis 40 39 35 34` 
*p=0.001; ^p=0.3; `p=0.5 
 
DIAMOND 
study(98) 
N= 5419 
 
 <61 61-70 71-80 >80 
N 718 1481 2203 1089 
ACE inhibitor 62 56 50 38* 
Digoxin 49 51 53 55^ 
Beta-blocker 15 15 13 8* 
Diuretics 79 86 86 87* 
*p<0.001; ^p=0.05 
 
DIG study(87) 
N= 7788 
 
 <50 50-59 60-69 70-79 ≥80 
 D P D P D P D P D P 
N 437 404 748 797 1465 1420 1013 1079 226 199 
Diure
tics 
77 75 79 78 79 82 85 86 89 92 
ACEi 94 96 92 96 93 94 94 92 93 91 
D=digoxin; P=placebo. 
 
The Carvedilol Heart 
Failure Registry(95) 
N=4280 
 
 <55 55-64 65-75 >75 
N 806 922 1363 1188 
ACEi 81 79 74 69* 
Diuretic 72 75 77 81* 
Digoxin 59 58 57 56^ 
*p<0.001; ^p=0.300 
 
PRIME-II study(88) 
N=311 
 
 38-62 63-69 70-73 74-80 
N 76 77 67 91 
ACE inhibitors 96 96 97 92 
Diuretics 96 100 99 99 
Digoxin 50 68 63 58 
Anti-arrhythmic 20 21 13 18 
Beta-blockers 12 8 15 8 
 
BEST(92) 
N= 2708 
 
 <65  ≥65  
 Bucindolol Placebo Bucindolol Placebo 
N 821 795 533 559 
ACE inhibitor 93 92 89 89* 
Angiotensin II 
antagonist 
5 7 7 7 
Digitalis 93 93 91 91 
Diuretic 94 93 94 94 
Spironolactone 4 4 2 4 
Vasodilator 42 45 53 52* 
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Hydralazine/Isos
orbide dinitrate 
31 33 39 36* 
Antiarrhythmic 3 2 5 3 
Anticoagulant 45 49 42 41 
Aspirin 41 41 49 51* 
Statin 21 23 25 24 
*Statistically significant 
 
CHARM study(99) 
N=7599 
 <50 50-59 60-69 70-79 >80 
N 605 1474 2351 2474 695 
Beta blocker 64 63 58 50 42* 
Diuretics 77 78 82 85 92* 
ACEi 49 46 44 37 27* 
Spironolactone 19 15 17 17 18 
Anticoagulation 28 29 30 33 30* 
Antiplatelet 51 62 64 60 56* 
Lipid lowering agents 38 47 45 41 23* 
*Statistically significant      
 
Val-HeFT(91) 
N= 5010 
 <65 ≥65 
N 2660 2350 
ACEi 95 90* 
Beta blocker 40 29* 
Diuretics 83 88^ 
Digoxin 68 66 
Calcium channel blocker 11 14* 
Spironolactone 6 4 
*p<0.001,^p=0.001   
 
DIG trial (103) 
N=7788 
 
 <65 ≥65 
N 3752 4036 
ACEi 94 93* 
Hydralazine and nitrates 1 1 
Diuretics 75 81* 
Potassium-sparing diuretics 8 7 
Potassium supplement  27 29* 
*statistically significant   
 
Italian Network on 
Congestive Heart 
Failure Registry(96) 
N=8178 
 ≤65 66-75 ≥75 
 AF No AF AF No AF AF No AF 
N 683 3578 638 2013 412 854 
B-blocker 18 25 11 17 5 8 
ACEi 84 86 77 80 71 74 
Digoxin 89 59 84 57 84 56 
Oral anticoagulant 72 24 58 17 27 9 
Aspirin 13 34 23 43 37 43 
Other antiarrhythmic 29 24 25 26 20 23 
Diuretics 92 78 92 85 90 85 
 
AREA IN-CHF 
study(89) 
N=467  
 <64 ≥64 
N 232 235 
ACEi 79 80 
ARBs 18 18 
ACEi or ARB 96 96 
B-blocker 85 73* 
Furosemide 53 68* 
Thiazides 4 5 
Nitrates 19 34* 
Amiodarone 16 19 
Aspirin 46 49 
Statins 49 41 
Dihydropyridines 5 1 
Calcium antagonist 0 1 
*p<0.01   
 
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; CCB=calcium channel blocker; 
DIG=Digitalis Investigation Group. 
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1.10 Demographic and physiological parameters in young adults with HF 
 
In young adults with HF, there is higher proportion of non-Caucasians in 
randomised clinical trials and registries from North America (Table 1.12). Younger adults 
have higher heart rate and diastolic blood pressure, but a lower systolic blood pressure. 
Young adults also have a higher body mass index (BMI) and a higher proportion of them 
are obese (BMI≥30kg/m2). 
 
1.11 Precipitating factors for HF hospitalisations in young adults with HF 
 
A study from Spain found no difference in precipitating factors for HF 
hospitalisations between those aged 40-74 years, and those aged 75 years and over.(111). 
To date no study has examined patients less than 40 years of age. 
 
1.12 Hospitalisation cost in young adults with HF 
 
Younger patients have a higher hospitalisation cost. Odds ratio for cost was: aged 
19-64 years OR 1.24 (95% CI: 1.18-1.29); aged 65-74 years OR 1.31 (95% CI: 1.25-1.37) 
and aged ≥85 years OR 0.44 (95%CI: 0.41-0.47) with age group 75-84 years as the referent 
group.(112) Younger patients (20-64 years) have higher fees in surgery, anaesthesia, 
haemodialysis, and blood or plasma compared to those aged ≥65 years.(10) With the 
increasing use of cardiac device therapy and ventricular assist device in young adults, the 
cost of managing young adults with HF is increasing.  
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Table 1.12. Demographic and physiological parameters  
 
Study Age 
SHIFT(100)  
N=6505 
Mean (SD) <53 53- <60 60- <69 ≥69 
N 1522 1521 1750 1712 
HR (b.p.m) 81(10) 80.5(10) 80(9) 79(29) 
SBP (mmHg) 118(16) 122(16) 122(16) 124(16) 
DBP (mmHg) 76(10) 77(10) 75(9) 75(9) 
p<0.0001     
 
DIG 
study(87) 
N= 7788 
 
Mean <50 50-59 60-69 70-79 ≥80 
 D P D P D P D P D P 
HR 
(b.p.m) 
81 82 81 82 78 78 77 78 78 78 
SBP 
(mmHg) 
121 122 121 122 128 128 131 130 132 130 
D=Digoxin, P= placebo 
 
BEST(92) 
N= 2708 
 
% or mean(SD) <65  ≥65  
 Bucindolol Placebo Bucindolol Placebo 
N 821 795 533 559 
African-American 28 27 17 16 
Heart rate 84(14) 83(14) 78(12) 78(12) 
SBP 116(18) 116(18) 119(18) 119(18) 
All statistically significant 
 
V-HeFT I 
and II(102) 
N= 1446 
 
Mean ≤55 56-60 51-65 >65 
V-HeFT I     
N 185 182 170 105 
HR (b.p.m.) 85 81 83 79* 
SBP (mmHg) 115 120 120 125* 
DBP (mmHg) 77 76 75 75 
V-HeFT II     
N 175 173 231 225 
HR (b.p.m.) 81 78 78 75* 
SBP (mmHg) 121 125 127 131* 
DBP (mmHg) 80 78 78 75* 
*p≤0.02     
 
Greater 
Worcester 
hospital(113) 
N=3722 
 
% <65 65-74 75-84 ≥85 
BMI (kg/m2)     
<18.5 9 18 33 41 
18.5-24.9 8 18 44 30 
25.0-29.9 14 27 38 21 
30.0-34.9 18 30 38 15 
≥35.0 39 26 27 7 
P<0.001     
 
HF ACTION 
study(84) 
N=2331 
 
% or median(IQR) <60 60-69 ≥70 
Total number 1214 640 477 
Black 42 25 19* 
White 52 69 79* 
Other 6 6 3* 
Weight (kg) 97(79-114) 88(77-102) 82 70-93) 
BMI (kg/m2) 32(27-38) 29(26-33) 27(24-31)* 
HR at rest 72(64-80) 68(62-75) 68(60-75)* 
SBP (mmHg) 110(100-122) 112(102-127) 118(104-130)* 
DBP (mmHg) 70(62-80) 70(60-78) 68(60-76)* 
*p<0.001    
 
MERIT-
HF(85) 
N=3991 
 
 <65  ≥65  
% or mean(SD) Placebo Metoprolol 
CR/XL 
Placebo Metoprolol 
CR/XL 
N 1009 1000 992 990 
Caucasian 92 92 97 96 
SBP (mmHg) 128(16) 129(16) 132(18) 132(18) 
DBP (mmHg) 80(9) 80(9) 77 (9) 77(9) 
HR (b.p.m) 84(10) 84(10) 81 (10) 81(10) 
BMI (kg/m2) 28(5) 28(5) 27(4) 26(4) 
All statistically significant 
 
The % or mean (SD) <55 55-64 65-75 >75 
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Carvedilol 
Heart Failure 
Registry(95) 
N=4280 
 
N 806 922 1363 1188 
Black 22 13 10 8* 
Heart rate 82 (15) 78 (14) 76 (13) 75 (13)* 
SBP 126 (21) 128 (20) 129 (20) 131 (21)* 
DBP 78 (13) 76 (11) 74 (11) 71 (12)* 
*p<0.001     
 
CARE 
HF(82) 
N=813 
 
% or mean SD <60 60-70 >71 
N 219  315  277 
BMI (kg/m2) 28(25-31) 28(24-30) 26(23-29) 
BMI >30, % 31 25 16 
BMI <20, % 4 7 12 
Heart rate (bpm) 70 (60-77) 72 (62-80) 69 (60-78) 
Lying SBP (mmHg) 115 (102-125) 117 (104-129) 121 (110-130) 
Lying DBP (mmHg) 71 (65-80) 71 (60-80) 69 (60-80) 
Standing SBP (mmHg) 112 (100-120) 112 (100-125) 116 (100-126) 
Standing DBP (mmHg) 72 (65-80) 70 (60-80) 68 (60-78) 
 
CHARM 
study(99) 
N=7599 
Mean (SD) <50 50-59 60-69 70-79 >80 
SBP (mmHg) 125 (18) 128 (18) 130 (19) 134 (19) 135 (20) 
DBP (mmHg) 79 (11) 78 (10) 77 (11) 76 (11) 74 (11) 
P<0.001      
 
IMPROVE 
HF(93) 
N= 15381 
 
% or median (IQR) ≤64 65-76 >76 
N 5307 5176 4791 
SBP (mmHg) 120 (107-130) 120 (109-131) 120 (110-132)* 
HR (b.p.m) 72 (65-80) 70 (64-78) 70 (64-77)* 
*p<0.001    
 
Val-
HeFT(91) 
 
N= 5010 
% or mean <65 ≥65 
N 2660 2350 
White 87 94 
SBP (mmHg) 121 127 
DBP (mmHg) 77 74 
Pulse (b.p.m.) 74 73 
All p<0.001   
 
DIG trial 
(103) 
N=7788 
% or mean (SD) <65 ≥65 
N 3752 4036 
Non-white 18 11 
BMI (kg/m2) 28 (6) 26 (5) 
HR (b.p.m) 79 (13) 77 (12) 
SBP (mmHg) 125 (20) 130 (21) 
DBP (mmHg) 76 (11) 74 (11) 
All p<0.0001   
 
GWTG-
HF(69) 
N=57937 
 
%  ≤65 66-77 76-85 >85 
 n= 16245 n= 12488 n= 18398 n= 10806 
Race     
Caucasian 52 70 81 84 
African American 32 16 8 6 
p<0.0001     
 
North 
American 
centers(90) 
N=546 
% or mean (SD) <65 ≥65 
N 328 218 
Caucasian 63 75* 
BMI 31 (7) 27 (5)^ 
*p=0.005; ^p<0.001   
 
AREA IN-
CHF 
study(89) 
N=467  
Median (IQR) <64 ≥64 
N 232 235 
BMI (kg/m2) 27(25-30) 26(24-29)* 
SBP (mmHg) 125(113-138) 130(120-140)* 
DBP (mmHg) 80(70-80) 80(70-80) 
Heart rate (bpm) 65(60-72) 66 (60-75) 
*p<0.01   
 
Brooklyn 
heart failure 
clinic(104) 
N=108 
Mean (SD) <60 ≥60 
 Black men Black women Black men Black women 
BMI (kg/m2) 33(2) 30(2) 26(1) 27(2) 
 
PRIME-II 
study(88) 
N=311 
 
Mean (SD) 38-62 63-69 70-73 74-80 
N 76 77 67 91 
SBP (mmHg) 125(18) 123(17) 123(19) 126(18) 
DBP (mmHg) 73(8) 75(9) 75(10) 76(9) 
Heart rate (bpm) 81(17) 81(15) 81(15) 81(14) 
 
DIAMOND 
study and 
Mean <65 65-74 75-84 ≥85 All 
N 1865 2769 3048 825 8507 
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ECHOS(101)  
N= 8507 
BMI (kg/m2) 28 26 25 24 26 
p<0.0001      
 
BMI=body mass index; b.p.m=beats per minute; DBP=diastolic blood pressure; HR=heart rate; IQR=interquartile range; 
SBP=systolic blood pressure; SD=standard deviation; 
	 76	
1.13 Prevalence of venous thrombo-embolism in young adults with HF 
 
Young adults (<40 years) who were hospitalised with HF have the highest 
prevalence of documented pulmonary embolism (1.15% in <40 years, 1.01% in 40-59 
years, 0.82% in 60-79 years, and 0.69% in >80 years) and deep vein thrombosis (1.68% in 
< 40 years, 1.33% in 40-59 years, 1.10% in 60-79 years, and 1.24% in >80 years) and 
decreases with age.(114)  
 
1.14 Quality of life in young adults with HF 
 
Compared to older patients, younger adults (<65 years) with HF have a worse 
quality of life (QOL) in both emotional and physical components of the Minnesota Living 
with Heart Failure (MLwHF) Questionnaire (Table 1.13).(91;115-117) Studies using other 
methods of assessing QOL reported similar findings.(82;90) Younger adults (<65 years) 
with HF have poorer mental and general health when measured using Short-Form (36) 
Health Survey.(117) 
  
1.15 HF Education in young adults with HF 
 
Younger adults with HF are more likely to receive HF education (66.2% in ≤64 
years, 60.6% in 65-76 years and 57.3% in >76 years, p<0.0001).(93)  
 
1.16 Influenza immunisation in young adults with HF 
 
In contrast to most HF interventions, influenza immunisation rates are lower in 
younger adults with HF.(33) In one study conducted in Kent, Surrey, and Sussex using the 
primary care research network, 60% and 70% of patients aged 45-54 and 55-64 years had 
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influenza immunisation in comparison 84.8%, 88.6%, and 92.3% of patients aged 65-74, 
75-84, and ≥85 years, respectively.(33)  
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Table 1.13. Quality of life in young adults with HF 
 
Study Quality of life 
Urban county hospital 
outpatient clinics(116) 
N= 165 
 
Mean (SD) Men, <65 Men, ≥65 Women, <65 Women, ≥65 
Chronic heart 
failure 
questionnaire 
    
Total scale 4.3 (0.14) 5.1 (0.31) 3.6 (0.14) 4.3 (0.22) 
Dyspnoea 4.3 (0.17) 5.4 (0.38) 3.9 (0.19) 4.3 (0.26) 
Fatigue 3.8 (0.16) 4.2 (0.41) 3.2 (0.17) 3.8 (0.27) 
Emotional 4.6 (0.15) 5.4 (0.31) 3.8 (0.16) 4.6 (0.22) 
Living with 
heart failure 
questionnaire 
    
Total scale 40.9 (3.2) 30.0 (5.5) 51.4 (3.8) 38.3 (4.8) 
Physical  18.5 (1.5) 15.6 (2.8) 23.0 (1.7) 18.3 (2.3) 
Emotional 8.9 (0.9) 4.4 (1.1) 12.2 (1.2) 9.1 (1.4) 
 
Outpatient academic HF 
practice, Baltimore, 
Maryland(117) 
N=155 
 
Mean (SD) ≤64 >64 p value 
SF-36 subscale    
Physical functioning 31.8 (11.9) 32.4 (1.4) 0.74 
Role-physical 34.8 (11.4) 35.0 (1.3) 0.90 
Bodily pain 40.4 (12.5) 45.5 (1.4) 0.015 
General health 33.2 (11.3) 36.9 (1.4) 0.053 
Vitality 42.9 (11.7) 45.7 (1.4) 0.15 
Social functioning 39.7 (13.2) 42.9 (1.6) 0.15 
Role-emotional 38.9 (13.3) 41.1 (1.6) 0.32 
Mental health 44.6 (15.0) 50.2 (1.4) 0.014 
MLwHF scale    
Total 46.0 (27.72) 32.7 (24.0) 0.0002 
Emotional component 8.9 (8.0) 6.1 (6.5) 0.022 
Physical component 20.1 (12.6) 15.6 (14.4) 0.042 
 
Val-HeFT(91) 
N= 5010 
Mean <65 ≥65 
 N= 2660 N= 2350 
MLHFQ overall score 35.7 28.7 
 
North American centers(90) 
N=546 
Mean (SD) <65 ≥65 
N 328 218 
KCCQ HRQL Score 54 (28) 60 (25) 
 
A-HeFT(118) 
N=1050 
Mean (SD) <65 ≥65 
MLHFQ overall score 55.0 (20.8) 41.0 (19.0) 
 
HRQL=health related quality of life; KCCQ=Kansas City Cardiomyopathy Questionnaire; MLwHF=Minnesota Living 
with Heart Failure Questionnaire; SD=standard deviation 
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1.17 Pharmacological treatment of HF in young adults with HF 
 
1.17.1 Angiotensin-neprilysin inhibitor 
 
 The effect of angiotensin-neprilysin inhibitor on mortality and morbidity 
(dichotomised at 65 years of age) were independent of age.(119;120)  
 
1.17.2 Angiotensin Converting Enzyme Inhibitor 
 
Landmark trials including the effects of enalapril on mortality in severe congestive 
heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study 
(CONSENSUS),(121) the Results of the Treatment Trial of the Studies of Left Ventricular 
Dysfunction (SOLVD),(122) and the effect of enalapril on mortality and the development 
of heart failure in asymptomatic patients with reduced left ventricular ejection fractions 
trial,(123) did not report age interaction.  
 
1.17.3 Beta-Blocker 
 
In the Metoprolol CR/XL Randomised Intervention Trial in Chronic Heart Failure 
(MERIT-HF) trial, the effects of metoprolol CR/XL on all-cause mortality, all-cause 
mortality or all-cause hospitalisation, and sudden death were independent of age 
(dichotomised at 65 years of age).(85) Similarly, the effects of carvedilol on mortality in 
the effect of carvedilol on morbidity and mortality of patients with chronic heart failure: 
the U.S. Carvedilol Heart Failure Study Group trial (dichotomised at 59 years), the 
mortality of patients with severe chronic heart failure: Results of the Carvedilol 
Prospective Randomized Cumulative Survival (COPERNICUS) study (dichotomised at 65 
years of age), were also independent of age.(124;125) 
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1.17.4 Angiotensin receptor blocker 
 
The effects of valsartan, losartan, and candesartan on mortality and morbidity 
outcomes in patients with HF are independent of age. The Valsartan Heart Failure Trial 
(Val-HeFT)(126), and the Heart failure Endpoint evaluation of Angiotensin II Antagonist 
Losartan (HEAAL) study dichotomised at 65 years (127), and the CHARM programme 
stratified patients into 5 age groups (<50, 50-59, 60-69, 70-79, and ≥80 years)(99), did not 
show any interaction between age and outcomes. 
 
1.17.5 Mineralocorticoid Receptor Antagonist 
 
The effects of spironolactone and eplerenone on all-cause mortality are independent 
of age. The Randomised ALdactone Evaluation Study (RALES) dichotomised at 67 years 
(128), and the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart 
Failure (EMPHASIS-HF) dichotomised at <65 years (129), showed the benefits of 
spironolactone and eplerenone were independent of age.  
 
1.17.6 Ivabradine/ Digoxin 
 
In a post-hoc analysis from the Systolic Heart failure treatment with the If inhibitor 
ivabradine Trial (SHIFT), there was significant interaction between age groups (<53, 53-
<60, 60-<69, and ≥69 years) and primary end point (cardiovascular death or hospital 
admission for worsening heart failure) [p for interaction= 0.038], as well as secondary end 
points of hospital admission for worsening heart failure [p for interaction= 0.019] and heart 
failure death [p for interaction= 0.013].(100) Patients aged <53 years benefited more from 
the treatment of ivabradine.  
 
There was no interaction between age and the treatment with digoxin on the 
composite end point in the DIG study.(87)  
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1.17.7 Hydralazine and Isosorbide Dinitrate  
 
The benefits of hydralazine and Isosorbide dinitrate on survival did not have any 
significant age interaction.(102)  
 
1.18 Device therapies of HF and heart transplantation in young adults with HF 
 
1.18.1 Implantable Cardioverter Defibrillator (ICD)/ Cardiac Resynchronisation 
Therapy (CRT) 
 
In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) comparing ICD 
group with placebo showed younger patients <65 years of age had more to gain from ICD 
therapy [HR for all-cause mortality 0.68(0.50-.93) in <65 years vs. HR 0.86(0.62-1.18) in 
>65 years].(130) In the Multicenter Automatic Defibrillator Implantation Trial II (MADIT 
II), the benefits of ICD in reducing all-cause mortality were independent of age.(131) 
 
The Multicenter InSync Randomised Clinical Evaluation (MIRACLE) and the 
Multicenter InSync ICD Randomised Clinical Evaluation (MIRACLE-ICD) trials enrolled 
patients with NYHA class III/IV, ejection fraction ≤35% and QRS duration of ≥130msec 
and stratified them into three age groups (<65 years, 65-75 years, and >75 years) reported 
the effects of CRT on the improvement of NYHA functional class and left ventricular 
ejection fraction were independent of age.(132)  
 
The effects of CRT on morbidity and mortality were independent of age in the 
Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure 
(COMPANION) trial(133), the Multicenter Automatic Defibrillator Implantation Trial 
with Cardiac Resynchronisation Therapy (MADIT-CRT)(134), the Resynchronisation-
Defibrillation for Ambulatory Heart Failure Trial (RAFT)(135), the Cardiac 
Resynchronisation-Heart Failure (CARE-HF) study(82), the CARE-HF extension phase 
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study,(136), and the REsynchronisation reVErses Remodelling in Systolic left vEntricular 
dysfunction (REVERSE) study(137). 
 
Younger patients are more likely to have CRT (≤65 years: 2.1% vs. >85 years: 
0.6%, p<0.0001) and implantable cardioverter defibrillator (≤65 years: 5.5% vs. >85 years: 
0.4%, p<0.0001) during their incident HF hospitalisation.(69) The use of ICD and/or CRT-
D are higher in younger patients (ICD or CRT therapy: 51.8% in ≤64 years, 56.5% in 65-
76 years and 43.0% in >76 years, p<0.001).(93) 
 
1.18.2 Ventricular Assist Devices (VAD) 
 
The Randomised Evaluation of Mechanical Assistance for the Treatment of 
Congestive Heart failure (REMATCH) study randomised 129 patients with end-stage HF 
who were ineligible for cardiac transplantation to implantation of a left ventricular assist 
device (LVAD) or optimal medical management.(138) LVAD reduced the risk of all-cause 
mortality. Subgroup analysis by age stratification (18-59 years, 60-69 years and ≥70 years) 
showed a significant reduction in the risk of death in patients aged 60-69 years with a 
LVAD compared to medical therapy (RR 0.49, 95%CI: 0.25-0.95). In the younger patients 
aged 18-59 years (RR 0.47, 95%CI: 0.17-1.28) and older patients aged ≥70 years (RR 0.59, 
95%CI: 0.31-1.15), there were a trend towards lower risk death.  
 
In the 6th INTERMACS annual report, patients aged <50 and 50-64 years have a 
better survival after continuous flow VAD implantations compared to those aged ≥65 
years.(139)  
 
1.18.3 Heart transplantation  
 
Heart transplantation should be considered in patients aged ≤70 years with end-
stage HF.(140;141) Although age is strictly not a contraindication to heart transplantation, 
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very few patients in the UK are transplanted above the age of 65 years.(7) A pragmatic age 
restriction to patients under 65 to 70 years has been justified for two reasons: 1) limited 
donor pool, and 2) increasing mortality with increasing age.(142)  
In 2006-2012, 16% and 45% of those who had a cardiac transplantation were aged 
18-39 and 40-59 years, respectively.(143) Cardiomyopathy remains as the main diagnosis 
for heart transplant up to age 59 years (74% in 18-39 years, 55% in 40-59 years, 40% in 
60-69 years, and 37% in ≥70 years; p<0.0001). Patients aged 18-39 years were most likely 
to be hospitalised at time of transplant (18-39 vs. ≥70 years: 51% vs. 40%; p<0.0001), be 
on intravenous inotropes (46% vs. 40%; p=0.0083), and supported by left ventricular assist 
device (30% vs. 18%; p<0.0001), right ventricular assist device (5.7% vs. 1.3%; 
p<0.0001), total artificial heart (1.1% vs. 0.0%; p=0.0140), or extracorporeal membrane 
oxygenation (2.1% vs. 0.0%; p<0.0001). Median survival is also highest in young adults 
aged 18-39 years (12.6 years in 18-39 years, 10.7 years in 40-59 years, 9.1 years in 60-69 
years, and 8.2 years in ≥70 years). Young adults aged 18-39 years are more likely to die of 
cardiac allograft vasculopathy, acute rejection, graft failure, but less likely to die of 
malignancy, infection, multi-organ failure, or renal failure.(143)  
 
 1.19 Conclusion 
 
The incidence and prevalence of HF in younger adults is lower compared to older 
age group. Unlike the older age groups where the incidence of HF continues to decline, the 
incidence in younger adults remains static with some studies suggesting that it is on the 
rise. Little is known about the incidence and prevalence of HF in young adults outside 
Europe and the North America. Mortality and HF hospitalisation in younger adults have 
seen little change in recent decade. Aetiology and co-morbidities of HF in young adults are 
poorly understood. Clinical presentation is also different in young adults. Further research 
of HF in young adults may help to understand and manage them better.  
  
	 84	
1.20 Aim of the thesis 
 
 Review of the literature demonstrated the lack of data in younger adults with HF 
especially those <40 years of age. Limited contemporary studies reported incidence of HF 
and trends in young adults with HF. Using a large linked hospital, outpatient and 
emergency department administrative database, I aim to explore the incidence of HF and 
its trends in young adults with HF.  
 
Similarly, no contemporary studies reported long-term mortality in young adults 
with HF. I aim to examine the long-term mortality and its trend in young adults with HF 
using a primary care and a secondary care linked hospital, outpatient and emergency 
department administrative databases.  
 
The understanding of how young adults with HF present with decompensated HF is 
also lacking. I aim to explore this using a randomised clinic trial dataset with detail 
documentation of patients’ symptoms and signs of HF and the precipitating factors leading 
to their HF hospitalisations.  
 
Along with examining how young adults with decompensated HF present to 
hospital, I will also explore what happen following their discharge from hospital using a 
linked hospital, outpatient and emergency department administrative database. The linked 
dataset allows me to examine how young adults with HF interact between outpatient clinic 
or emergency department and hospital admission.  
 
In summary, the aim of the thesis is to examine the characteristics of young adults 
with HF and their short and long term outcomes in a variety of different HF populations: a 
randomised clinical trial population; a meta-analysis consisted of patients from large HF 
registries, observation studies, and randomised trials; a primary care database which is the 
largest in the world; and a hospital administrative database with linked hospital, outpatient 
clinics, and emergency department databases. 
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1.21 Objectives 
 
In the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity 
programme (CHARM) study,  
• To describe the baseline characteristics of patients with HF by age 
• To examine the aetiology of HF by age 
• To describe the symptoms and signs of HF by age 
• To examine the differences in electrocardiograph and chest radiograph by age 
• To describe the quality of life measured by Minnesota Living with HF score by age 
• To determine the HF hospitalisation rates by age 
• To determine the mortality rates of patients with HF in a clinical trial 
In the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) study,  
• To describe the baseline characteristics of patients with HF by age 
• To examine the aetiology of HF by age 
• To determine the prognosis of HF by age and ejection fraction in clinical trials and 
observational studies 
In the U.K. Clinical Practice Research Datalink (CPRD) study,  
• To describe the baseline characteristics of patients with HF by age 
• To examine the prescription rates of HF medications by age 
• To determine the mortality rates by age and by year  
In the Alberta Ministry of Health and Wellness database,  
• To describe the baseline characteristics of patients with HF by age 
• To determine the incidence of first HF hospitalisation by age  
• To determine the non-fatal outcomes following index HF hospitalisation 
• To determine the mortality rate by age 
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Chapter 2 
 
Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 87	
2.1  Introduction 
 
The methods of each study are described in each individual chapter in detail. The 
following describe the statistical tests that are common to all the chapters. 
 
2.2  Analysis of Variance 
 
The one-way analysis of variance is used to compare means from three or more 
categories. It is based on variability between the group means. The ‘between group 
variance’ is the variability between the group means, and the ‘residual variance’ is the 
variability not due to the differences between the group. The ratio of the two variance 
is the F ratio, which follows the F distribution. The F ratio corresponds to the P value. 
P <0.05 is indicating the group means are different from each other.  
 
The test has two assumptions. Firstly, the continuous data are normally distributed 
within each group. The second, each group must have equal variance (standard 
deviation). Data were assessed to ensure that these assumptions were not violated.  
 
2.3  Chi-squared test 
 
The chi-squared test is a test to determine if there is an association between 
categorical variables. The test calculates the frequencies that would be expected if there 
were no association, and compares them to the observed numbers in each category in 
the table. If the observed numbers are significantly different to the expected numbers, 
this suggests there is an association. The greater the difference, the larger the chi-
squared value. It then gives a P value based on the chi squared distribution formula 
with n degree of freedom where n is given by (number of rows -1) x (number of 
columns-1).  
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The test requires large sample size and less than 20% of the expected frequencies to 
be less than 5 and none less than 1. If that assumption does not hold, Fisher’s exact test 
should be used. The test is also only valid if actual numbers are applied to the various 
categories and not proportions. The chi-squared test was therefore used to compare 
categorical variables except when the above assumptions were violated and a Fisher’s 
exact test was used.  
 
2.4  Cox regression 
 
Cox regression, also known as proportional hazards regression, is commonly used 
to analyse survival time data in medical research. It also allows assessment of the 
effects of various predictor variables on the time-to-event outcomes. The predictor 
variables can be continuous, binary, or categorical data. A regression coefficient is 
given to represent the relationship between each predictor variable and the time-to-
event outcome, after adjusting for all other variables in the model.  
 
2.5  Kaplan-Meier curves 
 
Kaplan-Meier curves display probabilities of survival over length of time on a 
graph. The x-axis is the length of survival time, and the y-axis is the cumulative 
probability of survival. The curve is stepped due to the occurrence of an event e.g. 
death.  
 
2.6  Logrank test 
 
Survival curves which consist of two groups or more on one graph require a 
statistical method that will compare the entire curve for each category. This can be 
done with the logrank test by utilising all the survival data from the entire curve. It is 
only a significance test giving a P value but not mortality estimate.  
 
2.7  Statistical software  
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Analyses were performed using SPSS version 22 unless otherwise stated.  
 
2.8  Statistical significance 
 
P value of less than 0.05 is considered statistically significant unless specified 
otherwise.  
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Chapter 3 
 
Clinical characteristics and outcomes of young and very young 
adults with heart failure: the CHARM programme. 
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3.1 Introduction 
 
Because HF predominantly affects the elderly, most reports have appropriately 
focused on older patients.(144-146) However, HF also afflicts younger individuals, 
although little is known about the characteristics of these patients and their outcomes. 
Existing studies have largely defined “younger” as age less than 65 or 60 years, probably 
because most studies have small numbers of adults in the third to sixth decades of 
life.(85;94;101) As a result, there are few data describing the symptom burden, quality of 
life and hospitalisation and mortality rates in HF patients aged 20 to 60 years even though 
it is in these individuals where estimates of prognosis may be most keenly sought by 
patients and their families. Additionally and related to the latter, it is in younger patients 
that the most invasive and expensive therapeutic interventions are most commonly 
considered.(147;148) Consequently, knowledge of the causes, characteristics and 
consequences of HF in young patients is clinically important. We therefore analysed the 
Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity 
programme (CHARM) database to provide a comprehensive description of heart failure in 
younger patients, comparing these individuals with older participants.  
 
The CHARM programme enrolled a broad spectrum of patients with chronic heart 
failure who were 18 years or older. Detailed information was collected on symptoms, 
signs, quality of life, treatment, precipitants of hospitalisation and non-fatal and fatal 
outcomes. 
 
3.2 Methods 
 
3.2.1 Study design 
 
The rationale, design, and baseline characteristics of patients in the CHARM 
programme and the primary analyses have been published in detail elsewhere.(149-154) 
The study was designed to assess the role of candesartan in managing a wide spectrum of 
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patients with HF. From the outset, the investigators were determined to enrol a wide 
representative population of patients with symptomatic HF. Among the wide spectrum of 
patients with HF, the use of candesartan was assessed in three distinct, parallel and linked 
populations to assess its impact on cardiovascular mortality and HF hospitalisation. Each 
arm of the study had the statistical power to detect an impact on cardiovascular mortality 
and HF hospitalisations.  
 
Patients with symptomatic HF (New York Heart Association [NYHA] class II-IV) 
for at least 4 weeks duration who were 18 years or older receiving standard therapy (beta-
blockers, diuretics, digitalis and spironolactone) were enrolled into one of three parallel 
clinical trials according to left ventricular ejection fraction (LVEF) and angiotensin 
converting enzyme inhibitor (ACEI) treatment: LVEF ≤ 40% and not receiving an ACEI 
due to previous intolerance (CHARM-Alternative); LVEF ≤ 40% receiving ACEI 
treatment (CHARM-Added), and LVEF > 40% (CHARM-Preserved). The overall 
CHARM programme was designed to have adequate statistical power to assess the impact 
of candesartan on reducing mortality in the overall population of all three parallel studies. 
Exclusion criteria included serum creatinine ≥ 265 µmol/L or more, serum potassium 5.5 
mmol/L or more, known bilateral renal artery stenosis, symptomatic hypotension, women 
of child bearing age potentially not using adequate contraception, critical aortic and mitral 
stenosis, myocardial infarction, stroke, or open-heart surgery in the previous 4 weeks, use 
of angiotensin-receptor blocker in the previous 2 weeks, any non-cardiac disease judged 
likely to limit 2-year survival, and unwillingness to consent. All participating centers 
received approval from local ethnics committees and all patients gave written consent prior 
to enrolment. 
 
 Between March 1999 and March 2001, 7599 patients (3803 candesartan, 3796 
placebo) were randomised to candesartan 4 or 8 mg once daily or matching placebo. The 
dosage was doubled every two weeks, as tolerated to a target dose of 32mg once daily, 
with recommended monitoring of blood pressure and serum potassium and creatinine. 
Visits were scheduled for every 4 months for a minimum duration of 2 years after the 
initial dose titration. The programme was concluded, as planned, 2 years after the final 
patient was randomised, with a median duration of follow-up of 37.7 months. 
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The present analysis groups patients into five age categories: 20-39 (n=120), 40-49 
(n=538), 50-59 (n=1527), 60-69 (n=2395), and ≥70 years (n=3019). The investigator-
reported primary aetiology of HF was systematically collected using case report form 
(CRF) which consisted of eight options (ischemic heart disease, idiopathic dilated 
cardiomyopathy, hypertension, valvular heart disease diabetes mellitus, alcohol-related, 
atrial fibrillation and others). Adherence to study drug was assessed at each follow up visit. 
At each visit investigators assessed adherence based on patient’s report, investigators 
inspection of pill bottles and a table count in cases of uncertainty. The investigators were 
asked to make an estimate of compliance with study drug by selecting one of the pre-
defined categories (>80%, 20-80%, and <20% adherence) on the CRF. We calculated 
adherence as ([the number of visit when pills were taken as prescribed >80% of the time 
divided by the number of visits actually made] x100).(155) Patients recruited at the 243 
sites in the United States and Canada were prospectively asked to participate in the 
CHARM health-related quality of life (HRQL) study. Enrolled patients completed the 
Minnesota Living with Heart Failure (MLwHF) questionnaire at baseline. The 
questionnaire contains 21 disease specific items with a score for each item ranging from 0 
to 5 and a summary score of 0 to 105 (higher score represents worse quality of life). Data 
regarding acute episodes of decompensation after randomization were prospectively 
collected by using a specifically designed endpoint form documenting evidence of 
worsening HF, precipitating or aggravating factors, and intravenous treatment.  
 
3.2.2 Statistical analysis 
 
Baseline characteristics are reported as means and standard deviations for 
continuous variables and proportions for categorical variables. Variables were compared 
across age categories using ANOVA for continuous variables and Chi-square or Fisher’s 
exact test for categorical variables. A conservative significance level of p<0.0001 was 
adopted for the comparison of baseline characteristics given the retrospective nature of the 
study and the multiple comparisons made. All-cause mortality (the primary endpoint of the 
overall programme), the composite endpoint of cardiovascular death or HF hospitalisation 
(the primary outcome of the three component trials), and the secondary pre-specified 
	 94	
endpoints were analysed by age group. Kaplan-Meier survival curves were plotted by age 
category, and event free survival estimated at one, two and three years. Cox’s proportional 
hazard models were used to estimate the hazard of younger age compared with the age 
group 60-69 year as the referent category, adjusted for the previously published predictors 
of mortality and morbidity specific to each endpoint in the CHARM trial.(156) These 
predictors were age, diabetes: insulin-treated, diabetes: other, ejection fraction (per 5% 
decrease below 45%), previous HF hospitalisation, cardiomegaly, diagnosis of chronic HF 
over 2 years ago, NYHA class III, NYHA class IV, and diastolic blood pressure for 
cardiovascular death or HF hospitalisation; and age, ejection fraction (per 5% decrease 
below 45%), diabetes: insulin-treated, diabetes: other, BMI (per 1 kg/m2 decreased below 
27.5), female, NYHA class III, NYHA IV, current smoker, and bundle branch block for all 
cause mortality. For the survival analyses and multivariable models a conventional level of 
significance was used (p<0.05) and results presented with 95% confidence intervals. 
 
3.3 Results 
 
3.3.1 Demography, aetiology, and ejection fraction 
 
Baseline characteristics stratified by age are presented in Table 3.1. There were 
120, 538, 1527, 2395, and 3019 in age groups 20-39, 40-49, 50-59, 60-69, and ≥70 years, 
respectively. Younger patients were less often of European origin (youngest vs. oldest: 
73% vs. 95%, p<0.0001) but more often of Black ethnicity (18% vs. 2%, p<0.0001), had a 
higher body mass index (29.8 kg/m2 vs. 27.0 kg/m2, p<0.0001) and were more likely to be 
obese (body mass index ≥35kg/m2: 23% vs. 6%, p<0.0001). All age groups were 
predominantly male with the proportion of females increasing with age especially in the 
oldest age group (71%, 77%, 76%, 71% and 61% male in age groups 20-39 years, 40-49 
years, 50-59 years, 60-69 years and ≥70 years respectively, p<0.0001) (Figure 3.1). 
 
In the youngest age group, the commonest investigator-reported aetiology of HF 
was idiopathic dilated cardiomyopathy (IDCM), followed by a presumed ischemic 
aetiology and hypertension. The proportion of patients with a presumed ischemic and 
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hypertensive aetiology increased progressively with age: ischemic from 15% to 66% and 
hypertensive from 5% to 15%, comparing youngest and oldest, respectively (p<0.0001). 
The relative proportion of patients with IDCM declined with age, from 62% in those age 
20-39 years to 9% ≥70 years (p<0.0001). Alcohol-related HF was more common in the 
youngest than in the oldest age group (3% vs. 0%, p<0.0001). 
 
The mean EF was lowest in the youngest age group and increased steadily with age 
(34%, 37%, 38%, 38% and 40% in age group 20-39 years, 40-49 years, 50-59 years, 60-69 
years and ≥70 years respectively; p<0.0001). Across the same age bands the prevalence of 
heart failure with reduced ejection fraction (HF-REF) [LVEF≤40%] was greatest in young 
patients and declined with age (70%, 66%, 64%, 63% and 55% respectively; p<0.0001) 
(Table 3.1; Figure 3.2). 
 
3.3.2 Comorbidities 
 
Myocardial infarction, angina, stroke, hypertension, diabetes, atrial fibrillation, 
previous coronary revascularisation and a pacemaker were less common in younger 
patients and increased in prevalence with advancing age (all p<0.0001) (Table 3.1). The 
prevalence of a prior HF hospitalisation was similar in all age categories likely reflecting 
the inclusion criteria in CHARM Added (patients in NYHA class II required 
hospitalisation for a cardiac condition within the past 6 months) and CHARM Preserved 
(patients required prior hospitalisation for a cardiac condition at any time). The prevalence 
of smoking peaked in the age-group 40-49 years (30%) and declined thereafter (8% in the 
elderly). 
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Table 3.1. Baseline characteristics stratified by age 
	
Age Groups 20-39 
n=120 
40-49 
n=538 
50-59 
n=1527 
60-69 
n=2395 
≥70 
n=3019 
P value 
Male 71 77 76 71 61 <0.0001 
Ethnicity European 73 82 86 91 95 <0.0001 
Ethnicity Black 18 10 6 4 2 <0.0001 
Body mass index (kg/m2) 29.8 (7.3) 30.7 (6.6) 29.6 (5.9) 28.4 (5.1) 27.0 (4.7) <0.0001 
Body mass index (kg/m2)       
<22.5 13 7 8 10 16 <0.0001 
22.5-24.9 13 10 12 17 21  
25.0-29.9 37 35 38 42 41  
30.0-34.9 15 27 26 22 17  
≥35.0 23 21 16 10 6  
HF-REF vs. HF-PEF       
Ejection fraction (%) 34 (14) 37 (14) 38 (14) 38 (15) 40 (15) <0.0001 
HF-REF [EF≤40%] 70 66 64 63 55 <0.0001 
HF-PEF [EF>40%]  30 34 36 37 45 <0.0001 
Primary aetiology (%)       
Ischemic heart disease. 15 45 58 65 66 <0.0001 
Idiopathic dilated cardiomyopathy 62 35 24 17 9 <0.0001 
Hypertension 5 12 11 12 15 <0.0001 
Valvular Heart Disease 3 2 1 2 3 0.001 
Alcohol-related 3 2 2 1 0 <0.0001 
Atrial Fibrillation 1 1 2 2 3 <0.0001 
Medical History (%)       
Prior HF hospitalisation 83 71 71 71 71 0.257 
Myocardial infarction 16 43 51 55 55 <0.0001 
Angina (present) 5 19 24 25 24 <0.0001 
Stroke 3 6 6 9 11 <0.0001 
Hypertension 26 48 52 56 58 <0.0001 
Diabetes Mellitus 15 24 30 32 26 <0.0001 
Atrial Fibrillation 13 13 19 26 36 <0.0001 
CABG 4 14 21 27 25 <0.0001 
PCI 8 19 20 17 14 <0.0001 
Permanent pacemaker 3 4 5 7 12 <0.0001 
Current smoker 26 30 23 15 8 <0.0001 
Medications (%)       
ACE inhibitor 53 48 47 43 35 <0.0001 
Beta-blocker 62 63 63 57 48 <0.0001 
Spironolactone 20 19 15 17 17 0.097 
Digitalis 64 46 43 43 42 <0.0001 
Diuretics 80 77 78 82 87 <0.0001 
Medications [EF≤40%] (%)       
ACE inhibitor 69 64 62 57 49 <0.0001 
Beta-blocker 66 63 63 56 48 <0.0001 
Spironolactone 27 24 19 21 19 0.073 
Digitalis 71 58 54 53 50 <0.0001 
Diuretics 82 85 85 88 91 <0.0001 
Adherence measure (%)       
Adherence to study drug 80 87 89 90 88 0.001 
ACE=angiotensin converting enzyme; CABG=coronary artery bypass grafting; HF=heart failure; 
PCI=percutaneous coronary intervention; PEF=preserved ejection fraction; REF=reduced ejection fraction; 
SD=standard deviation. 
Values are given as mean (standard deviation) or as percentage (%) 
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Figure 3.1. Distribution by age and sex 
 
 
Figure 3.2. Histogram for HF-REF and HF-PEF by age 
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3.3.3 Symptoms and signs 
 
The association between age and present symptoms (i.e. at randomisation) was 
inconsistent. (Table 3.2)  In youngest patients, dyspnoea on level ground was less frequent 
(45% <40 years vs. 68% in ≥70 years, p<0.0001), yet PND was more prevalent (22% <40 
years vs. 12% ≥70 years, p=0.001). The prevalence of rest dyspnoea, dyspnoea on 
climbing and orthopnoea was similar across all age categories. The youngest patients 
reported the worst quality of life scores, which improved with increasing age (mean 
MLwHF scores 52.6, 50.8, 47.1, 38.9 and 35.3 in age group 20-39, 40-49, 50-59, 60-69 
and ≥70 years respectively; P<0.0001). 
 
Past signs and present signs (i.e. reported prior to and at the time of randomisation) 
were consistent.  The prevalence of JVP elevation was similar across age categories. A S3 
gallop and hepatomegaly were more common in younger patients. Comparing youngest 
against oldest: S3 gallop 46% vs. 20% previously and 31% vs. 11% at randomisation; 
hepatomegaly 28% vs. 14% previously and 10% vs. 7% at randomisation (all p<0.0001). 
By contrast, signs of fluid extravasation (peripheral oedema and basilar pulmonary 
crackles) were less common in the younger patients. Systolic blood pressure was lowest 
and mean heart rate highest in younger patients (121 vs. 134 mmHg and 78 vs. 72 
beats/min comparing <40 years against ≥70 years respectively, p<0.0001).  
 
3.3.4 Investigations 
 
A normal ECG was uncommon irrespective of age (9% vs. 8% youngest vs. oldest). 
(Table 3.3) Specific abnormalities were significantly less common in younger patients and 
increased with age, including atrial fibrillation or flutter (4% vs. 20%), bundle branch 
block (22% vs. 26%), paced rhythm (1% vs. 10%) and pathological Q waves (10% vs. 
23%) (all p<0.0001). The exception was left ventricular hypertrophy, which occurred most 
frequently in the youngest age group (24% vs. 15%, p=0.032).  
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Radiological changes at randomisation were uncommon. Previous radiological 
abnormalities, however, exhibited a similar pattern to clinical signs (Table 3.3). 
Cardiomegaly was more common and fluid extravasation was less common in the young 
(interstitial pulmonary oedema 20% vs. 28%, bilateral effusions 6% vs. 19%, p<0.0001). 
The mean sodium, potassium, urea and creatinine were lower in younger patients, whereas 
the mean haemoglobin, white cell and platelet count were higher. 
 
3.3.5 Baseline Medications 
 
Compared with the oldest, the youngest patients were more likely to receive an 
ACE inhibitor (53% vs. 35%, p<0.0001), a beta-blocker (62% vs. 48%, p<0.0001), 
spironolactone (20% vs. 17%, p=0.097) and digoxin (64% vs. 42%, p<0.0001) (Table 3.1). 
Diuretic use was lowest in those aged 40 to 49 years and increased with age (80%, 77%, 
78%, 82% and 87% in age group 20-39 years, 40-49 years, 50-59 years, 60-69 years and 
≥70 years respectively; p<0.0001). These overall figures may be confounded by the higher 
proportion of HF-REF in young patients. However, similar therapeutic trends occurred 
comparing youngest with oldest in HF-REF alone: ACEI (69% vs. 49%, p<0.0001), beta-
blockers (66% vs. 48%, p<0.0001), spironolactone (27% vs. 19%, p=0.073), and digoxin 
(71% vs. 50%, p<0.0001). 
 
3.3.6 Adherence  
 
  Adherence to study drug was the lowest in the youngest age group (80%, 87%, 
89%, 90% and 88% in age categories 20-39, 40-49, 50-59, 60-69 and ≥70 years 
respectively, p=0.001).  
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Table 3.2. Symptoms and signs stratified by age 
 
Age Groups 20-39 
n=120 
40-49 
n=538 
50-59 
n=1527 
60-69 
n=2395 
≥70 
n=3019 
P value 
NYHA Class       
• II 53 49 48 46 42 <0.0001 
• III 45 49 50 52 55  
• IV 2 2 2 3 3  
Minnesota score       
Mean (SD) 52.6 (27.6) 50.8 (24.9) 47.1 (24.3) 38.9 (23.9) 35.3 (21.6) <0.0001 
Median (IQR) 61.0  
(28.0-73.0) 
51.5  
(32.5-72.0) 
48.0  
(28.0-65.0) 
38.0  
(18.0-58.0) 
33.0  
(18.0-50.0) 
<0.0001 
Past symptoms       
Dyspnoea at rest 62 53 48 47 49 0.009 
Dyspnoea on flat 80 75 77 73 72 0.004 
Dyspnoea on climbing 79 78 78 76 72 <0.0001 
Orthopnoea 67 51 49 49 47 0.001 
Paroxysmal nocturnal dyspnoea 63 46 43 40 38 <0.0001 
Present symptoms       
Dyspnoea at rest 11 12 11 11 11 0.898 
Dyspnoea on flat 45 59 60 63 68 <0.0001 
Dyspnoea on climbing 93 90 92 91 91 0.790 
Orthopnoea 26 22 20 19 21 0.086 
Paroxysmal nocturnal dyspnoea 22 17 13 13 12 0.001 
Heart rate & BP       
Heart rate 78 (12) 76 (14) 74 (14) 72 (13) 72 (13) <0.0001 
Systolic BP (mm Hg) 121 (17) 126 (18) 128 (18) 130 (19) 134 (19) <0.0001 
Diastolic BP (mm Hg) 78 (10) 79 (11) 78 (10) 77 (11) 75 (11) <0.0001 
Pulse pressure (mmHg) 43 (13) 46 (12) 50 (14) 54 (15) 59 (16) <0.0001 
Past signs       
Jugular venous pressure >6cm 36 27 28 25 26 0.038 
Hepatomegaly 28 26 21 17 14 <0.0001 
Peripheral oedema 53 49 50 51 54 0.039 
Basilar pulmonary crackles 49 43 47 51 54 <0.0001 
S3 gallop 46 33 27 23 20 <0.0001 
Present signs       
Jugular venous pressure >6cm 10 9 9 9 10 0.719 
Hepatomegaly 10 14 13 11 7 <0.0001 
Peripheral oedema 19 21 24 26 30 <0.0001 
Basilar pulmonary crackles 8 12 12 14 19 <0.0001 
S3 gallop 31 15 12 12 11 <0.0001 
BP=blood pressure; IQR=interquartile range; NYHA=New York Heart Association classification; 
SD=standard deviation. 
Values are given as mean (standard deviation) or as percentage (%)	  
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Table 3.3. Investigative findings stratified by age 
	
Age Groups 20-39 
n=120 
40-49 
n=538 
50-59 
n=1527 
60-69 
n=2395 
≥70 
n=3019 
P value 
Electrocardiogram       
Normal 9 12 13 9 8 <0.0001 
Atrial fib/flutter 4 7 11 14 20 <0.0001 
Bundle branch block 22 17 22 25 26 <0.0001 
Paced rhythm 1 3 3 5 10 <0.0001 
Pathological Q waves 10 26 27 28 23 <0.0001 
Left ventricular hypertrophy 24 17 16 16 15 0.032 
Other abnormality 53 46 42 41 42 0.051 
Chest X-Ray       
Interstitial pulmonary oedema 20 18 22 24 28 <0.0001 
Bilateral effusion  6 7 11 13 19 <0.0001 
Cardiomegaly 51 39 39 37 39 0.020 
Ejection fraction       
Ejection fraction (%) 34 (14) 37 (14) 38 (14) 38 (15) 40 (15) <0.0001 
Biochemistry       
Sodium (mmol/l) 139.5 
(3.7) 
139.5  
(3.4) 
140.2  
(2.8) 
140.4  
(2.9) 
140.5  
(3.1) 
<0.0001 
Potassium (mmol/l) 4.3  
(0.5) 
4.3  
(0.5) 
4.3  
(0.4) 
4.4 
(0.5) 
4.4  
(0.4) 
<0.0001 
Urea (mg/dl) 14.7  
(6.8) 
17.2  
(14.9) 
16.6  
(11.4) 
18.6  
(12.5) 
19.8  
(13.1) 
<0.0001 
Creatinine (mg/dl) 1.0 
(0.3) 
1.1  
(1.6) 
1.1  
(0.4) 
1.2  
(0.4) 
1.3  
(0.7) 
<0.0001 
Haematological       
Haemoglobin (g/dl) 14.2  
(1.5) 
14.1  
(1.6) 
13.9  
(1.5) 
13.6  
(1.7) 
13.3  
(1.6) 
<0.0001 
White cell count (103/mm3) 7.6  
(2.5) 
7.9  
(2.4) 
7.5  
(2.1) 
7.3  
(2.1) 
7.2  
(2.3) 
0.001 
Platelet count (103/mm3) 223.2 
(105.4) 
192.8 
(127.1) 
171.7 
(132.7) 
150.7 
(126.4) 
130.8 
(114.5) 
<0.0001 
Mean corpuscular volume (µm3) 89.0  
(5.9) 
89.9  
(5.3) 
91.5  
(5.3) 
92.0  
(6.1) 
92.6  
(6.0) 
<0.0001 
Values are given as mean (standard deviation) or as percentage (%) 
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3.3.7 Heart failure hospitalisation after randomisation 
 
Patients aged 40 to 59 years had the lowest HF hospitalisation rate at 1, 2, and 3 
years. (Figure 3.3) The youngest patients had similar HF hospitalisation rates to the oldest 
(20-39 years vs. ≥70 years: 1 year 15% vs. 14%; 2 years 20% vs. 22%; 3 years 24% vs. 
28%). HF hospitalisation rates at 3 years were 24%, 15%, 15%, 22% and 28% in age 
categories 20-39, 40-49, 50-59, 60-69 and ≥70 years respectively. Younger patients were 
more likely to present with exertional dyspnoea, orthopnoea, nocturnal dyspnoea and 
fatigue at the time of HF hospitalisation (Table 3.4). As with clinical signs and past 
investigations, pulmonary oedema and radiological signs of HF were again less common in 
younger patients (youngest vs. oldest 24% vs. 35% and 28% vs. 53% respectively). 
 
Lifestyle factors were often thought to have contributed to HF hospitalisation in 
younger patients, who were two to three times less likely to adhere to their medications and 
dietary restrictions (Table 3.4). Comparing youngest (20-39 years) with oldest (≥70 years) 
patients: medication non-adherence was 24% vs. 7% (p=0.001), dietary adherence 21% vs. 
9% (p=0.002), reported alcohol excess 3% vs. 1% (p<0.0001).  No significant difference 
was observed between age groups in acute treatment with intravenous diuretics, inotropes 
or vasodilators. 
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Figure 3.3. HF Hospitalisation by age groups 
 
 
Age Groups 20-39 
n=120 
40-49 
n=538 
50-59 
n=1527 
60-69 
n=2395 
≥70 
n=3019 
P value 
Hospitalisation rates [%(95% CI)] 
One year 15 (9-22) 8 (6-11) 7 (6-8) 11 (10-12) 14 (13-15) <0.0001 
Two year 20 (12-27) 12 (9-15) 12 (10-13) 18 (16-19) 22 (20-23) <0.0001 
Three year 24 (17-32) 15 (12-18) 15 (13-17) 22 (20-24) 28 (27-30) <0.0001 
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Table 3.4. Clinical presentation, precipitating factors and treatment related to unplanned 
hospitalisation for heart failure occurring after randomisation 
	
Age Groups 20-39 
n=120 
40-49 
n=538 
50-59 
n=1527 
60-69 
n=2395 
≥70 
n=3019 
P value 
Hospital stay       
Bed days [median (IQR)] 12 (6-33) 8 (4-21) 10 (4-21) 12 (6-25) 11 (5-21) 0.007 
Clinical presentation        
Increasing dyspnoea on exertion 93 92 85 86 82 0.016 
Orthopnoea 62 52 58 48 48 0.018 
Nocturnal dyspnoea 48 48 42 36 36 0.051 
Increasing peripheral oedema 41 51 52 46 45 0.052 
Increasing fatigue or decreasing 
exercise tolerance 
62 66 60 54 51 0.005 
Renal hypoperfusion 7 11 18 20 20 0.051 
Clinical pulmonary oedema 24 19 32 35 35 0.022 
Radiological sign of heart failure 28 43 46 48 53 0.005 
Precipitating factors        
Non-adherence with cardiac 
medications 
24 13 15 7 7 0.001 
Excessive salt intake/ dietary non-
adherence 
21 24 17 12 9 0.002 
Alcohol excess 3 4 4 1 1 <0.0001 
Inappropriate decrease of anti-
failure therapy 
7 5 3 6 6 0.055 
Cardiac arrhythmias 17 22 26 29 28 0.002 
Acute myocardial ischaemia 3 1 3 5 8 0.014 
Intravenous treatment       
Diuretic 93 94 92 90 92 0.085 
Inotropic agent 24 20 17 22 17 0.042 
Vasodilator 10 15 13 17 17 0.072 
CI=confidence interval; IQR=interquartile range. 
Values are given as median (IQR) or as percentage (%). 
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3.3.8 Mortality and cardiovascular outcomes 
 
Crude mortality for any cause at 3 years was lowest in the youngest age group and 
increased with age, although only markedly above 60 years (12% < 40 years, 13% 40-49 
years, 13% 50-59 years, 19% 60-69 years, and 31% ≥70 years, p<0.0001) (Figure 3.4). 
This remained the case after adjusting for previously published predictors of mortality and 
morbidity (Figure 3.5). The inclusion of the ethnicity (European origin, Black, South 
Asian, Arab/Middle East, Oriental, Malay or other) and geographical regions of patients 
into the model made little difference to the adjusted outcomes and there was no interaction 
between age and ethnicity (p=0.71) or age and regions (p=0.28). The respective hazard 
ratios for age group <40, 40-49 and 50-59 years referenced to 60-69 years were 0.60 (95% 
CI 0.36-1.00) [p=0.049], 0.63 (95% CI 0.50-0.81) [p<0.0001] and 0.64 (95% CI 0.54-0.75) 
[p<0.0001] for all-cause mortality; for cardiovascular death 0.71 (95% CI 0.42-1.18) 
[p=0.186], 0.78 (95% CI 0.60-1.00) [p=0.054] and 0.70 (95% CI 0.59-0.84) [p<0.0001]. 
 
 The association between age and cardiovascular death or HF hospitalisation was 
non-linear. The youngest age group had similar risk of cardiovascular death or HF 
hospitalisation to the referent age group 60-69 years (HR 0.99 [95% CI 0.71-1.38], 
p=0.930). This was driven by the aforementioned higher risk of HF hospitalisation in the 
youngest age group (Figure 3.5). However, the absolute number of events in this group 
was small resulting in wide confidence intervals. 
Figure 3.4. Kaplan-Meier mortality curves in age categories for all-cause mortality 
	
	
	
 
 
Cumulative mortality rate [%(95% CI)] 
1-year 2-year 3-year 
20-39 years 6 (2-10) 8 (3-13) 12 (6-18) 
40-49 years 5 (4-7) 10 (7-12) 13 (11-16) 
50-59 years 5 (4-6) 9 (8-11) 13 (12-15) 
60-69 years 6 (5-7) 13 (11-14) 19 (18-21) 
≥ 70 years 10 (9-11) 21 (20-23) 31 (30-33) 
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Figure 3.5. Adjusted hazard ratios for the primary outcome, secondary components and 
all-cause mortality by age categories, with 60-69 years as the reference group 
	
	
CI=confidence interval; CV=cardiovascular; HF=heart failure. 
*Adjusted for age, diabetes: insulin-treated, diabetes: other, ejection fraction (per 5% decrease below 45%), 
previous HF hospitalisation, cardiomegaly, diagnosis of chronic HF over 2 years ago, NYHA class III, 
NYHA class IV, and diastolic blood pressure. 
†Adjusted for age, ejection fraction (per 5% decrease below 45%), diabetes: insulin-treated, diabetes: other, 
BMI (per 1 kg/m2 decreased below 27.5), female, NYHA class III, NYHA IV, current smoker, and bundle 
branch block.  
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3.4 Discussion 
 
With nearly 2,200 patients younger than 60 years, I have demonstrated some 
striking differences from older patients with HF. Younger patients with HF have different 
demographics, aetiology, co-morbidity, symptoms, signs, quality of life, investigative 
findings, treatment adherence, potential precipitants of decompensation and non-fatal and 
fatal outcomes. I am not aware of any similarly comprehensive study of younger patients 
with heart failure. 
 
3.4.1 Characteristics 
 
That more younger patients were black is consistent with epidemiological studies in 
the USA showing that African-Americans have a higher risk of developing heart failure 
than whites and do so at a younger age.(157) Similarly, a higher proportion of younger 
patients had an investigator-reported aetiology of IDCM (and a smaller proportion an 
ischemic aetiology), is consistent with the occurrence of symptomatic coronary heart 
disease later in life.(145;158) Previous clinical trials(14;82;88;89) and 
survey/registries(94;95;159) reported a higher proportion of IDCM in younger patients 
with HF. Interpretation of this apparent association between age and aetiology requires 
consideration of both numerator and denominator. In fact, the incidence and prevalence of 
IDCM increase steadily with age in the general population.(160;161) However, the 
incidence and prevalence of the two commonest alternative aetiologies (ischaemia and 
hypertension) rise even more rapidly with age, thus diminishing the relative frequency of 
DCM in patients with an established diagnosis of HF. 
 
The lower prevalence of all co-morbidities, including diabetes mellitus, 
hypertension and stroke, likewise reflects the conditions occurring beyond middle-
age.(93;94;145) As comorbidities (along with age) are among the most powerful predictors 
of prognosis, these findings are central to the much better survival of younger patients (see 
below).(101;162) Atrial fibrillation was also significantly less common in younger patients 
whether identified by medical history at baseline (13% versus 36% youngest versus oldest) 
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or on the baseline ECG (4% versus 20%). This suggests that atrial fibrillation may be an 
age-related comorbidity in heart failure rather than just a consequence of heart failure, 
especially as severity of heart failure (associated with the prevalence of AF) did not differ 
greatly across age groups.(69;93;94) Interestingly, the youngest age group combined the 
lowest prevalence of AF with highest prescribing rate of digoxin. Trial enrolment from 
1999 closely followed publication of the Digitalis Investigation Group trial. Most likely, 
the aforementioned higher hospitalisation rates, non-ischemic aetiology, radiologic 
cardiomegaly and worse LVEF and quality of life prompted physicians to prescribe 
digoxin more frequently in younger patients.(163) 
 
3.4.2 Symptoms and signs 
 
Although younger patients had a slightly but significantly more favourable NYHA 
class profile (i.e. a greater proportion NYHA class II/smaller proportion NYHA class 
III/IV) than older participants, they had strikingly worse HRQL, as assessed by the 
MLwHF. This disconnects between NYHA class and MLwHF score is of interest and may 
in part reflect the difference between a physician-based assessment (NYHA class) and a 
patient-reported one (MLwHF). That younger patients report worse HRQL has been 
reported before and likely reflects the greater impact of heart failure symptoms and 
functional limitation in an age group that is more active (or desires to be more active) in 
meeting the demands of employment and family/social commitments.(90;117) Of interest, 
in connection with this, younger patients reported more heart-failure related symptoms in 
the past. Although this finding was not so clear for the current symptoms reported by 
patients at baseline, the difference in symptoms between younger and older patients was 
also noted during episodes of decompensation after randomization.   
 
The pattern of HF signs also differed strikingly between younger and older 
subjects. In particular, younger patients seemed less likely to develop peripheral or 
pulmonary oedema. Evidence for this was seen in previous and current signs and in chest 
radiographic findings (pulmonary oedema and effusions less frequent) collected at 
baseline; the same differences were noted during episodes of decompensation reported 
after randomization. Intriguingly, less peripheral oedema was noted in younger subjects 
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despite a higher prevalence of an elevated JVP and hepatomegaly in these patients 
(compared with older ones) and less pulmonary oedema despite a lower LVEF and higher 
prevalence of a third heart sound. This suggests, perhaps, that peripheral and pulmonary 
endothelial integrity diminishes with age, leading to increasing capillary “leakiness”. These 
findings also have potential clinical importance for the recognition of heart failure in 
younger individuals. Heart failure is unlikely to be high on the list of differential diagnoses 
in young subjects with breathlessness and if the most easily detectable and commonly 
recognized signs of heart failure (i.e. peripheral and pulmonary oedema) are less common 
in these individuals, the diagnosis may be delayed. 
 
Other clinical and investigative findings in younger subjects of relevance to patient 
management were lower systolic blood pressure, better renal function and less frequent 
bundle branch block. 
 
3.4.3 HF hospitalisations 
 
One particularly unique aspect of the current study was the prospective collection 
of information about acute episodes of decompensation after randomization using a 
specifically designed endpoint form. Non-adherence with medication and life-style 
measures was reported as a possible contributor to heart failure worsening significantly 
more frequently in younger than in older subjects. Previous studies reported conflicting 
results, some supporting ours,(164;165) and others not.(111) The recent Get With The 
Guidelines-Heart Failure (GWTG-HF) program, which prospectively included 95127 
patients hospitalised with acute HF, reported patients with non-adherence (less compliant 
with medication or dietary restriction or both) were younger (non-adherence vs. adherence 
64 years vs. 74 years, p<0.0001).(164) After multivariate analysis, younger age was 
independently associated with non-adherence (Odds ratio for the outcome of non-
adherence in younger age [per each year decrease]: 1.022 [95% CI: 1.019-1.026], 
p<0.001). Younger patients with heart failure may therefore merit particular attention in 
terms of education and other interventions to improve adherence. In keeping with their 
lower prevalence of comorbidity, younger patients were less likely to have decompensation 
attributed to myocardial ischemia or arrhythmias. 
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3.4.4 Outcomes 
 
Finally, I demonstrated a possible important divergence between fatal and non-fatal 
outcomes in younger versus older patients. As expected, younger patients had a 
significantly lower mortality rate than older subjects. However, there was a suggestion that 
the youngest patients (aged 20-39 years) may have relatively high hospitalisation rates, 
more in keeping with those aged ≥ 60 years than those aged 40 – 59 years. This divergence 
was not unexpected given the lower mortality in the youngest patients which increased the 
period at risk of further hospital admission. Coupled with non-adherence to study drug, 
cardiac medications, dietary restriction and alcohol excess, this may explain the disconnect 
of higher HF hospitalisation alongside lower mortality in the youngest compared to older 
patients. The modest number of patients in the youngest age group with a wide confidence 
interval reduces certainty in this finding. However, the longer duration of admission 
experienced by these patients is consistent with the possibility that they had more severe 
heart failure, as was the greater use of digoxin (despite less atrial fibrillation) and 
spironolactone in this age group. Of additional interest, mortality rates appeared to be 
relatively flat across the age range 20-59 years, only increasing notably in subjected aged 
60-69 years and rising again substantially in those aged 70 years or above; this three-step 
pattern was as apparent for death from cardiovascular causes only and persisted after 
adjustment for differences in known prognostic variables that differed in frequency across 
the age groups. 
 
3.5 Limitations 
 
 A number of limitations merit consideration. The number of patients in the 
youngest age group was small. This resulted in wider confidence intervals and a greater 
degree of uncertainty when interpreting results. Symptoms are susceptible to recall bias. 
The aetiology of HF and ECG interpretation were reported by individual site investigators 
rather than by a core laboratory with standardized definitions. Systematic investigation of 
the aetiology of HF was not mandatory in the study protocol.  Serum albumin was not 
available for the entire cohort. The study excluded the sickest young patients on heart 
transplant waiting list. This might have altered the mortality and morbidity outcomes. 
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Conversely the inclusion and exclusion criteria of a trial tend to have a greater impact on 
the older participants who have more comorbidities (as we have found here again in 
CHARM). Therefore, older participants are likely to be healthier and consequently I 
believe that the inclusion and exclusion criteria are likely to have biased the true difference 
between young and old towards the null, underestimating the difference. 
 
3.6 Conclusion 
 
In summary, comparing with older patients, younger patients with HF have a 
markedly different clinical characteristics, including a different pattern of symptoms and 
signs which could lead to delayed diagnosis, a poorer health related quality of life, more 
hospitalisations attributed to non-adherence but lower mortality, with relatively low rates 
of death until the age of 60 year. 
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Chapter 4 
 
Heart failure in younger patients: the Meta-analysis Global 
Group in Chronic Heart Failure (MAGGIC) database. 
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4.1 Introduction 
 
Although the overall prevalence of heart failure (HF) in the general adult 
population is 1–2%,(166;167) the majority of those affected are elderly.(51) Prior studies 
on the epidemiology and prognosis of HF have focussed on older 
individuals.(12;24;168;169) There is limited information on the causes and consequences 
of HF in younger patients (<60 years) especially those aged <40 years.(93;94) This is 
primarily because no single epidemiological study, registry or clinical trial has included 
sufficient numbers of such individuals to draw robust conclusions. Yet it is often in these 
younger patients that the most searching questions about aetiology and prognosis are 
asked.  
 
The Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) has collated 
individual patient data from 31 studies (24 observational studies including the Euro Heart 
Failure Survey(170) and 7 randomised controlled trials of either pharmacotherapy or 
management interventions). The data provides an opportunity to address these deficiencies 
in our understanding of HF in younger patients.(171) 
 
4.2 Methods 
 
4.2.1 Study design 
 
 
The details of the rationale, methods, inclusion and exclusion criteria and results of 
the meta-analysis have been published previously.(171) A comprehensive literature search 
of Embase, Medline and PubMed was undertaken for observational studies and randomised 
controlled trials published to the end of 2008, using the following keywords: heart failure, 
left ventricle, prognosis, outcome, and preserved. The reference lists of each article and 
conference abstracts were scrutinised and investigators and authors contacted. Abstracts, 
unpublished studies and articles published in languages other than English were not 
excluded. The inclusion criteria were that each study had a prospective study design, that 
left ventricular ejection fraction (LVEF) was not an inclusion criterion and all-cause 
mortality was reported. Each individual study was approved by the local ethics committees 
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and the meta-analysis was approved by The University of Auckland Human Subjects 
Ethics Committee.  
 
Principal investigators from 56 potentially suitable studies were invited to 
participate in the meta-analysis, from which 31 investigators contributed individual patient 
data. These data included demographics (age, sex, and ethnicity), medical history 
(myocardial infarction, coronary revascularisation, diabetes, hypertension, atrial 
fibrillation, stroke, lung disease, peripheral artery disease, and smoking), aetiology 
(defined by individual studies; idiopathic included those labelled as idiopathic or dilated 
cardiomyopathy), medical treatment (angiotensin converting enzyme inhibitor [ACEI], 
angiotensin receptor blocker [ARB], beta-blocker, diuretics, and aldosterone antagonist), 
symptom status (New York Heart Association [NYHA] functional class, dyspnoea, 
paroxysmal nocturnal dyspnoea, and oedema), clinical variables (heart rate, blood pressure, 
and pulmonary rales), laboratory variables (serum sodium, creatinine, and EF), and 
outcomes (deaths and follow up duration). The results from the MAGGIC meta-analysis 
demonstrated that patients with HF with preserved LVEF (HF-PEF) have lower risk of 
death from any cause than patients with reduced LVEF (HF-REF).(171) In the present 
study patients were stratified into 6 age categories (<40, 40-49, 50-59, 60-69, 70-79, and 
≥80 years) and report their clinical characteristics and outcomes. 
 
4.2.2 Statistical analysis 
 
The current analyses included all subjects in the MAGGIC dataset for whom LVEF 
category (HF-PEF or HF-REF) was known. Baseline characteristics are presented as means 
and standard deviations for continuous variables and proportions for categorical variables. 
Variables were compared across age categories using ANOVA for continuous variables 
and Chi-square for categorical variables.  For all analyses the primary outcome was rate of 
death from any cause at 3 years from hospital discharge or baseline study visit. Mortality 
estimates, stratified by age and sex, at 1, 2 and 3 years and deaths per 1000 patient-years 
were calculated. Baseline characteristics, mortality rates, and survival curves were 
stratified by ejection fraction as HF-REF and HF-PEF.  Cox’s proportional hazard models 
were used to estimate the hazard of younger age compared with the age group 50-59 years 
as the referent category. All models were adjusted for sex, aetiology (ischaemic vs. non-
ischaemic), LVEF (reduced [defined as LVEF <50%] vs. preserved), history of 
hypertension, diabetes, and atrial fibrillation, and stratified by individual study. Included 
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variables were selected based on clinical relevance and where data were available for 
>90% of the patients in the MAGGIC dataset.  Data regarding NYHA functional class and 
medications were less complete, so models were re-analysed with these variables included 
as a sensitivity analysis. The presence of an age-sex interaction was assessed in the main 
model. Mortality curves for each age category were created using adjusted models that 
were not stratified by individual study. Analyses were performed using SAS version 9.2. 
 
4.3 Results 
 
4.3.1 Demography 
 
Thirty-one studies contributed data on 41,926 patients whose baseline 
characteristics are presented in Table 4.1. The relative proportion of women increased with 
age (29% <40 years, 22% 40-49 years, 23% 50-59 years, 27% 60-69 years, 38% 70-79 
years, and 52% ≥80 years; p<0.0001). 
 
4.3.2 Comorbidities 
 
 Younger patients had the lowest prevalence of comorbidities (<40 vs. ≥80 years: 
hypertension 22% vs. 43%, p<0.0001; MI 14% vs. 35%, p=0.019; AF 9% vs. 30%, 
p<0.0001; and diabetes 9% vs. 18%, p<0.0001) [Table 1]. The prevalence of comorbidities 
increased with age. 
 
4.3.3 Aetiology 
 
 The aetiology of HF varied with age. Since the term ‘idiopathic’ may refer to 
dilated cardiomyopathy (typically inferring reduced ejection fraction), aetiology was 
examined separately in the overall population and those with HF-REF (Table 1). In both 
cohorts, the youngest age group had the highest proportion of ‘idiopathic’ cardiomyopathy, 
which declined sharply above 40 years of age (Overall 63% <40 years, 37% 40-49 years, 
28% 50-59 years, 20% 60-69 years, 12% 70-79 years and 7% ≥80 years; p<0.001). This 
reflected converse parallel trends in the proportion of patients with ischaemic and 
hypertensive aetiology which both increased with age: aetiology presumed to be ischaemic 
increased from 16% of those aged <40 years to 68% ≥80 years (p<0.0001); hypertensive 
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from 5% <40 years to 17% ≥80 years (p=0.18). The proportion of HF attributed to alcohol 
was low in all age categories, ranging from 0% to 4%. 
 
4.3.4 HF-REF and HF-PEF  
 
Median EF was lowest in the youngest and progressively increased with age (31% 
<40 years, 33% 40-49 years, 33% 50-59 years, 34% 60-69 years, 37% 70-79 years and 
42% ≥80 years; p<0.0001). The proportion of patients with HF-PEF (LVEF ≥50%) trebled 
from youngest to oldest age groups: 14% in < 40 years of age to 39% in those age ≥ 80 
(p<0.0001) [Table 1]. 
 
4.3.5 Clinical status, blood pressure, heart rate, and treatment 
 
Younger patients were predominantly in NYHA functional class I or II. The 
proportion of patients in NYHA functional class III and IV increased with age. Mean 
systolic blood pressure was lowest in the youngest age group (118±19 mmHg <40 years 
vs. 137±26 mmHg ≥80 years; p<0.0001). Younger patients were more likely to receive 
disease-modifying medical therapies, including an ACEI or ARB, a beta-blocker, and 
spironolactone. Younger patients were also more often treated with digoxin, despite their 
much lower prevalence of atrial fibrillation. Excluding the DIG trial from the analysis, 
similar patterns were observed. By contrast, younger patients were less likely to receive 
diuretics (70% <40 years vs. 85% ≥80 years; p<0.0001). 
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Table 4.1. Baseline characteristics for patients from the MAGGIC meta-analysis by age 
categories 
 
Age (years) <40 40-49 50-59 60-69 70-79 ≥80 p value 
N (31 studies) 876 2638 6894 12071 13368 6079  
Women (%) 29 22 23 27 38 52 <0.0001 
• RCTs. 29 22 23 26 35 51  
• Observational studies. 29 22 22 29 40 53  
Medical history        
Hypertension (%) 22 37 41 44 46 43 <0.0001 
MI (%) 14 38 46 50 47 35 0.019 
Atrial fibrillation (%) 9 9 14 18 25 30 <0.0001 
Diabetes (%) 9 18 24 27 25 18 <0.0001 
Aetiology        
All patients        
Ischaemic 16 46 57 65 69 68 <0.0001 
Hypertensive 5 10 9 10 13 17 0.180 
Idiopathic 63 37 28 20 12 7 <0.0001 
Alcoholic 3 3 2 1 1 0 <0.0001 
Atrial fibrillation 9 4 4 4 5 8 <0.0001 
Patients with HFREF        
Ischaemic 17 46 58 68 73 76 <0.0001 
Hypertensive 4 8 8 8 9 10 0.170 
Idiopathic 65 38 29 21 14 9 <0.0001 
Alcoholic 3 4 2 1 1 0 <0.0001 
Atrial fibrillation 11 4 3 2 3 5 <0.0001 
Clinical status        
NYHA class(%) 
(I/II/III/IV) 
 
21/50/25/4 
 
14/50/31/5 
 
11/50/34/5 
 
10/49/35/6 
 
9/45/38/9 
 
9/40/37/14 
 
<0.0001 
Heart rate (b.p.m) [SD] 81 (17) 80 (16) 79 (17) 78 (17) 79 (19)  82 (22) 0.820 
SBP (mmHg) [SD] 118 (19) 124 (20) 126 (21) 130 (22) 134 (23) 137 (26) <0.0001 
DBP (mmHg) [SD] 76 (12) 79 (13) 78 (12) 77 (12) 76 (13) 76 (14) <0.0001 
Medication        
All patients        
ACEI or ARB  80 77 74 71 65 53 <0.0001 
Beta-blocker 45 47 47 39 34 26 <0.0001 
Spironolactone 26 26 23 22 21 19 <0.0001 
Digoxin 49 47 44 44 42 41 <0.0001 
Diuretic 70 75 78 81 84 85 <0.0001 
Patients with HFREF        
ACEI or ARB  84 82 80 77 73 63 <0.0001 
Beta-blocker 47 47 48 40 39 27 <0.0001 
Spironolactone 28 28 25 24 23 22 <0.0001 
Digoxin 52 51 48 48 45 43 <0.0001 
Diuretic 71 77 79 72 85 87 <0.0001 
Ejection Fraction        
median EF (%), IQR 
31 (23, 42) 33 (24, 32) 33 (24, 43) 34 (26, 46) 37(27, 51) 42 (30, 58) <0.0001 
HF-PEF (%) 14 15 17 21 38 39 <0.0001 
ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; b.p.m=beats per minute; 
DBP=diastolic blood pressure; HF-PEF=heart failure with preserved ejection fraction (LVEF >50%); HF-
REF: heart failure with reduced ejection fraction; IQR=inter-quartile range; LVEF=left ventricular ejection 
fraction; MI=myocardial infarction, NYHA=New York Heart Association functional class; SBP=systolic 
blood pressure; SD=standard deviation.  
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4.3.6 Mortality 
 
During 3 years follow up 10,747 patients died. Deaths per 1000 patient-years 
increased with age from 64 (95% CI 53,78) in the youngest to 276 (95% CI 266,287) in the 
oldest age group. Likewise, the probability of death was lowest in the youngest age group 
and increased with age (Table 4.2). The estimated 3 year cumulative mortality was 16.5% 
< 40 years, 16.2% 40-49 years, 18.2% 50-59 years, 26.2% 60-69 years, 37.5% 70-79 years 
and 57.2% ≥ 80 years (Table 4.2). There was no significant age-sex interaction for all-
cause mortality. The mortality rates in younger patients with HF-PEF were half that of 
patients with HF-REF (deaths per 1000 patient-years: HF-PEF vs. HF-REF: 19.3 vs. 70.9 
in < 40 years, 31.7 vs. 68.9 in 40-49 years, and 42.1 vs. 80.0 in 50-59 years) (Table 4.3). 
The deaths per 1000 patient-years were similar for patients in the RCTs compared to those 
in the observational studies.  
 
After adjusting for sex, ischaemic aetiology, diabetes, hypertension and atrial 
fibrillation, mortality remained lowest in the youngest patients (< 60 years) in patients with 
both HF-REF and HF-PEF (Figure 4.1A and 4.1B). The hazard ratios for all-cause 
mortality increased with increasing age, being lowest in those aged <60 years (Figure 4.2). 
The hazard ratios for the 3 youngest age groups (<40 years, 40-49 years and 50-59 years) 
did not differ significantly. A sensitivity analysis incorporating NYHA class, ACEI, ARB 
and beta-blocker use did not alter the effect of age on outcome.  
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Table 4.2. Mortality probability estimates (%) stratified by sex and age categories at 1, 2 
and 3 years, adjusted for ischemic aetiology, diabetes, hypertension, EF group (HF-REF 
vs. HF-PEF), and atrial fibrillation. 
 
Age groups  <40 40-49 50-59 60-69 70-79 ≥80 
One year all patients 6.7 6.6 7.5 11.2 16.7 28.2 
 male 7.3 6.9 7.7 11.5 17.3 28.9 
 female 5.4 5.9 7.3 10.8 15.8 26.8 
Two years all patients 11.7 11.5 13.0 19.1 27.8 44.5 
 male 12.9 12.2 13.6 19.9 29.3 46.4 
 female 9.1 9.8 12.1 17.5 25.2 41.1 
Three years all patients 16.5 16.2 18.2 26.2 37.5 57.2 
 male 18.1 17.1 19.1 27.6 39.5 59.5 
 female 12.6 13.7 16.7 24.0 33.8 52.9 
Age-sex interaction p=0.78 
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Table 4.3. Deaths per 1000 patient years stratified by age and ejection fraction 
 
Age (years) <40 40-49 50-59 60-69 70-79 ≥80 
All Studies       
Whole group 64.2 
(52.6, 77.6) 
60.1 
(53.7, 67.2) 
73.2 
(68.8, 77.8) 
109.5 
(105.3, 109.7) 
161.1 
(156.2, 166.2) 
276.0 
(265.7, 286.6) 
HF-PEF 19.3 
(0.61, 46.5) 
31.7 
(20.8, 46.5) 
42.1 
(34.6, 50.8) 
78.5 
(71.2, 86.4) 
125.9 
(118.0, 134.3) 
239.9 
(225.1, 255.4) 
HR-REF 70.9 
(57.9, 86.1) 
68.9 
(61.6, 77.0) 
80.0 
(74.9, 85.3) 
118.0 
(113.0, 123.0) 
176.0 
(170.0, 182.0) 
301.0 
(287.0, 316.0) 
Observational studies       
Whole group 68.7 
(51.4, 90.1) 
69.6 
(57.8, 80.1) 
77.3 
(69.7, 89.6) 
113.8 
(106.5, 121.6) 
174.4 
(166.2, 182.8) 
289.5 
(275.3, 304.3) 
HF-PEF 31.5 
(1.0,71.9) 
48.6 
(26.0, 81.7) 
59.9 
(45.0, 76.0) 
88.5 
(76.3, 102.2) 
143.2 
(130.6, 156.7) 
255.4 
(235.3, 276.7) 
HR-REF 76.8 
(56.7, 102.0) 
73.3 
(60.3, 88.4) 
81.9 
(73.2, 91.5) 
122.9 
(114.0, 132.4) 
189.9 
(179.5, 200.7) 
315.7 
(296.0, 336.3) 
RCTs only       
Whole group 60.6 
(45.8, 78.6) 
60.6 
(52.9, 69.2) 
71.1 
(65.8, 76.7) 
107.4 
(102.4, 112.5) 
140.8 
(135.0, 146.9) 
259.9 
(245.3, 275.3) 
HF-PEF 
- 23.7 (12.8, 40.2) 
31.6 
(23.6, 41.5) 
72.2 
(63.3, 81.9) 
112.3 
(102.3, 122.9) 
219.2 
(197.9, 242.3) 
HF-REF 66.6 
(50.4, 86.5) 
66.9 
(58.14, 76.6) 
79.0 
(72.9, 85.5) 
116.1 
(110.3, 122.0) 
167.5 
(160.1, 175.3) 
285.6 
(266.0, 306.2) 
P value  (observational vs RCTs) 
Whole Group 0.530 0.230 0.200 0.160 <0.0001 0.006 
HF-PEF - 0.089 0.002 0.041 0.0002 0.002 
HF-REF 0.490 0.440 0.600 0.210 <0.0001 0.039 
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Figure 4.1 Mortality curve adjusted for sex, ischemic aetiology, diabetes, hypertension, 
and atrial fibrillation stratified by age for A) HF-REF and B) HF-PEF. 
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Figure 4.2 Adjusted hazard ratios for all-cause mortality by age categories, with 50-59 
years as the reference group 
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4.4 Discussion 
 
Young patients with HF have different demographics, aetiology, clinical 
characteristics and survival compared to older age groups. 
 
4.4.1 Aetiology and demographics 
 
Presumed “idiopathic” dilated cardiomyopathy is relatively more common in young 
patients. The relative frequency of DCM is ten times higher in the youngest (< 40 years) 
compared to the oldest (63% v 7%). These proportions are comparable to previous clinical 
trials(82;87;90) and registries(93-96), which reported a higher prevalence of presumed 
non-ischaemic (25-58%) or idiopathic dilated aetiology (6-40%) in those aged <50-65 
years, compared to 2-36% in those aged ≥70-80 years. In both the current analysis and 
previous reports, whether patients truly had non-ischaemic aetiology is unknown, as 
routine coronary angiography or testing for myocardial ischaemia was not mandated. 
Similarly, thorough investigation for the cause of heart failure (for example with genetic 
testing and cardiac magnetic resonance imaging) was uncommon. Our large population 
from both observational studies and randomized trials emphasises that presumed DCM is 
very common in the young and very young. Close links with cardiac genetic services are 
useful for investigation of the index case and extended families.(172;173) Identification of 
abnormal cardiac structure and asymptomatic left ventricular dysfunction in family 
members permits risk stratification and treatment prior to the onset of symptoms of HF. 
Cardiovascular imaging, investigation for endocrine, nutritional and biochemical causes 
are mandatory, and myocardial biopsy should also be considered.(174) As anticipated, very 
few young patients have HF-PEF (e.g. 14% in those aged <40 years). 
 
The preponderance of men in younger age groups was striking, with at least 70% 
males in every age category below 70 years, and was apparent in both cohort studies (52% 
of our patients) and randomized controlled trials (48%). More than half of the 
observational patient data originate from the Euro Heart Failure Survey and Italian 
Network on Congestive Heart Failure registry, which are broadly representative of patients 
hospitalised with HF or referred to HF clinics.(170;175) Peripartum cardiomyopathy 
should increase the proportion of women in younger age groups, though may have been 
underrepresented in cohort studies from hospitals without maternity services. Furthermore, 
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pharmacological trials often excluded pregnant or lactating women. Young women with 
HF are thus most likely underrepresented. 
 
The preponderance of men in younger age groups is also reported in community 
echocardiographic studies,(34;39;47;51;176) epidemiology and large cohort studies of 
cardiomyopathy,(160;177) cardiomyopathy registries,(178;179) and genetic studies in 
patients with cardiomyopathy.(180-182) X-linked laminopathies and dystrophin defects 
such as Becker’s and Duchenne’s muscular dystrophy must contribute.(183;184) 
Dystrophin defects are most prevalent in younger (<30 years) men.(185) Certain mutations 
in cardiac troponin T or cardiac β-myosin heavy chain in patients with DCM result in early 
onset ventricular dysfunction and HF.(186;187) In patients with hypertrophic 
cardiomyopathy, men have more hypertrophy and a higher risk of left ventricular systolic 
dysfunction.(188) Arrhythmogenic right ventricular cardiomyopathy likewise exhibits a 
male preponderance with greater right ventricular dilatation.(189) Perhaps men 
preferentially inherit as yet unidentified genetic conditions causing dilated 
cardiomyopathy. A male preponderance of occult coronary disease and excess alcohol 
consumption is also possible. In addition, gender specific biological differences may play a 
role, including differences in cellular remodelling in response to wall stress e.g. after 
myocardial infarction.(190) Finally, the proportion of women rises sharply from around 70 
years, suggesting survivorship (i.e. women’s greater life expectancy) contributes. No 
matter the explanation, clinicians investigating young men with symptoms compatible with 
HF should be mindful to exclude the diagnosis. 
 
4.4.2 Ejection fraction and medications 
 
Young patients with HF have more severe left ventricular systolic dysfunction than 
their elderly counterparts, mandating therapy with ACEI, beta-blocker and spironolactone 
in most cases. Among the youngest patients in MAGGIC, prescribing rates of ACEI were 
50% greater and beta-blocker rates almost double those observed in the elderly. While 
these differences are multifactorial, prescribing by indication and contraindication likely 
play a part: the prevalence of HF-REF is highest in the youngest, while comorbidities 
precluding therapy (e.g. chronic kidney disease and severe obstructive airways disease) are 
least prevalent in these patients. There are no evidence-based pharmacological treatments 
with prognostic benefit in HF-PEF.(5) The greater likelihood of patient with HF-REF 
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being managed in specialist cardiology services is associated with higher levels of 
pharmacotherapy.(146;170) 
 
4.4.3 Symptoms 
 
Despite having more severe left ventricular systolic dysfunction, younger patients 
in MAGGIC reported less marked symptoms as represented by NYHA class III/IV. NYHA 
functional class increased progressively with every decade. The DIG study reported similar 
findings (i.e. worse left ventricular systolic function but fewer symptoms in the young) 
albeit in a randomised clinical trial.(87) A small number of young patients with severe 
symptoms may have been excluded from our analysis and DIG due to listing for cardiac 
transplantation. Alternate reasons why younger patients have better NYHA functional class 
are incompletely understood, but may partly reflect fewer comorbidities such as atrial 
fibrillation or airways disease. 
 
4.4.4 Outcomes 
 
The three year mortality rate was relatively low in all age groups under the age of 
60 years: 16.5%, 16.2% and 18.2% in those aged <40, 40-49 and 50-59 years respectively. 
Prior epidemiological studies have reported worse three years outcomes in younger age 
groups compared to our findings. In patients with HF aged 45-54 years in UK primary care 
followed from 1991, the 3 year mortality was 47% and 24% in men and women 
respectively.(168) Five-year mortality in patients aged <55 years was 39.4% in a 
previously hospitalised Scottish population studied from 1986-2003.(67) Conversely, the 
mortality rate in younger patients with HF is still significantly higher than the general 
population in the same age categories (death per 1000/year: 0.2 to 1.2 <40 years, 1.1 to 2.5 
40-49 years and 2.6 to 6.2 in 50-59 years compared to our study 64.2 <40 years, 60.1 40-
49 years and 73.2 50-59 years).(191;192) 
 
The MAGGIC dataset includes 31 studies without EF as an inclusion criterion 
conducted over several decades. The deaths/1000 patient-years for the younger patients in 
the current analysis were similar among the RCTs and observational studies. The lower 
mortality rates in our dataset could reflect improved pharmacotherapies, but are unlikely to 
be a consequence of device-based therapies, as most of the included studies predate the 
increased uptake of device-based therapies for HF. The clinical relevance of our 
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observations is clear. Clinicians managing young patients with HF can inform and counsel 
patients appropriately, rather than citing outcomes from elderly cohorts. Patients need to 
know their predicted longer-term prognosis with modern medical and device therapy. To 
what extent these better outcomes are sustained is of interest. Mode of death was not 
included in MAGGIC (as it was not recorded in many of the included studies). Future 
studies should establish whether younger patients are more likely to die suddenly or from 
progressive pump failure. Potential therapeutic strategies to reduce mortality include 
implantable cardioverter defibrillators, cardiac resynchronisation therapy, ventricular 
assists devices, cardiac transplantation, and novel pharmacological agents. The impact of 
these strategies in part relates to the mode of death. 
 
4.5 Limitations 
 
 A number of limitations merit consideration. The meta-analysis included individual 
patients’ data from 31 randomised trials and observational studies, the variables collected 
being determined by each original study. Data on medications, NYHA functional class, 
echocardiographic and laboratory variables were not universally available in all patients. 
However, only variables with data available for at least 90% of the patients were included. 
Other important prognostic variables were not selected due to missing data, which could 
bias the analysis. The primary outcome, all-cause mortality, increases with age in part due 
to greater cardiovascular and non-cardiovascular comorbidity. However, too few studies 
provided cause-specific death to analyse cardiovascular death as opposed to all-cause 
mortality. The balance and competing risks between pump failure, sudden cardiac death, 
other cardiovascular death (e.g. myocardial infarction), and non-cardiovascular death are 
likely age dependent. 
 
4.6 Conclusion 
 
Younger patients with HF have different clinical profile including different 
aetiologies, more severe left ventricular dysfunction but less severe symptoms, and a lower 
three-year mortality. These differences are important to clinicians managing younger 
patients with H and also to younger patients with HF themselves who can be reassured by 
their dramatically better outcomes. 
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Chapter 5 
 
Characteristics, treatment and outcomes of young adults newly 
diagnosed with heart failure: an analysis from the UK Clinical 
Practice Research Datalink. 
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5.1 Introduction 
 
Around 900,000 people in the UK and 15 million people in Europe suffer from 
HF.(1;193)  There are limited data with regards to how young patients differ from older 
patients with HF.  Young patients with HF do appear to differ in several respects. 
 
The U.K. Clinical Practice Research Datalink (CPRD) is a large and well-validated 
primary care database. 654 practices contribute information, covering approximately 8% of 
the UK population,(194-196) with 5.1 million active patients and 66 million person-years.  
The database records data on demographics, diagnoses, prescriptions, investigations, 
hospitalisations and mortality. This rich dataset offers an opportunity to investigate the 
characteristics and outcomes of young adults with heart failure. 
 
Two previous studies have reported on HF using the CPRD dataset.  The first 
excluded those under 45 years and predated (1991-1994) the widespread use of evidence-
based pharmacological and device therapies.(20) The second described cases in 1996 only 
and was limited to reporting clinical characteristics.  Patients aged less than 40 were not 
included.(197)  
 
This study examines how young adults (aged less than 60 years) with HF differ 
from older adults with HF in the modern era, in terms of demographics, co-morbidities, 
treatment, and prognosis. 
 
5.2 Methods 
 
5.2.1 Dataset 
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This is a retrospective cohort study using data from the U.K. Clinical Practice Research 
Datalink (CPRD). The dataset is a large and well-validated primary care database with 654 
practices contribute information, covering approximately 8% of the UK population. The 
diagnosis of HF in this dataset has previously been validated.  
 
5.2.2 Study population 
 
The study population consisted of all patients permanently registered with one of 
the 654 practices contributing to the November 2012 release of CPRD.  
 
Patients with a first diagnosis of HF were identified after a 1-year screening period.  
The 1-year screening period provides adequate time to establish patients’ baseline 
comorbidities and treatments before following them for an event in any newly registered 
patients with a practice.  Similarly, in a newly registered practice with the CPRD, the 1-
year screening period starts after the up-to-standard date, which is the date when the 
practice’s records were deemed adequate for research purpose by the CPRD.  HF was 
defined as a medical code for  ‘heart failure, cardiac failure, myocardial failure, cardiac 
dropsy, RV failure, LV failure, impaired LV function, weak heart, low output syndrome, 
cardiac asthma, cardiac insufficiency or myocardial insufficiency’ in patient records. The 
accuracy of the U.K. CPRD diagnosis of HF has previously been validated.(198) The study 
cohort included all incident cases of HF who were at least 20 years of age at the time of 
diagnosis.  The study population was stratified into 7 age categories: 20-29, 30-39, 40-49, 
50-59, 60-69, 70-79 and ≥80 years.  
 
5.2.3 Medical codes used for HF 
 
398,884,1223,2062,2906,4024,5141,5942,7251,9913,10079,10154,11424,12590,13189,15
058,17278,18853,19066,21235,23481,23707,24503,26242,27679,27884,27964,32671,328
98,32911,46672,46912,51214,68682,94870,8966,7321,558,11284,5155,5255,18793,12550
,9524,11351,5293,22262,43618,26082,48466 
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5.2.4 Follow-up 
 
The follow up period started with the date HF was diagnosed and ended with the 
earliest of date of death, date of leaving the practice or practice’s last data collection date. 
 
5.2.5 Outcomes and covariates 
 
For each patient, the database for the most recent of the following prior to date of 
HF diagnosis was searched: heart rate, systolic blood pressure, diastolic blood pressure and 
body mass index (BMI); any history of cardiovascular disease, congenital heart disease, 
diabetes, thyroid disease, cancer, connective tissue disease, alcohol related disease, chronic 
kidney disease, COPD, asthma, anaemia, depression and cardiac procedure/surgery; the 
most recent smoking and alcohol status prior to the index date; and medication in the year 
prior to the index date. These baseline characteristics were summarised by age categories. 
 
Prescription rates for ACEi or ARB, β blocker, and aldosterone antagonist between 
2006 and 2011 and all cause mortality were summarised by age categories. I reported 
prescription rates between 2006 and 2011 to reflect the most contemporary prescribing 
practice.  
 
5.2.6 Statistical analysis 
 
Differences in baseline characteristics between age groups were tested using a 
generalised linear model with binomial errors for dichotomous data or normal errors for 
other data.  For incident cases in 2006-11 prescription rates were estimated at 1, 3 and 6 
months, and 1 and 5 years after diagnosis from Kaplan-Meier curves for each age group.  
All-cause mortality rates were estimated at 30 days and 1, 5, and 10 years from Kaplan-
Meier curves for each age and sex group, separately for incident cases occurring in 1988-
1993, 1994-1999, 2000-2005 and 2006-2011. 
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Adjusted hazard ratios for all-cause death were estimated for each age group 
relative to the 60-69 year group using proportional hazard models. A p value of <0.05 was 
considered statistically significant.  All analyses were performed using SAS 9.1 
 
5.3 Results 
 
5.3.1 Baseline characteristics 
 
Among 3 706 480 patients identified from the CPRD, there were 119,554 incident 
cases of HF in patients aged at least 20 years between 1988 and 2011.  There were more 
men than women in all age groups below 80 year of age (Figure 5.1). Baseline 
characteristics are summarised in Table 5.1.  
 
5.3.1.1 Heart rate, blood pressure, and body mass index 
 
Younger patients had higher heart rates, lower blood pressures and lower body 
mass indices. (Table 5.1) 
 
5.3.1.2 Comorbidities 
 
Ischaemic heart disease, hypertension and valvular heart disease were less common 
in younger age groups (Table 5.1). Congenital heart disease and myocarditis were more 
common in the young. Atrial fibrillation, diabetes, and stroke were less common in 
younger age categories. Depression was more prevalent in the younger age groups.  
Among patients aged <60 years, chronic kidney disease was most prevalent in patients 
aged 20-29 years (7.9% 20-29 years, 6.3% 30-39 years, 4.1% 40-49 years, and 4.6% 50-59 
years; p<0.001).  A third of patients aged 20-29 years were diagnosed with asthma prior to 
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their index HF diagnosis.  A history of pulmonary embolism was less common in the 
young.   
 
5.3.1.3 Baseline medications 
 
Despite the higher prevalence of depression in the youngest age group, the use of 
anti-depressants in younger patients was low.  However, among patient aged <60 years, 
anti-psychotics were prescribed most frequently in patients aged 20-29 years (9.9% in 20-
29 years vs. 6.6% in 50-59 years; p<0.001).  
 
5.3.2 Prescription rates initiated after diagnosis of HF between 2006 and 2011 
 
At all time points below 1 year, younger patients were less frequently prescribed 
ACEi or ARBs.  The younger the patients the less often they received these therapies. 
(Table 5.2)  Rates of β blocker prescriptions were also low. The 20-29 years group 
received less β blockers 5 years after diagnosis of HF. Aldosterone antagonists were 
similarly less often prescribed in younger age groups.  For example, at 5 years 17.8% of 
patients aged 20-29 received aldosterone antagonists compared to 36.9% of those aged 
over 80.   
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Figure 5.1. Distribution of patients with newly diagnosed HF by age categories and sex. 
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Table 5.1. Baseline characteristics at index diagnosis of HF by age. 
 
  Age at diagnosis  
 N 20-29 30-39 40-49 50-59 60-69 70-79 ≥ 80 P value1 
Demographic          
Cases 119,554 203 522  2,099  7,128  19,405  40,813  49,384   
Men (%) 50.1 55.7 64.2 68.1 69.4 63.0 53.4 38.7  
Examination (means)          
Heart rate (beats/min,) 24,044 85.5 83.9 83.3 80.4 78.2 76.9 76.0 <0.001 
Systolic blood pressure 
(mmHg) 109,637 121.9 129.4 134.7 139.7 144.7 148.9 151.6 
<0.001 
Diastolic blood pressure 
(mmHg) 109,628 75.1 80.5 83.5 84.2 83.3 82.3 81.5 
<0.001 
Body mass index (kg/m2) 86,110 25.8 28.7 29.8 29.6 28.8 27.5 26.0 <0.001 
Comorbidities (%)          
Cardiovascular          
Ischaemic heart disease 39,793 5.9 12.5 24.8 33.7 38.7 36.6 29.1 <0.001 
Hypertension 57,034 16.3 21.1 29.7 39.6 46.6 50.6 48.1 <0.001 
Hyperlipidaemia 13,332 1.5 5.2 10.7 15.9 17.0 13.4 6.5 <0.001 
Valvular heart disease 5,810 3.0 5.9 4.2 4.4 4.8 5.0 4.8 <0.001 
Atrial fibrillation 22,358 4.4 9.0 10.2 12.8 16.1 19.3 20.6 <0.001 
Myocarditis 112 2.0 1.1 0.8 0.4 0.1 0.0 0.0 <0.001 
Stroke 18,695 3.9 3.3 4.1 7.6 11.7 15.5 19.2 <0.001 
Pulmonary embolism 2,604 1.0 1.5 1.6 2.1 2.2 2.3 2.1 0.038 
Peripheral arterial 
disease 9,859 2.0 1.1 2.5 5.5 8.8 9.7 7.6 
<0.001 
Congenital Heart Disease          
Any congenital heart 
disease 339 6.9 5.2 2.3 0.7 0.4 0.2 0.1 
<0.001 
Diabetes 19,729 9.4 13.8 15.7 19.2 21.4 18.7 12.5 <0.001 
Any thyroid disease 9,501 3.0 5.0 4.4 5.2 6.6 8.0 9.0 <0.001 
All cancer 10,407 3.0 3.8 3.3 4.3 6.2 9.1 10.3 <0.001 
Connective tissue disease          
Any connective tissue 
disease  4,905 5.4 2.9 3.0 3.7 4.6 4.4 3.7 
<0.001 
Connective tissue 
disease 1,521 2.0 1.0 0.8 0.9 1.3 1.2 1.4 
0.002 
Rheumatoid arthritis 3,045 1.5 1.1 1.7 2.2 3.0 3.0 2.1 <0.001 
Others          
Chronic kidney disease 11,587 7.9 6.3 4.1 4.6 6.5 9.4 12.2 <0.001 
COPD 15,774 3.0 2.7 4.1 9.9 15.4 16.1 10.9 <0.001 
Asthma 17,837 29.1 21.8 18.8 17.2 18.0 16.7 11.6 <0.001 
Anaemia 16,555 6.9 8.0 8.4 7.0 8.9 12.7 18.1 <0.001 
Depression 24,279 24.6 31.2 30.5 26.4 23.3 19.8 18.1 <0.001 
Cardiac procedure/surgery          
PCI 2,197 1.5 1.1 3.4 3.4 3.2 2.0 0.8 <0.001 
CABG 4,907 0.5 0.8 3.2 6.1 7.1 5.3 1.7 <0.001 
Social history (%)          
Smoking status          
Current smoker 19,289 19.2 38.9 36.4 32.9 25.7 16.7 8.4 <0.001 
Ex-smoker 29,479 9.4 12.6 18.8 25.3 29.5 27.8 20.5 <0.001 
Alcohol status          
Heavy drinker  1,376 3.4 4.4 4.0 3.2 2.2 1.0 1,376 <0.001 
Medications (%)          
Cardiovascular          
ACEi 35,672 22.2 29.9 34.2 35.7 35.0 31.4 25.5 <0.001 
ARB 6,315 3.4 5.0 4.3 4.9 5.5 5.9 4.8 <0.001 
ACEi or ARB 40,314 24.1 32.6 37.0 38.8 38.8 35.7 29.3  
B-blocker 11,372 10.8 13.8 15.2 13.3 12.0 9.6 7.7 <0.001 
Aldosterone antagonist 4,889 5.9 5.9 7.0 5.4 4.6 3.9 3.7 <0.001 
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Diuretic 59,355 17.2 28.2 32.8 37.8 44.9 50.3 53.8  
Digoxin 15,831 5.9 6.5 6.4 8.5 10.4 13.1 15.6 <0.001 
Isosorbide dinitrate + 
hydralazine 1,813 1.0 0.0 0.8 1.3 1.6 1.7 1.4 
<0.001 
Hydralazine 302 0.5 0.0 0.1 0.2 0.3 0.3 0.2 0.368 
Isosorbide dinitrates 11,679 0.0 2.1 5.5 8.7 10.6 10.3 9.5 <0.001 
Nicorandil 4,141 0.0 1.3 2.8 3.7 4.4 3.6 3.0 <0.001 
Ivabradine 74 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.003 
Warfarin 13,884 7.9 12.3 12.0 12.4 13.7 13.4 9.2 <0.001 
Any anti-platelets 50,598 7.9 13.8 27.3 34.4 43.0 43.8 43.0 <0.001 
Aspirin 48,157 7.9 13.6 26.3 32.8 41.0 41.6 40.9 <0.0001 
Clopidogrel 5,373 0.0 2.1 5.1 5.7 5.2 4.6 4.0 <0.001 
Dipyridamole 1,672 0.0 0.2 0.3 0.9 1.2 1.5 1.7 <0.001 
Statin 28,992 3.9 13.6 23.2 30.7 32.8 28.1 17.0 <0.001 
Calcium channel 
blockers 32,291 10.3 11.9 17.9 25.5 30.1 29.8 24.3 
<0.0001 
Amiodarone 4,146 3.4 4.0 2.8 3.9 4.1 3.9 2.8 <0.001 
Diabetic          
Sulphonylureas 8,290 0.5 1.9 3.8 6.5 8.3 8.2 5.6 <0.001 
Biguanides 8,301 0.0 5.2 6.5 10.0 10.7 8.2 4.1 <0.001 
Thiazolidinediones 1,195 0.0 0.4 0.8 1.4 1.5 1.3 0.6 <0.001 
Insulin 4,718 4.4 7.3 6.7 6.7 6.8 4.4 1.9 <0.001 
Chronic airway disease          
β agonist 24,646 17.7 22.8 20.2 23.6 25.5 23.3 16.1 <0.001 
Anti-muscarinic 10,065 1.0 1.9 3.9 7.8 10.5 10.2 6.5 <0.001 
Theophylline 3,566 0.5 1.1 1.4 2.7 4.2 3.7 2.0 <0.001 
Oxygen 1,806 3.4 1.0 1.0 1.3 1.9 1.8 1.2 <0.001 
NSAIDs          
Non-selective NSAIDs 29,703 18.7 16.3 21.5 23.1 26.4 25.8 24.0 <0.001 
Selective COX-2 
inhibitors 2,934 2.0 1.3 1.7 2.0 2.4 2.5 2.5 
0.004 
Anti-depressants          
Tricyclic anti-
depressants 11,725 4.4 7.3 11.4 10.8 10.5 9.8 9.3 
<0.001 
SSRIs 8,382 5.9 11.1 11.8 9.5 7.8 6.4 6.7 <0.001 
Duloxetine 97 0.0 0.8 0.2 0.2 0.1 0.1 0.1 <0.001 
Mirtazapine 729 0.5 2.1 0.8 0.9 0.5 0.5 0.6 <0.001 
Venlafaxine 694 2.5 2.9 1.5 1.1 0.7 0.5 0.5 <0.001 
Anti-psychotics          
Anti-psychotic drugs 10,412 9.9 8.2 7.5 6.6 6.8 7.8 10.5 <0.001 
1 From generalised linear models with binomial errors for dichotomous data or normal errors for other data. 
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; CABG=coronary artery bypass grafting; 
COPD=chronic obstructive pulmonary disease; COX-2=cyclooxygenase-2; NSAIDs=non-steroidal anti-inflammatory drugs; 
PCI=percutaneous coronary intervention;  
 
Table 5.2. Prescription rates in patients with index diagnosis of HF between 2006-2011, including patients who had received the treatment prior to 
diagnosis. 
% (95% CI) Age at diagnosis 
 20 to 29 30 to 39 40 to 49 50 to 59 60 to 69 70 to 79 ≥ 80 
N 82 219 803 2252 5333 9964 12838 
ACEi or ARB  
1 month 39.4 (28.7,50.0) 48.8 (42.2,55.5) 56.6 (53.2,60.1) 58.0 (56.0,60.1) 58.9 (57.6,60.2) 56.0 (55.1,57.0) 49.0 (48.1,49.8) 
3 months 60.5 (49.8,71.2) 69.9 (63.7,76.0) 77.5 (74.6,80.4) 78.8 (77.1,80.5) 77.5 (76.3,78.6) 74.6 (73.7,75.4) 64.9 (64.0,65.7) 
6 months 64.3 (53.8,74.8) 76.4 (70.6,82.2) 80.8 (78.0,83.6) 83.0 (81.5,84.6) 81.2 (80.2,82.3) 78.8 (78.0,79.6) 68.9 (68.0,69.7) 
1 year 67.1 (56.7,77.4) 77.5 (71.8,83.2) 82.8 (80.2,85.5) 85.6 (84.1,87.1) 83.8 (82.7,84.8) 82.0 (81.2,82.8) 71.8 (71.0,72.7) 
5 years 81.1 (68.0,94.2) 79.4 (73.7,85.0) 87.3 (84.5,90.0) 89.5 (88.0,91.0) 90.0 (88.9,91.0) 88.5 (87.6,89.4) 80.7 (79.5,82.0) 
B-blocker         
1 month 25.8 (16.3,35.3) 35.9 (29.5,42.3) 39.6 (36.2,43.0) 38.8 (36.8,40.8) 34.6 (33.3,35.9) 30.2 (29.3,31.1) 25.3 (24.5,26.1) 
3 months 41.9 (31.2,52.7) 52.7 (45.9,59.4) 56.0 (52.5,59.4) 53.2 (51.2,55.3) 47.9 (46.6,49.3) 43.3 (42.3,44.3) 35.6 (34.8,36.5) 
6 months 45.8 (34.9,56.7) 57.2 (50.5,63.9) 60.3 (56.9,63.7) 57.8 (55.8,59.9) 53.2 (51.8,54.5) 48.2 (47.2,49.2) 39.4 (38.5,40.3) 
1 year 49.9 (38.9,61.0) 60.4 (53.8,67.1) 63.6 (60.2,67.0) 61.8 (59.8,63.9) 57.6 (56.3,59.0) 52.3 (51.3,53.3) 43.0 (42.1,43.9) 
5 years 57.6 (46.3,68.8) 69.7 (62.6,76.8) 73.4 (69.8,77.0) 70.9 (68.7,73.0) 69.7 (68.2,71.2) 66.9 (65.6,68.1) 57.8 (56.3,59.2) 
Aldosterone antagonist  
1 month 6.2 (0.9,11.4) 14.3 (9.6,18.9) 16.3 (13.7,18.9) 14.0 (12.6,15.5) 13.1 (12.2,14.0) 11.7 (11.1,12.3) 11.0 (10.5,11.6) 
3 months 13.6 (6.1,21.0) 21.8 (16.3,27.3) 24.2 (21.2,27.2) 20.9 (19.2,22.6) 20.2 (19.2,21.3) 17.8 (17.0,18.5) 17.1 (16.4,17.7) 
6 months 14.8 (7.1,22.6) 25.7 (19.9,31.6) 26.7 (23.6,29.8) 23.9 (22.2,25.7) 23.4 (22.3,24.6) 21.0 (20.2,21.9) 20.1 (19.3,20.8) 
1 year 16.2 (8.1,24.2) 27.3 (21.3,33.3) 30.2 (27.0,33.4) 27.5 (25.6,29.4) 27.0 (25.8,28.3) 24.4 (23.5,25.3) 23.6 (22.8,24.4) 
5 years 17.8 (9.3,26.2) 36.2 (29.1,43.4) 38.6 (34.7,42.6) 36.6 (34.2,38.9) 38.9 (37.3,40.6) 37.8 (36.5,39.1) 36.9 (35.5,38.2) 
Digoxin         
1 month 2.4 (0.0, 5.8) 6.9 (3.5,10.3) 9.0 (7.0,11.0) 9.0 (7.9,10.2) 10.9 (10.1,11.8) 13.5 (12.8,14.1) 16.4 (15.8,17.1) 
3 months 7.4 (1.7,13.1) 9.8 (5.8,13.7) 12.5 (10.2,14.8) 12.6 (11.2,13.9) 15.9 (14.9,16.8) 18.8 (18.1,19.6) 22.8 (22.1,23.5) 
6 months 8.6 (2.5,14.8) 9.8 (5.8,13.7) 13.8 (11.4,16.2) 13.8 (12.3,15.2) 17.5 (16.4,18.5) 20.7 (19.9,21.5) 24.7 (24.0,25.5) 
1 year 10.0 (3.4,16.5) 10.8 (6.6,15.0) 14.4 (12.0,16.9) 15.0 (13.5,16.4) 19.2 (18.1,20.2) 22.4 (21.6,23.3) 26.5 (25.7,27.3) 
5 years 10.0 (3.4,16.5) 14.3 (8.9,19.6) 18.0 (15.1,21.0) 20.1 (18.2,22.0) 24.4 (23.1,25.7) 29.6 (28.5,30.7) 35.1 (33.8,36.4) 
   ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; CI=confidence interval.  
5.3.3 Mortality 
 
Mortality rates following a diagnosis of HF improved over the last two decades in 
all age groups. (Table 5.3) Since 2000, 1 and 5 year mortality rates have generally been 
lowest in younger patients and increased with age, rising more sharply from 50 years of 
age. After multivariate adjustment, patients aged 30-39 years had the lowest risk of death 
[HR 0.49 (95% CI: 0.40-0.61)] compared to the reference age group 60-69 years. (Table 
5.4)  The youngest men are an exception. Men aged 20-29 years had a similar risk of death 
to the reference age group 60-69 years [HR 1.02 (95% CI: 0.72-1.45)], which was 
significantly greater than men aged 30-39 and 40-49 years. 
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Table 5.3. Mortality stratified by sex, year, and age. 
	
% (95% CI) Age group 
 20 to 29 30 to 39 40 to 49 50 to 59 60 to 69 70 to 79 ≥ 80 
Men        
1988-1993, 
N 
17 14 102 426 1425 2469 1868 
1994-1999, 
N 
10 46 243 1051 2889 5648 4392 
2000-2005, 
N 
42 120 512 1818 4286 7794 6937 
2006-2011, 
N 
44 155 573 1650 3619 5880 5910 
30 days        
1988-1993 35.3  
(12.6,58.0) 
21.4 
(0.0,42.9) 
13.7 
(7.0,20.4) 
11.5 
(8.5,14.5) 
10.7 
(9.1,12.4) 
13.1 
(11.8,14.4) 
15.9 
(14.2,17.6) 
1994-1999 20.0  
(0.0,44.8) 
32.6 
(19.1,46.2) 
11.5  
(7.5,15.5) 
12.0 
(10.0,14.0) 
9.4  
(8.4,10.5) 
12.0 
(11.2,12.9) 
16.4 
(15.3,17.5) 
2000-2005 4.8  
(0.0,11.2) 
3.3  
(0.1, 6.6) 
4.7  
(2.9, 6.5) 
5.6  
(4.6, 6.7) 
5.6  
(4.9, 6.2) 
7.6  
(7.0, 8.2) 
12.6 
(11.9,13.4) 
2006-2011 4.5  
(0.0,10.7) 
5.2  
(1.7, 8.7) 
4.9  
(3.1, 6.7) 
4.4  
(3.4, 5.4) 
4.2  
(3.6, 4.9) 
4.9  
(4.4, 5.5) 
11.3 
(10.5,12.1) 
1 year        
1988-1993 47.1 
(23.3,70.8) 
35.7 
(10.6,60.8) 
22.7 
(14.5,30.9) 
20.1 
(16.3,23.9) 
25.1 
(22.9,27.4) 
31.8 
(30.0,33.7) 
38.0 
(35.8,40.2) 
1994-1999 30.0  
(1.6,58.4) 
34.9 
(21.1,48.6) 
17.0 
(12.2,21.7) 
19.8 
(17.4,22.2) 
21.5 
(20.0,23.0) 
28.5 
(27.3,29.7) 
38.1 
(36.6,39.5) 
2000-2005 14.6  
(3.8,25.5) 
5.9  
(1.7,10.1) 
9.6  
(7.1,12.2) 
12.2 
(10.7,13.7) 
15.4 
(14.3,16.5) 
22.5 
(21.5,23.4) 
34.6 
(33.5,35.7) 
2006-2011 11.5  
(2.0,21.0) 
7.8  
(3.6,12.0) 
7.1  
(5.0, 9.2) 
8.9  
(7.5,10.2) 
11.8 
(10.7,12.8) 
16.5 
(15.5,17.4) 
32.7 
(31.4,33.9) 
5 years        
1988-1993 66.9 
(43.8,90.0) 
35.7 
(10.6,60.8) 
40.6 
(30.8,50.4) 
42.0 
(37.2,46.8) 
53.2 
(50.6,55.9) 
66.1 
(64.2,68.0) 
79.3 
(77.3,81.3) 
1994-1999 64.0 
(32.4,95.6) 
54.4 
(39.5,69.4) 
33.9 
(27.7,40.0) 
38.8 
(35.8,41.8) 
46.6 
(44.7,48.4) 
61.8 
(60.5,63.1) 
78.2 
(76.9,79.6) 
2000-2005 23.3  
(9.8,36.7) 
22.0 
(14.0,30.0) 
20.4 
(16.8,24.1) 
27.0 
(24.9,29.1) 
37.2 
(35.7,38.7) 
53.3 
(52.2,54.5) 
74.7 
(73.6,75.8) 
2006-2011 14.1  
(3.6,24.6) 
13.6 
(7.4,19.7) 
18.4 
(14.3,22.6) 
20.1 
(17.6,22.5) 
31.5 
(29.5,33.4) 
46.5 
(44.8,48.3) 
71.7 
(70.0,73.4) 
10 years        
1988-1993 73.5 
(51.7,95.4) 
63.3 
(35.7,90.9) 
59.4 
(49.2,69.5) 
62.0 
(57.1,66.8) 
73.9 
(71.5,76.3) 
87.1 
(85.6,88.5) 
95.9 
(94.8,97.0) 
1994-1999 82.0  
(52.5, 100) 
60.0 
(45.0,74.9) 
46.1 
(39.4,52.7) 
55.0 
(51.8,58.2) 
69.1 
(67.3,70.9) 
83.5 
(82.4,84.6) 
95.3 
(94.5,96.1) 
2000-2005  32.5 
(21.8,43.1) 
29.8 
(25.1,34.6) 
41.3 
(38.6,44.1) 
58.7 
(56.9,60.6) 
77.5 
(76.3,78.8) 
93.4 
(92.5,94.3) 
Women        
1988-1993, 
N 
5 13 48 246 986 2593 3464 
1994-1999, 
N 
16 34 125 504 1914 5411 7953 
2000-2005, 
N 
28 63 235 757 2405 6597 10868 
2006-2011, 
N 
41 77 261 676 1881 4421 7992 
30 days        
1988-1993 20.0  
(0.0,55.1) 
15.4 
(0.0,35.0) 
18.8 
(7.7,29.8) 
7.7   
(4.4,11.1) 
11.1 
(9.1,13.0) 
11.7 
(10.5,13.0) 
17.5 
(16.2,18.7) 
1994-1999 12.5  
(0.0,28.7) 
8.8  
(0.0,18.4) 
18.5 
(11.6,25.3) 
10.5 
(7.8,13.2) 
10.0 
(8.6,11.3) 
10.5 
(9.7,11.4) 
16.2 
(15.4,17.0) 
2000-2005 3.6  
(0.0,10.4) 
1.6  
(0.0, 4.7) 
8.5  
(4.9,12.1) 
4.6  
(3.1, 6.1) 
5.9  
(5.0, 6.9) 
7.5  
(6.9, 8.2) 
12.9 
(12.3,13.6) 
2006-2011 4.9  
(0.0,11.5) 
7.8  
(1.8,13.8) 
3.8  
(1.5, 6.2) 
4.1  
(2.6, 5.6) 
4.8  
(3.9, 5.8) 
5.6  
(4.9, 6.3) 
12.8 
(12.1,13.6) 
1 year        
1988-1993 40.0  15.4 22.9 17.2 22.5 24.4 35.7 
	 140	
(0.0,82.9) (0.0,35.0) (11.0,34.8) (12.5,22.0) (19.9,25.2) (22.7,26.1) (34.0,37.3) 
1994-1999 19.8  
(0.0,40.0) 
21.0 
(7.1,34.8) 
28.2 
(20.3,36.1) 
19.1 
(15.7,22.6) 
19.8 
(18.1,21.6) 
23.7 
(22.6,24.9) 
34.5 
(33.5,35.6) 
2000-2005 11.5  
(0.0,23.7) 
9.7  
(2.3,17.0) 
12.8 
(8.5,17.1) 
10.7 
(8.5,12.9) 
14.2 
(12.8,15.6) 
19.1 
(18.1,20.0) 
32.0 
(31.1,32.9) 
2006-2011 9.9  
(0.7,19.1) 
10.6 
(3.7,17.6) 
9.7  
(6.1,13.3) 
9.6  
(7.3,11.8) 
12.4 
(10.9,13.9) 
16.9 
(15.8,18.0) 
32.8 
(31.8,33.9) 
5 years        
1988-1993 40.0  
(0.0,82.9) 
15.4 
(0.0,35.0) 
37.4 
(23.2,51.6) 
33.8 
(27.7,39.9) 
45.8 
(42.6,49.0) 
52.9 
(50.9,54.9) 
72.9 
(71.3,74.5) 
1994-1999 36.2 
(10.1,62.3) 
31.1 
(14.9,47.2) 
36.7 
(28.1,45.2) 
35.9 
(31.6,40.3) 
41.6 
(39.3,43.9) 
50.8 
(49.4,52.2) 
70.0 
(68.9,71.1) 
2000-2005 28.3 
(10.5,46.2) 
17.4 
(7.5,27.3) 
25.0 
(19.3,30.7) 
26.4 
(23.1,29.7) 
34.2 
(32.3,36.2) 
45.9 
(44.6,47.1) 
68.7 
(67.8,69.7) 
2006-2011 14.2  
(2.2,26.2) 
15.5 
(6.2,24.7) 
19.1 
(13.2,24.9) 
23.6 
(19.3,27.8) 
32.0 
(29.3,34.8) 
40.8 
(38.9,42.8) 
68.7 
(67.2,70.2) 
10 years        
1988-1993 40.0  
(0.0,82.9) 
32.3 
(6.1,58.5) 
47.2 
(32.3,62.1) 
50.0 
(43.3,56.7) 
65.5 
(62.3,68.7) 
75.4 
(73.6,77.2) 
91.5 
(90.3,92.6) 
1994-1999 57.5 
(19.3,95.7) 
40.3 
(21.9,58.8) 
51.1 
(41.9,60.4) 
52.2 
(47.5,56.9) 
60.6 
(58.2,63.0) 
73.9 
(72.6,75.2) 
90.9 
(90.1,91.7) 
2000-2005 34.8 
(14.5,55.1) 
24.1 
(12.4,35.8) 
36.4 
(29.2,43.7) 
44.7 
(40.5,49.0) 
54.7 
(52.2,57.1) 
69.0 
(67.6,70.4) 
89.8 
(89.0,90.7) 
CI=confidence interval. 
Table 5.4. Hazard ratios (HR) by age categories and sex for all cause death 
	
 
Age group 
20 to 29 30 to 39 40 to 49 50 to 59 60 to 69 70 to 79 ≥ 80 
N 
HR 
(95%CI) N 
HR 
(95%CI) N 
HR 
(95%CI) N 
HR 
(95%CI) N HR N 
HR 
(95%CI) N 
HR 
(95%CI) 
All deaths                
Unadjusted Male 
31 
0.98 
(0.69,1.40) 57 
0.52 
(0.40,0.68) 261 
0.49 
(0.43,0.55) 1,247 
0.66 
(0.62,0.71) 4,150 1 9,401 
1.57 
(1.52,1.63) 9,483 
2.63 
(2.53,2.73) 
Female 
14 
0.57 
(0.34,0.96) 27 
0.45 
(0.31,0.66) 147 
0.67 
(0.57,0.79) 535 
0.70 
(0.64,0.77) 2,352 1 7,541 
1.42 
(1.36,1.49) 14,630 
2.60 
(2.49,2.72) 
Adjusted 
for 
covariates 
Male 
31 
1.02 
(0.72,1.45) 57 
0.52 
(0.40,0.68) 261 
0.50 
(0.44,0.57) 1,247 
0.68 
(0.64,0.72) 4,150 1 9,401 
1.54 
(1.49,1.60) 9,483 
2.55 
(2.46,2.65) 
Female 
14 
0.56 
(0.33,0.94) 27 
0.43 
(0.30,0.63) 147 
0.66 
(0.56,0.78) 535 
0.70 
(0.64,0.77) 2,352 1 7,541 
1.43 
(1.36,1.50) 14,630 
2.63 
(2.52,2.76) 
CI=confidence interval; N=total number of death. 
	
5.4 Discussion 
 
In this large primary care database with nearly 10,000 patients younger than 60 
years, I have demonstrated important differences from older patients with HF, namely 
aetiology, comorbidities, HF treatment rates, and mortality rates. 
 
5.4.1 Heart rates 
 
 Prior to first presentation with heart failure younger patients had higher heart rates.  
Perhaps the lack of ankle oedema and crackles in younger patients (previously described 
by our group in the CHARM dataset) means that diagnosis is delayed and, consequently, 
the patient is sicker with a higher heart rate.(199)   
 
5.4.2 Comorbidities 
 
 As previously described, coronary heart disease, hypertension and valvular heart 
disease are less common in younger age groups.  Congenital heart disease accounted for 
6.9% of cases of heart failure in patients aged 20-29.  This proportion increased over 2 
decades (0.0% in 1988-1992 to 8.6% in 2008-2011) in patients aged 20-29.  Myocarditis, 
although still an uncommon cause of HF in the young, was a more frequent prior diagnosis 
in younger adults with HF.  Experimental studies suggest that testosterone might play a 
major role in the development of myocarditis by increases viral binding, modification of 
immune system, inhibition of anti-inflammatory cells, and increases cardiac fibrosis genes 
expression.(200;201) Myocardial fibrosis measured by Cardiac Magnetic Resonance 
(CMR) Imaging in patients with acute myocarditis was more frequent and more severe in 
patients aged <40 years.(202) 
 
 A diagnosis of depression was more common in younger adults with HF, occurring 
in approximately a quarter to a third of patients. These findings concur with a previous 
study of depression in hospitalised patients with HF, in which younger age was an 
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independent predictor of depression across all New York Heart Association functional 
classes (age <60 vs. ≥60 years HR 1.95 [95% CI 1.36-2.81], p=0.0003).(203) Younger 
patients with HF are recognised to have worse quality of life.(199) This greater functional 
limitation, resulting in an inability to meet family and social commitments, may to some 
extent explain the greater prevalence of depression.  Anti-psychotics are most frequently 
taken by patients aged 20-29.  Clozapine and other antipsychotics are known to cause HF.  
How often these drugs are causative is currently unclear. 
 
 A third of the patients aged 20-29 years had a diagnosis of asthma at index 
diagnosis of HF.  To provide context, the lifetime prevalence of asthma was much lower in 
a study utilising CPRD data from 422 primary care practices in England (Age-sex 
standardised rate: 15-44 years 12.7%, 45-64 years 9.1%, and >65 years 9.6%).(204)  HF 
may be incorrectly labelled as asthma for many reasons. Younger patients are not expected 
to have HF. They also present with breathlessness and cough, with fewer classical signs of 
HF such as crepitation or peripheral oedema.(199) Misdiagnosis may not be the only 
reason for this finding. The use of β agonists in patients with pulmonary disease is also 
associated with incident HF and increased HF hospitalisation.(205) Oral bambuterol was 
associated with an increased incident of HF compared with the reference drug nedocromil 
(age and sex adjusted relative risk: 3.41 [95% CI: 1.99 to 5.86]; p<0.0001).(206) Similarly, 
patients with COPD receiving β agonists have an increased risk of HF hospitalisation in a 
nested case control analysis comparing patients who inhaled respiratory drugs with and 
without cardiovascular events using the Manitoba Health database between 1996 and 
200.(207) Perhaps chronic beta-receptor stimulation induces adverse remodelling, the 
opposite of beta-blocker effects. Sustained tachycardia associated with prolonged exposure 
to β agonists may also increase the risk of HF and related adverse outcome.  
 
5.4.3 Treatments 
 
 Between 2006 and 2011, patients aged 20-29 years had the lowest treatment rates 
for ACEi/ARB, β blocker, and aldosterone antagonist.  Why this should be is difficult to 
explain.  The higher proportions of chronic kidney disease and asthma may have deterred 
clinicians from optimising HF medications in the younger patients (Table 5.5, and 5.6).  
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Previous studies reported higher proportions of younger patients were prescribed HF 
medications between 2005 and 2007.(69;82;93) However, these studies defined ‘young’ as 
less than 60 to 65 years and may reveal similar findings to ours if patients less than 60 to 
65 years were stratified into more than one group. Grouping patients < 60 years in our 
cohort demonstrated higher prescription rates for HF medications in younger patients 
congruent with previous studies. (Table 5.7)  
 
5.4.4 Mortality 
 
Mortality rates in younger age groups were dramatically lower compared to older 
patients. A recent Swedish study reported a 1 year mortality rate of 12.2% in age group 18-
34 years, 10.6% in 35-44 years, 12.2% in 45-54 years, and 26.6% in 55-84 years between 
2002 and 2006.(17) In comparison, between 2006 and 2011, I reported a 1-year mortality 
rates of 10.7% in age group 20-29 years, 8.8% in 30-39 years, 7.9% in 40-49 years, 9.1% 
in 50-59 years, 12.0% in 60-69 years, 16.6% in 70-79 years, and 32.8% in those aged ≥80 
years.  For comparison, the annual mortality rates for the population of England and Wales 
in 2011 across the respective age bands was: 0.05%, 0.08%, 0.18%, 0.42%, 1.02%, 2.80%, 
and 10.43%. The mortality rates in patients with HF were substantially higher. Five-year 
mortality rates have continued to improve albeit to a lesser degree in those aged ≥70 years. 
Improving uptake of pharmacological and device therapy may further reduce mortality and 
morbidity, particularly in the younger age group. Physicians can now reassure younger 
patients of their better prognosis with these data.  
 
5.5 Limitations 
 
Although this study was conducted using a large well-validated database, a few 
limitations merit consideration.  I relied on physician diagnoses or documentation of heart 
failure, comorbidities, and risk factors without independent confirmation of diagnoses or 
data on left ventricular ejection fraction.  The prevalence of co-morbidities (e.g. ischaemic 
heart disease, hypertension, diabetes, etc.) may be lower than expected.  The recording of 
these co-morbidities was less systematic prior to the introduction of the Quality and 
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Outcomes Framework (QOF) in 2004, which reimburses general practices for specifying 
this information. However, previous studies have validated the accuracy of these diagnoses 
in CPRD.(198) However, the study validating HF code in this study did not include 
younger patients less than 35 years.  The numbers in the younger age groups were small 
with wide confidence interval resulting in greater uncertainty when interpreting results.  
 
5.6 Conclusion 
 
Younger adults with HF have different characteristics including different aetiologies, 
comorbidities, lower treatment rates and lower mortality rates. Between 1988 and 2011, 
mortality rates have continued to improve in all age groups.  
 
 
Table 5.5. Prescription rates in patients with index diagnosis of HF between 2006-2011 and with asthma, including patients who had received the 
treatment prior to diagnosis. 
% (95% CI) Age at diagnosis 
 20 to 29 30 to 39 40 to 49 50 to 59 60 to 69 70 to 79 80 plus 
N 25 51 179 395 1001 1872 1813 
ACEi or ARB         
 1 month 32.0 (13.7,50.3) 45.1 (31.4,58.8) 57.8 (50.6,65.1) 56.2 (51.3,61.1) 59.7 (56.6,62.7) 55.3 (53.1,57.6) 50.3 (48.0,52.7) 
 3 months 52.0 (32.4,71.6) 62.7 (49.5,76.0) 77.6 (71.5,83.8) 76.3 (72.1,80.6) 77.0 (74.3,79.6) 72.6 (70.6,74.7) 66.4 (64.1,68.6) 
 6 months 56.0 (36.5,75.5) 71.0 (58.5,83.6) 82.3 (76.7,88.0) 80.0 (76.0,84.0) 80.4 (77.9,82.9) 76.9 (75.0,78.9) 70.2 (67.9,72.4) 
 1 year 56.0 (36.5,75.5) 73.1 (60.8,85.4) 83.6 (78.1,89.1) 81.7 (77.8,85.6) 82.8 (80.4,85.3) 80.6 (78.7,82.4) 72.7 (70.5,74.9) 
 5 years 73.6 (55.9,91.3) -( 0.0, 100) 89.3 (83.5,95.2) 85.7 (81.9,89.5) 91.7 (89.1,94.3) 87.4 (85.3,89.5) 81.4 (78.6,84.3) 
B-blocker         
 1 month 12.0 (0.0,24.7) 31.4 (18.6,44.1) 30.3 (23.6,37.1) 26.2 (21.8,30.5) 20.0 (17.5,22.4) 18.7 (17.0,20.5) 16.2 (14.5,18.0) 
 3 months 24.0 (7.3,40.7) 45.2 (31.5,58.8) 44.6 (37.2,51.9) 36.8 (32.0,41.5) 28.0 (25.2,30.8) 26.5 (24.5,28.5) 23.2 (21.2,25.2) 
 6 months 32.4 (13.9,51.0) 53.3 (39.5,67.1) 49.2 (41.8,56.6) 40.2 (35.4,45.1) 32.6 (29.6,35.5) 30.5 (28.4,32.6) 25.8 (23.7,27.9) 
 1 year 32.4 (13.9,51.0) 53.3 (39.5,67.1) 51.1 (43.7,58.5) 44.7 (39.8,49.7) 36.0 (33.0,39.1) 33.5 (31.3,35.7) 28.7 (26.5,30.9) 
 5 years 51.4 (30.6,72.1) 56.4 (42.3,70.5) 69.5 (58.8,80.2) 52.4 (46.6,58.2) 52.0 (47.8,56.1) 48.0 (44.9,51.1) 45.6 (41.2,49.9) 
Aldosterone antagonist  
 1 month 8.0 (0.0,18.6) 11.8 (2.9,20.6) 16.8 (11.3,22.3) 14.0 (10.6,17.4) 15.0 (12.8,17.3) 12.8 (11.3,14.3) 12.0 (10.5,13.5) 
 3 months 12.0 (0.0,24.7) 15.7 (5.7,25.7) 27.1 (20.5,33.6) 23.0 (18.8,27.2) 21.8 (19.3,24.4) 19.5 (17.7,21.3) 18.4 (16.5,20.2) 
 6 months 12.0 (0.0,24.7) 23.7 (12.0,35.4) 32.4 (25.5,39.3) 26.4 (22.1,30.8) 24.8 (22.1,27.5) 22.5 (20.6,24.5) 22.0 (20.0,24.0) 
 1 year 12.0 (0.0,24.7) 28.0 (15.5,40.4) 36.1 (28.9,43.2) 29.8 (25.2,34.4) 28.7 (25.8,31.6) 26.8 (24.7,28.9) 25.5 (23.4,27.6) 
 5 years 16.6 (1.7,31.6) 39.0 (24.4,53.6) 44.0 (35.3,52.8) 38.5 (33.1,43.9) 41.5 (37.6,45.4) 40.8 (37.8,43.8) 38.0 (34.6,41.4) 
Digoxin         
 1 month 8.0 (0.0,18.6) 9.8 (1.6,18.0) 11.8 (7.1,16.5) 11.7 (8.5,14.9) 13.0 (10.9,15.1) 15.7 (14.1,17.4) 17.8 (16.0,19.6) 
 3 months 16.0 (1.6,30.4) 9.8 (1.6,18.0) 15.2 (9.9,20.5) 14.8 (11.3,18.3) 18.6 (16.2,21.0) 21.5 (19.6,23.4) 24.6 (22.5,26.6) 
 6 months 16.0 (1.6,30.4) 9.8 (1.6,18.0) 17.0 (11.4,22.5) 15.6 (12.0,19.2) 20.1 (17.6,22.6) 23.6 (21.6,25.5) 26.2 (24.1,28.2) 
 1 year 16.0 (1.6,30.4) 9.8 (1.6,18.0) 17.6 (12.0,23.2) 17.0 (13.2,20.7) 22.2 (19.6,24.9) 25.4 (23.4,27.4) 28.0 (25.9,30.2) 
 5 years 16.0 (1.6,30.4) 15.8 (2.1,29.5) 23.3 (15.7,31.0) 21.9 (17.4,26.4) 28.7 (25.4,31.9) 33.7 (30.9,36.4) 37.3 (34.1,40.6) 
Table 5.6. Prescription rates in patients with index diagnosis of HF between 2006-2011 and with chronic kidney disease, including patients who had 
received the treatment prior to diagnosis. 
% (95% CI) Age at diagnosis 
 20 to 29 30 to 39 40 to 49 50 to 59 60 to 69 70 to 79 80 plus 
N 6 13 49 205 855 2840 4764 
ACEi or ARB        
 1 month 50.0 (10.0,90.0) 46.2 (19.1,73.3) 48.3 (34.1,62.6) 51.7 (44.8,58.6) 51.5 (48.1,54.8) 53.5 (51.7,55.3) 49.1 (47.7,50.6) 
 3 months 50.0 (10.0,90.0) 76.9 (54.0,99.8) 59.3 (45.2,73.4) 69.3 (62.9,75.8) 72.7 (69.6,75.7) 72.3 (70.6,74.0) 64.9 (63.5,66.3) 
 6 months 66.7 (28.9, 100) 76.9 (54.0,99.8) 61.6 (47.6,75.6) 72.9 (66.6,79.2) 75.3 (72.3,78.3) 76.9 (75.3,78.5) 68.8 (67.5,70.2) 
 1 year 66.7 (28.9, 100) 84.6 (65.0, 100) 63.8 (50.0,77.7) 76.0 (69.8,82.1) 78.1 (75.2,81.0) 80.3 (78.8,81.9) 71.6 (70.2,73.0) 
 5 years -(0.0, 100) -(0.0, 100) -(0.0, 100) 80.3 (72.9,87.7) 87.2 (83.9,90.4) 87.7 (85.8,89.6) 79.5 (77.6,81.4) 
B-blocker         
 1 month 33.3 ( 0.0,71.1) 23.1 ( 0.2,46.0) 37.2 (23.6,50.8) 39.4 (32.6,46.1) 34.4 (31.2,37.6) 33.4 (31.6,35.1) 28.4 (27.1,29.7) 
 3 months 33.3 ( 0.0,71.1) 30.8 ( 5.7,55.9) 43.6 (29.5,57.6) 51.2 (44.3,58.2) 47.0 (43.6,50.4) 47.3 (45.4,49.1) 39.4 (38.0,40.8) 
 6 months 33.3 ( 0.0,71.1) 38.5 (12.0,64.9) 54.4 (40.2,68.6) 56.3 (49.3,63.2) 53.3 (49.9,56.7) 51.2 (49.4,53.1) 43.1 (41.7,44.6) 
 1 year 33.3 ( 0.0,71.1) 38.5 (12.0,64.9) 58.8 (44.7,72.8) 61.7 (54.8,68.7) 58.4 (55.0,61.8) 55.6 (53.7,57.5) 46.8 (45.3,48.3) 
 5 years .  ( 0.0, 100) 70.7 (40.7, 100) 66.9 (51.2,82.5) 74.1 (67.0,81.1) 72.3 (67.8,76.7) 68.5 (65.9,71.2) 62.0 (59.5,64.5) 
Aldosterone antagonist        
 1 month 16.7 (0.0,46.5) 30.8 (5.7,55.9) 10.5 (1.8,19.2) 10.8 (6.5,15.1) 14.7 (12.3,17.1) 11.8 (10.6,13.0) 11.1 (10.2,12.0) 
 3 months 16.7 (0.0,46.5) 38.5 (12.0,64.9) 12.6 (3.2,22.0) 15.5 (10.5,20.5) 21.5 (18.7,24.2) 18.2 (16.8,19.6) 17.3 (16.2,18.4) 
 6 months 16.7 (0.0,46.5) 38.5 (12.0,64.9) 14.8 (4.7,24.9) 18.1 (12.8,23.5) 24.3 (21.4,27.2) 21.5 (19.9,23.0) 20.4 (19.2,21.6) 
 1 year 16.7 (0.0,46.5) 38.5 (12.0,64.9) 19.2 (7.9,30.5) 22.1 (16.2,28.0) 27.1 (24.1,30.2) 24.9 (23.2,26.5) 23.8 (22.5,25.1) 
 5 years -(0.0, 100) 38.5 (12.0,64.9) 31.8 (12.8,50.9) 27.8 (20.9,34.8) 40.0 (35.5,44.5) 39.3 (36.6,41.9) 38.0 (35.5,40.5) 
Digoxin         
 1 month 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 6.2 (0.0,13.0) 7.4 (3.8,11.0) 8.7 (6.8,10.6) 12.6 (11.4,13.9) 15.2 (14.2,16.3) 
 3 months 0.0 (0.0, 0.0) 7.7 (0.0,22.2) 8.3 (0.5,16.2) 10.5 (6.2,14.7) 14.0 (11.7,16.4) 17.6 (16.2,19.0) 20.6 (19.4,21.8) 
 6 months 0.0 (0.0, 0.0) 7.7 (0.0,22.2) 8.3 (0.5,16.2) 11.0 (6.7,15.3) 15.8 (13.3,18.3) 19.6 (18.1,21.1) 22.2 (21.0,23.5) 
 1 year 0.0 (0.0, 0.0) 7.7 (0.0,22.2) 8.3 (0.5,16.2) 12.6 (8.0,17.3) 18.7 (16.0,21.3) 21.2 (19.7,22.7) 23.9 (22.6,25.1) 
 5 years -(0.0, 100) 7.7 (0.0,22.2) 8.3 (0.5,16.2) 14.8 (9.7,19.9) 25.2 (21.3,29.1) 29.5 (27.2,31.8) 32.6 (30.3,35.0) 
Table 5.7. Prescription rates in patients with index diagnosis of HF between 2006-2011, 
including patients who had received the treatment prior to diagnosis 
	
% (95% CI) Age at diagnosis 
 <60 60 to 69 70 to 79 80 plus 
N 3356 5333 9964 12838 
ACEi or ARB      
 1 month 56.6 (55.0,58.3) 58.9 (57.6,60.2) 56.0 (55.1,57.0) 49.0 (48.1,49.8) 
 3 months 77.5 (76.0,78.9) 77.5 (76.3,78.6) 74.6 (73.7,75.4) 64.9 (64.0,65.7) 
 6 months 81.6 (80.3,82.9) 81.2 (80.2,82.3) 78.8 (78.0,79.6) 68.9 (68.0,69.7) 
 1 year 84.0 (82.7,85.3) 83.8 (82.7,84.8) 82.0 (81.2,82.8) 71.8 (71.0,72.7) 
 5 years 88.2 (86.9,89.5) 90.0 (88.9,91.0) 88.5 (87.6,89.4) 80.7 (79.5,82.0) 
B-blocker      
 1 month 38.5 (36.9,40.2) 34.6 (33.3,35.9) 30.2 (29.3,31.1) 25.3 (24.5,26.1) 
 3 months 53.6 (51.9,55.3) 47.9 (46.6,49.3) 43.3 (42.3,44.3) 35.6 (34.8,36.5) 
 6 months 58.1 (56.4,59.8) 53.2 (51.8,54.5) 48.2 (47.2,49.2) 39.4 (38.5,40.3) 
 1 year 61.9 (60.2,63.6) 57.6 (56.3,59.0) 52.3 (51.3,53.3) 43.0 (42.1,43.9) 
 5 years 71.1 (69.3,72.9) 69.7 (68.2,71.2) 66.9 (65.6,68.1) 57.8 (56.3,59.2) 
Aldosterone antagonist      
 1 month 14.4 (13.2,15.6) 13.1 (12.2,14.0) 11.7 (11.1,12.3) 11.0 (10.5,11.6) 
 3 months 21.6 (20.2,23.0) 20.2 (19.2,21.3) 17.8 (17.0,18.5) 17.1 (16.4,17.7) 
 6 months 24.5 (23.0,26.0) 23.4 (22.3,24.6) 21.0 (20.2,21.9) 20.1 (19.3,20.8) 
 1 year 27.9 (26.3,29.4) 27.0 (25.8,28.3) 24.4 (23.5,25.3) 23.6 (22.8,24.4) 
 5 years 36.6 (34.7,38.5) 38.9 (37.3,40.6) 37.8 (36.5,39.1) 36.9 (35.5,38.2) 
Digoxin      
 1 month 8.7 (7.8, 9.7) 10.9 (10.1,11.8) 13.5 (12.8,14.1) 16.4 (15.8,17.1) 
 3 months 12.2 (11.1,13.4) 15.9 (14.9,16.8) 18.8 (18.1,19.6) 22.8 (22.1,23.5) 
 6 months 13.4 (12.2,14.6) 17.5 (16.4,18.5) 20.7 (19.9,21.5) 24.7 (24.0,25.5) 
 1 year 14.4 (13.2,15.6) 19.2 (18.1,20.2) 22.4 (21.6,23.3) 26.5 (25.7,27.3) 
 5 years 19.0 (17.5,20.5) 24.4 (23.1,25.7) 29.6 (28.5,30.7) 35.1 (33.8,36.4) 
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Chapter 6 
 
Heart failure in young vs. older adults: Data from the Alberta 
Ministry of Health and Wellness database. 
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6.1 Introduction  
 
HF is a major public health issue and predominantly affects the elderly.(166;208) A 
limited number of studies have examined the characteristics of younger patients (<60 
years) with HF and their attendance at the outpatient clinic, presentation to the emergency 
department, or admission to hospital, as most registries only hold hospitalisation data. 
Therefore, most epidemiological studies rely on hospitalisation data to determine the 
incidence, prevalence, and mortality rates of patients with HF neglecting those managed in 
the outpatient or emergency departments. A better understanding of younger patients with 
HF in these settings will enable health services to allocate and utilize resources more 
effectively. Accurate studies of the characteristics and outcomes of heart failure in younger 
patients will allow us to inform these patients better with respect to their likely prognosis.  
 
 The province of Alberta, Canada, consists of approximately 4.1 million residents, 
whom all have free access to a public health system including inpatient, outpatient, and 
emergency room physician services.(209) Utilising data from the administrative health 
care databases maintained by the Alberta Ministry of Health, our aim was to examine the 
incidence, characteristics, and outcomes in young (40-59 years) and very young (<40 
years) adults with HF. 
 
6.2 Methods 
 
6.2.1 Databases 
 
The statistician linked four databases maintained by the Alberta Ministry of Health, 
which records all contacts with the publically funded health care system for every citizen 
in Alberta, Canada.(210;211) The four databases are: 1) the Discharge Abstract Database, 
which records information (e.g.: dates, responsible diagnosis and up to 24 other diagnoses, 
comorbidities, procedures, length of stay and discharge status) on all admissions; 2) the 
Ambulatory Care Database, which records all visits to hospital-based physician office or 
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emergency departments and includes up to six diagnosis fields; 3) the Physician Claims 
Database, which tracks all physicians’ claims from outpatient services and records up to 3 
diagnostic codes per encounter; 4) the Population Registry, which records all the basic 
demographic and geographic information of all 4.1 million citizens. Each patient has a 
unique personal identifier allowing linkage of patient information across the databases.  
 
6.2.2 Study population – incident and prevalent HF 
 
All patients over 20 years of age with a first hospitalisation with HF as principal 
diagnosis between 1st April 1999 and 31st March 2009 in Alberta, Canada were identified. 
Patients with a HF hospitalisation in the five preceding years were excluded.  Patients with 
a first HF hospitalisation were stratified into 1) first hospitalisation without prior diagnosis 
of HF at outpatient clinic or emergency department, and 2) first hospitalisation with a prior 
diagnosis of HF at outpatient clinic or emergency department. The combined of these is the 
incidence of first hospitalisation for HF.  
 
Patients were identified using the international classification of disease (ICD)-9 
(428) and ICD-10 (I50) codes for HF. The specificity and sensitivity of HF coding within 
this registry has previously been validated and was 98.7% and 77.3%, 
respectively.(209;212) If patients have had multiple contacts with different health care 
facilities within 24 hours, we used a hierarchical method to define the location of index HF 
diagnosis (i.e. inpatient superseded those from emergency department, and these supersede 
those from the outpatient setting).(213) 
 
Co-morbidities were identified by using ICD codes for secondary diagnoses during 
the first HF hospitalisation and from any hospital visits within one year prior to the first HF 
hospitalisation. Socioeconomic status was examined by assigning a median Statistics 
Canada neighbourhood household income in Canadian dollars to patients based on their 
recorded place of residence.  
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6.2.3 Variables and Outcomes 
  
Patients based on their age at first HF hospitalisation were stratified into 5 age 
categories: 20-39, 40-59, 60-69, 70-79 and ≥80 years. The following variables and 
outcomes were examined: 1) Baseline characteristics (sex, ethnicity, co-morbidities, and 
socioeconomic status measured by median household income using census data.); 2) First 
hospitalisation rates for HF without any prior diagnosis of HF in emergency department or 
outpatient clinic by age categories; 3) Number of patients with a first hospitalisation for HF 
with a prior diagnosis of HF at the outpatient clinic or emergency department and time 
from diagnosis to first hospitalisation; 4) One-year outcomes (presentation to emergency 
department, any re-hospitalisation, cardiovascular re-hospitalisation, HF re-hospitalisation, 
and number of days spent in hospital) after first HF hospitalisation diagnosis; and 5) 
Unadjusted and adjusted in-hospital, 30-day, 1-year and 5-year case fatality.  
 
6.2.4 Statistical analysis 
  
Results are presented as means and standard deviations or medians and interquartile 
range for continuous variables and proportions for categorical variables. Variables were 
compared across age categories using ANOVA for continuous variables and Chi-square for 
categorical variables. Cox’s proportional hazard models were used to estimate the hazard 
of younger age compared with the referent age category 60-69 years. The model was 
adjusted for age, comorbidities, deprivation, and year of admission. All test were two sided 
with a level of significance set at P <0.05. Analyses were performed using SAS version 
9.2.  
 
6.3 Results 
 
6.3.1 Baseline characteristics 
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72977 patients were identified at their first HF admission in the period between 1st 
April 1999 and 31st March 2009. Overall, 36711 (50.3%) were women, and 33675 (46.1%) 
had prevalent HF. Baseline characteristics are presented separately for those with incident 
HF (defined as patients without prior diagnosis of HF in an outpatient clinic or emergency 
department) (Table 6.1), and those with prevalent HF (defined as a prior HF diagnosis in 
an outpatient clinic or emergency department in the period from 1st April 1994 until the 
first HF hospitalisation (Table 6.2).  
 
Among patients with first hospitalisation without prior diagnosis of HF at 
outpatient clinic or emergency department, younger patients had fewer co-morbidities 
(Table 6.1). Younger patients had lower proportion of atrial fibrillation, hypertension, and 
peripheral arterial disease. The proportions of patients with prior MI or revascularisation 
were lowest in the patients aged 20-39 years and increased with age up to 60-69 years. 
Congenital heart disease was most prevalent in age group 20-39 years especially in men. 
Among patients <60 years, women had higher proportions of chronic obstructive 
pulmonary disease and malignant disease compared to men.  
 
Similarly, among patients with first hospitalisation with prior diagnosis of HF at 
outpatient clinic or emergency department, younger patients had fewer co-morbidities 
(Table 2). Patients aged 20-39 years had the lowest proportions of previous MI or 
revascularisation. These proportions peaked at age group 60-69 years and decreased after. 
Younger (<60 years) patients had higher proportions of asthma and congenital heart 
disease. Renal failure was most prevalent in women aged 20-39 years, but least prevalent 
in younger men. Among patients aged <60 years, women had higher proportions of 
malignant disease, diabetes mellitus, and congenital heart disease compared to men.  
 
6.3.2 Incidence of first hospitalisation with HF  
 
The incidence rates of HF hospitalisations in both men and women declined from 
1999 to 2008 (Figure 6.1). With the exception of the age group 20-39 years, the incidence 
of HF was higher in men than in women.   
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Table 6.1. Baseline characteristics of patients with first HF hospitalisation without a prior 
diagnosis of HF in either the emergency department or outpatient clinic by age categories  
 
  Age 
  20-39 40-59 60-69 70-79 ≥80 
N (%) M F M F M F M F M F 
 
310 
(49.5) 
316 
(50.5) 
3050 
(62.3) 
1849 
(37.7) 
3772 
(58.9) 
2631 
(41.1) 
6011 
(52.7) 
5406 
(47.4) 
6435 
(40.3) 
9522 
(59.7) 
Co-morbidities                     
Prior MI 22  (7.1) 
17  
(5.4) 
967 
(31.7) 
296 
(16.0) 
1264 
(33.5) 
531 
(20.2) 
1839 
(30.6) 
1108 
(20.5) 
1543 
(24.0) 
1606 
(16.9) 
Prior 
revascularisation 
13  
(4.2) 
7  
(2.2) 
605 
(19.8) 
149 
(8.1) 
616 
(16.3) 
233 
(8.9) 
754 
(12.5) 
385 
(7.1) 
272 
(4.2) 
217 
(2.3) 
AF 42 (13.6) 
13  
(4.1) 
667 
(21.9) 
235 
(12.7) 
1074 
(28.5) 
553 
(21.0) 
2076 
(34.5) 
1672 
(30.9) 
2271 
(35.3) 
3336 
(35.0) 
Hypercholesterolemia 5  (1.6) 
4  
(1.3) 
316 
(10.4) 
129 
(7.0) 
413 
(11.0) 
235 
(8.9) 
480 
(8.0) 
389 
(7.2) 
238 
(3.7) 
303 
(3.2) 
Hypertension 106 (34.2) 
77 
(24.4) 
1717 
(56.3) 
922 
(49.9) 
2390 
(63.4) 
1711 
(65.0) 
3960 
(65.9) 
3923 
(72.6) 
3888 
(60.4) 
6718 
(70.6) 
CVD 11  (3.6) 
17  
(5.4) 
199 
(6.5) 
131 
(7.1) 
425 
(11.3) 
257 
(9.8) 
929 
(15.5) 
733 
(13.6) 
1148 
(17.8) 
1550 
(16.3) 
Diabetes mellitus 51 (16.5) 
56 
(17.7) 
999 
(32.8) 
596 
(32.2) 
1385 
(36.7) 
970 
(36.9) 
1998 
(33.2) 
1723 
(31.9) 
1620 
(25.2) 
1943 
(20.4) 
Malignant disease 10  (3.2) 
15  
(4.8) 
180 
(5.9) 
210 
(11.4) 
443 
(11.7) 
368 
(14.0) 
1121 
(18.7) 
698 
(12.9) 
1256 
(19.5) 
961 
(10.1) 
PAD 15  (4.8) 
7  
(2.2) 
249 
(8.2) 
137 
(7.4) 
568 
(15.1) 
273 
(10.4) 
1051 
(17.5) 
686 
(12.7) 
1011 
(15.7) 
950 
(10.0) 
Renal failure 52 (16.8) 
34 
(10.8) 
385 
(12.6) 
216 
(11.7) 
518 
(13.7) 
324 
(12.3) 
1028 
(17.1) 
727 
(13.5) 
1349 
(21.0) 
1295 
(13.6) 
COPD 58 (18.7) 
88 
(27.9) 
845 
(27.7) 
707 
(38.2) 
1544 
(40.9) 
1190 
(45.2) 
2657 
(44.2) 
2150 
(39.8) 
2618 
(40.7) 
2874 
(30.2) 
Asthma 30  (9.7) 
54 
(17.1) 
256 
(8.4) 
349 
(18.9) 
325 
(8.6) 
385 
(14.6) 
517 
(8.6) 
567 
(10.5) 
405 
(6.3) 
613 
(6.4) 
Congenital heart 
disease 
43 
(13.9) 
25  
(7.9) 
96  
(3.2) 
60  
(3.2) 
57  
(1.5) 
45  
(1.7) 
74  
(1.2) 
66  
(1.2) 
45  
(0.7) 
54  
(0.6) 
Household income, Canadian dollars 
Median (IQR) 
56073 
(41872, 
76076) 
55018 
(41696, 
76231) 
56067 
(42390, 
75483) 
53654 
(40026, 
71766) 
54479 
(41735, 
73334) 
52831 
(40713, 
70980) 
53436 
(41686, 
72125) 
51984 
(40472, 
70833) 
51725 
(40472, 
70668) 
51189 
(40038, 
71675) 
AF=atrial fibrillation; COPD=chronic obstructive pulmonary disease; CVD= cerebrovascular disease; IQR=inter-quartile 
range; MI=myocardial infarction; PAD=peripheral arterial disease 
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Table 6.2 Baseline characteristics of patients with first HF hospitalisation with a prior 
diagnosis of HF in either the outpatient clinic or emergency department by age categories  
 
  Age 
  20-39 40-59 60-69 70-79 ≥80 
N (%) M F M F M F M F M F 
 
79 
(54.9) 
65 
(45.1) 
1262 
(60.4) 
826 
(39.6) 
2521 
(60.3) 
402 
(24.2) 
5548 
(55.5) 
4445 
(44.5) 
7278 
(42.1) 
9992 
(57.9) 
Co-morbidities                     
Prior MI 11 (13.9) 
6  
(9.2) 
410 
(32.5) 
167 
(20.2) 
938 
(37.2) 
402 
(24.2) 
1935 
(34.9) 
1115 
(25.1) 
1902 
(26.1) 
1927 
(19.3) 
Prior 
revascularisation 
1  
(1.3) 
0  
(0.0) 
116 
(9.2) 
37 
(4.5) 
213 
(8.5) 
79 
(4.8) 
354 
(6.4) 
166 
(3.7) 
141 
(1.9) 
110  
(1.1) 
AF 13 (16.5) 
10 
(15.4) 
368 
(29.2) 
168 
(20.3) 
876 
(34.8) 
502 
(30.3) 
2348 
(42.3) 
1645 
(37.0) 
3049 
(41.9) 
4196 
(42.0) 
Hypercholesterolemia 1  (1.3) 
4   
(6.2) 
132 
(10.5) 
52 
(6.3) 
263 
(10.4) 
136 
(8.2) 
404 
(7.3) 
278 
(6.3) 
242 
(3.3) 
284  
(2.8) 
Hypertension 26 (32.9) 
20 
(30.8) 
799 
(63.3) 
536 
(64.9) 
1746 
(69.3) 
1212 
(73.1) 
3823 
(68.9) 
3227 
(72.6) 
4518 
(62.1) 
7039 
(70.5) 
CVD 4  (5.1) 
4  
(6.2) 
102 
(8.1) 
84 
(10.2) 
272 
(10.8) 
186 
(11.2) 
879 
(15.8) 
633 
(14.2) 
1291 
(17.7) 
1659 
(16.6) 
Diabetes mellitus 11 (13.9) 
18 
(27.7) 
513 
(40.7) 
349 
(42.3) 
1181 
(46.9) 
745 
(44.9) 
2127 
(38.3) 
1653 
(37.2) 
1830 
(25.1) 
2223 
(22.3) 
Malignant disease 2  (2.5) 
3  
(4.6) 
55 
(4.4) 
59 
(7.1) 
281 
(11.2) 
168 
(10.1) 
833 
(15.0) 
437 
(9.8) 
1311 
(18.0) 
855  
(8.6) 
PAD 2  (2.5) 
7 
(10.8) 
144 
(11.4) 
70 
(8.5) 
423 
(16.8) 
206 
(12.4) 
1008 
(18.2) 
532 
(12.0) 
1127 
(15.5) 
1033 
(10.3) 
Renal failure 11 (13.9) 
18 
(27.7) 
223 
(17.7) 
155 
(18.8) 
509 
(20.2) 
290 
(17.5) 
1270 
(22.9) 
766 
(17.2) 
1698 
(23.3) 
1641 
(16.4) 
COPD 25 (31.7) 
17 
(26.2) 
502 
(39.8) 
415 
(50.2) 
1303 
(51.7) 
857 
(51.7) 
2882 
(52.0) 
2189 
(49.3) 
3602 
(49.5) 
3670 
(36.7) 
Asthma 15 (19.0) 
10 
(15.4) 
175 
(13.9) 
200 
(24.2) 
340 
(13.5) 
298 
(18.0) 
650 
(11.7) 
672 
(15.1) 
621 
(8.5) 
885 
(8.9) 
Congenital heart 
disease 
14 
(17.7) 
20 
(30.8) 
51 
(4.0) 
45 
(5.5) 
58 
(2.3) 
49 
(3.0) 
69 
(1.2) 
59 
(1.3) 
52 
(0.7) 
66  
(0.7) 
Household income, Canadian dollars 
Median (IQR) 
51889 
(40078, 
69714) 
56469 
(42848, 
82840) 
53881 
(41251, 
72125) 
53619 
(40472, 
71436) 
54159 
(41096, 
72235) 
51598 
(39716, 
69513) 
52788 
(41442, 
70658) 
50803 
(40322, 
69746) 
50645 
(40042, 
67933) 
49725 
(39168, 
67670) 
AF=atrial fibrillation; COPD=chronic obstructive pulmonary disease; CVD= cerebrovascular disease; IQR=inter-quartile 
range; MI=myocardial infarction; PAD=peripheral arterial disease 
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Figure 6.1. Incidence (per 1000 population) of first hospitalisation for HF without a prior 
diagnosis of HF in either the emergency department or outpatient clinic stratified by age 
for a) Men b) Women 
 
a) Men 
 
 
 
 
 Age 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 p value 
20-39 0.08 0.07 0.06 0.06 0.05 0.05 0.08 0.07 0.05 0.04 0.04 
40-59 0.80 0.77 0.84 0.66 0.71 0.57 0.67 0.54 0.53 0.55 <0.0001 
60-69 5.08 4.41 4.30 3.95 3.57 3.45 2.86 2.56 2.59 2.40 <0.0001 
70-79 12.55 11.24 10.42 9.68 9.04 8.58 7.61 6.50 6.52 5.75 <0.0001 
≥80 29.67 27.57 25.04 23.56 22.97 20.84 20.91 17.81 15.60 16.00 <0.0001 
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b) Women 
 
 
 
 Age 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 p_value 
20-39 0.07 0.08 0.09 0.08 0.05 0.07 0.05 0.06 0.05 0.06 0.02 
40-59 0.53 0.48 0.46 0.44 0.49 0.42 0.36 0.34 0.35 0.32 <0.0001 
60-69 3.38 3.33 2.97 2.71 2.56 2.07 2.07 1.82 1.83 1.45 <0.0001 
70-79 9.61 8.50 8.47 7.11 6.91 5.89 5.83 5.43 5.29 4.50 <0.0001 
≥80 25.01 23.18 20.93 20.21 18.90 17.77 16.25 14.48 14.67 13.17 <0.0001 
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6.3.3 Time from diagnosis of HF at outpatient clinic or emergency department to 
first hospitalisation with HF 
 
Younger patients with a prior diagnosis of HF at outpatient clinic or emergency 
department were admitted to hospital with first HF hospitalisation sooner than older age 
group; median duration: 20-39 vs. ≥80 years: 401 vs. 1311 days in men, and 776 vs. 1435 
days in women (Table 6.3). 
 
Table 6.3. Time from a prior diagnosis of HF in either the outpatient clinic or emergency 
department to first hospitalisation for HF 
 
  Age 20-39 40-59 60-69 70-79 ≥80 
  M F M F M F M F M F 
Duration, 
mean 
(SD) 
997.1 
(1288.8) 
1164.2 
(1099.6) 
1086.7 
(1102.3) 
1223.0 
(1193.2) 
1227.4 
(1115.9) 
1299.2 
(1158.7) 
1367.1 
(1124.5) 
1391.0 
(1135.4) 
1447.7 
(1140.4) 
1563.4 
(1161.4) 
Duration, 
median 
(IQR) 
401  
(93, 
1565) 
776  
(269, 
1746) 
749  
(157, 
1753) 
824  
(220, 
1957) 
962  
(257, 
1923) 
1045 
(265, 
2022) 
1180 
(400, 
2076) 
1223 
(399, 
2104) 
1311 
(511, 
2189) 
1435 
(578, 
2309) 
IQR=inter-quartile range; SD=standard deviation 
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6.3.4 One-year outcomes after first HF hospitalisation 
 
Patients aged 20-39 years had the highest emergency department visit within a year 
of first hospitalisation for HF compared to old age group (Table 6.4). However, the 
proportions of all cause, cardiovascular, or HF related hospitalisation were lower in 
patients aged 20-39 years.  
 
Table 6.4. One-year non-fatal outcomes by age categories in patients hospitalised with HF  
 
  
 N (%) or 
median (IQR) 
Age 
20-39 40-59 60-69 70-79 ≥80 
M F M F M F M F M F 
Any ED visit 242 (62.2) 
243 
(63.8) 
2477 
(57.4) 
1700 
(63.6) 
3776 
(60.0) 
2638 
(61.5) 
6789 
(58.7) 
5854 
(59.4) 
7594 
(55.4) 
10885 
(55.8) 
Any re-
hospitalisation 
158 
(40.6) 
152 
(39.9) 
1777 
(41.2) 
1269 
(47.4) 
2933 
(46.6) 
2029 
(47.3) 
5536 
(47.9) 
4632 
(47.0) 
6217 
(45.3) 
8636 
(44.3) 
CV re-
hospitalisation 
130 
(33.4) 
117 
(30.2) 
1577 
(36.6) 
1047 
(39.1) 
2643 
(42.0) 
1750 
(40.8) 
5032 
(43.5) 
4168 
(42.3) 
5638 
(41.1) 
7844 
(40.2) 
HF re-
hospitalisation 
67 
(17.2) 
62 
(16.3) 
852 
(19.8) 
549 
(20.5) 
1580 
(25.1) 
1048 
(24.4) 
3214 
(27.8) 
2736 
(27.8) 
3994 
(29.1) 
5570 
(28.5) 
CV=cardiovascular; ED=emergency department; HF=heart failure; IQR=interquartile range.  
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6.3.5 Mortality rate at 30 days, 1 year, and 5 years 
 
The youngest age group had the lowest 30 days, 1 and 5 year mortality rates (Table 
6.5). Of those who died within a year from their HF hospitalisation, approximately half of 
the deaths occurred within 30 days of HF hospitalisation. The adjusted case fatality ratios 
remained lowest in the youngest age group (Table 6.6). Younger men (<60 years) had a 
lower hazard ratio (HR) for all cause mortality compared to women of the same age 
category.  
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Table 6.5. Case fatality stratified by age categories after first hospitalisation with HF 
between 1999 and 2009 a) 30 days, b) 1 year, and c) 5 years 
 
a) 30 days        
 
N (%) Age 20-39 40-59 60-69 70-79 ≥80 
M F M F M F M F M F 
  389 (50.5) 
381 
(49.5) 
4312 
(61.7) 
2675 
(38.3) 
6293 
(59.5) 
4290 
(40.5) 
11559 
(54.0) 
9851 
(46.0) 
13713 
(41.3) 
19514 
(58.7) 
Thirty 
day 
death 
26  
(6.7) 
40  
(10.5) 
353  
(8.2) 
262  
(9.8) 
717 
(11.4) 
491 
(11.5) 
1931 
(16.7) 
1387 
(14.1) 
3470 
(25.3) 
3890 
(19.9) 
 
b) 1 year           
 
N (%) Age 20-39 40-59 60-69 70-79 ≥80 
M F M F M F M F M F 
  382 (50.8) 
370 
(49.2) 
4210 
(61.7) 
2609 
(38.3) 
6172 
(59.5) 
4199 
(40.5) 
11360 
(54.0) 
9690 
(46.0) 
13374 
(41.2) 
19085 
(58.8) 
One 
year 
death 
50  
(13.1) 
60  
(16.2) 
631 
(15.0) 
460 
(17.6) 
1312 
(21.3) 
880 
(21.0) 
3550 
(31.3) 
2506 
(25.9) 
6018 
(45.0) 
7019 
(36.8) 
 
c) 5 years           
 
N (%) 
Age 
20-39 40-59 60-69 70-79 ≥80 
M F M F M F M F M F 
  222 (47.8) 
242 
(52.2) 
2616 
(61.5) 
1638 
(38.5) 
4092 
(59.5) 
2791 
(40.6) 
7733 
(53.7) 
6661 
(46.3) 
8642 
(40.8) 
12545 
(59.2) 
Five 
year 
death 
60  
(27.0) 
76  
(31.4) 
795 
(30.4) 
556 
(33.9) 
1904 
(46.5) 
1186 
(42.5) 
4813 
(62.2) 
3594 
(54.0) 
7047 
(81.5) 
9270 
(73.9) 
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Table 6.6. Adjusted Case Fatality (Multivariable analysis adjusted for comorbidities, 
income, and year of admission) 
 
 
  
 Adjusted Case Fatality, OR (95% CI) 
 30 Day 1 Year 5 Years 
Age Men Women Men Women Men Women 
20-39 0.56  
(0.37, 0.84) 
0.90  
(0.64, 1.28) 
0.60  
(0.44, 0.82) 
0.77  
(0.57, 1.04) 
0.51  
(0.37, 0.70) 
0.69  
(0.51, 0.92) 
40-59 0.74  
(0.65, 0.85) 
0.85  
(0.72, 1.00) 
0.73  
(0.65, 0.81) 
0.83  
(0.73, 0.95) 
0.59  
(0.53, 0.65) 
0.71  
(0.62, 0.81) 
60-69 1 1 1 1 1 1 
70-79 1.43  
(1.31, 1.58) 
1.28  
(1.14, 1.43) 
1.54  
(1.43, 1.66) 
1.33  
(1.22, 1.46) 
1.70  
(1.57, 1.84) 
1.59  
(1.44, 1.74) 
≥80 2.31  
(2.11, 2.53) 
2.00  
(1.80, 2.22) 
2.64  
(2.46, 2.84) 
2.32  
(2.01, 2.29) 
4.43  
(4.07, 4.83) 
3.99  
(3.65, 4.37) 
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6.4 Discussion 
 
In this cohort study, utilising the linked health registers of Alberta, Canada, 
younger patients with HF differed from the elderly HF patients in a number of ways 
including comorbidity burden, incidence of first hospitalisation, and fatal and non-fatal 
outcomes.  
 
 Younger patients with HF had less comorbidity. In patients with prevalent HF, time 
from diagnosis of HF at outpatient clinic or emergency department to first HF 
hospitalisation were markedly shorter in younger compared to older patients. Perhaps not 
surprisingly, younger patients have lower mortality.  
 
6.4.1 Incidence of HF 
 
 The incidence of HF is declining from 1999 to 2008 in all age categories albeit to a 
lesser degree in patients aged 20-39 years. The is consistent with recent data from the 
Olmsted County, Minnesota, demonstrating age- and sex-adjusted incidence of HF 
declined from 315.8 per 100 000 in 2000 to 219.3 per 100 000 in 2010.(214) This 
improvement may reflect the declining incidence of myocardial infarction,(215;216) the 
greater awareness and better treatment of hypertension,(217) and the improving outcomes 
for patients with diabetes.(218)  
 
6.4.2 Hospitalisations 
 
After presenting to outpatient clinic or emergency department with a diagnosis of 
HF, patients aged 20-39 years were admitted to hospital much sooner than older patients. 
The Alberta dataset are unique as it allows the linkage of hospitalisation data with 
outpatient clinic and emergency department data making it possible to determine time from 
initial diagnosis anywhere in the health care system until first hospitalisation for HF. There 
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might be a few plausible explanations to this. Younger patients have different aetiology of 
HF and some of these might be more severe.(199;219) In our study, the youngest age 
group had the highest prevalence of congenital heart disease. Certain mutations such as 
dystrophin defects are more prevalent in younger men and others such as mutations in 
cardiac troponin T or cardiac β-myosin heavy chain resulted in early onset ventricular 
dysfunction and HF in patients with DCM.(185-187) X-linked laminopathies and 
dystrophin defect may have played a role.(183;184) In other cohorts, ejection fraction is 
lowest in younger patients (I do not have information on EF in this study), which might 
have prompted physicians to admit them.(199;219) Unlike older patients who might be 
more readily attributing their HF symptoms and functional limitation to age, younger 
patients with higher societal and family demands might be more likely to seek help. 
 
After discharge from first HF hospitalisation, younger patients were more likely to 
present to emergency department but less likely to be re-hospitalised for all cause, CV or 
HF. This could partly be explained by the lack of classical clinical and radiological signs of 
HF in younger patients with HF.(199) Younger patients are less likely to have peripheral 
oedema, pulmonary rales, and radiological evidence of pulmonary oedema.(199) 
Physicians managing younger patients in emergency department may have been reassured 
by the absence of these classical HF signs and symptoms and discharged patients. 
Conversely, younger patients with decompensated HF have fewer comorbidities and likely 
to exhibit less frailty. Physicians managing them may felt appropriate to manage them as 
an outpatient. 
 
6.4.3 Mortality 
 
 Younger patients have lower mortality in both men and women. Compared to the 
60-69 years age group, the correlation between younger age and mortality was stronger in 
men. The observed mortality rates are comparable to previous HF epidemiological 
studies.(12;17;67) However, it might be more reasonable to compare their outcomes to 
their peers rather than older patients. Comparing to the age-sex specific mortality rates in 
the general populations in Alberta, Canada, younger patients have the highest standardized 
mortality ratio, hence depicting a greater relative risk compared to older patients with HF. 
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In our study, men aged <60 years had a lower mortality rate compared to women aged <60 
years, which is contrary to previous studies that has reported worse survival in men with 
HF.(220;221) A possible explanation could be the higher proportions of congenital heart 
disease and malignant disease in younger women in our data.  
 
6.5 Limitations 
 
 Although use of the linked administrative datasets in Alberta means that we could 
capture all interactions with the health care system and follow all patients over time, there 
are some limitations which warrant consideration. The diagnosis of HF was obtained from 
hospital administrative registries, therefore relies on the accuracy of patient records and the 
responsible physicians. However, the Alberta administrative data have been validated for 
patients with HF and for comorbidities. Data on ejection fraction, laboratory results, 
biomarkers, causes of HF, and prescribing data are lacking. The numbers of younger 
patients are small; hence, there are greater uncertainties of the results.  
 
6.6 Conclusions 
 
 Comparing to older patients, younger adults with HF were admitted to hospital for 
HF sooner after a diagnosis of HF at the emergency department or the outpatient clinics 
and were also more likely to be diagnosed with HF for the first time in the hospital rather 
than as an outpatient. After first HF hospitalisation, younger patients were more likely to 
present to emergency department but less likely to be re-hospitalised. Mortality rates in 
younger adults with HF were low.  
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Chapter 7 
 
Final discussion 
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In this thesis, I have examined the clinical characteristics and outcomes of younger 
adults with HF in 4 different populations: a randomised clinical trial, a meta-analysis, a 
primary care database, and a hospital administrative database. Compared with older 
patients, younger patients with HF have a different clinical profile, including a different 
pattern of symptoms and signs, aetiology, comorbidities, treatments, more hospitalisations 
and a better survival.  
 
 Very little has been published previously on the symptoms and signs of HF in 
younger patients with HF. In the CHARM programme, a third heart sound and 
hepatomegaly were more commonly found in younger adults compared to older patients. 
However, peripheral oedema and pulmonary crackles were less common in younger adults. 
Chest radiographic findings were congruent with these findings, with abnormalities such as 
pulmonary oedema or pleural effusion being much less common in younger adults. 
Similarly, during acute episode of decompensated HF requiring hospitalisation, clinical 
pulmonary oedema and radiological signs of heart failure were less common in younger 
adults. These differences in clinical and radiological findings in younger adults with HF 
can easily mislead physicians and delay diagnosis when faced with a younger patient with 
breathlessness. These findings are novel and unique to this dataset owing to the detail 
documentation of symptoms and signs and radiological findings in a randomised trial 
compared to other dataset.  
 
 The aetiology of HF in younger adults <40 years has previously been ill-defined. In 
both CHARM and MAGGIC, dilated cardiomyopathy was the most common aetiology of 
HF in younger adults aged <40 years. In both of these studies, the aetiology of HF was 
investigator reported, without systematic pre-specified assessments.  
 
 As may be expected, younger patients have fewer cardiovascular comorbidities 
(ischaemic heart disease, previous myocardial infarction, hypertension, stroke, diabetes, 
atrial fibrillation, percutaneous coronary intervention and coronary artery bypass grafting), 
findings which are consistent in all four datasets. However, compared to older patients, the 
proportions of asthma and depression were higher in younger adults in the CPRD. Almost 
a quarter to a third of patients aged 20-29 and 30-39 years had a diagnosis of asthma or 
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depression at index HF diagnosis. Similarly, in the Alberta database, younger patients aged 
20-39 had a higher proportion of asthma at index HF hospitalisation compared to older 
patients. It is not clear why this should be the case. Depression is known to be prevalent 
among patients with HF. Younger patients with HF have worse health related quality of 
life. This is possibly explained by the greater disparity between their functional status and 
expectations. The demands from employment and family, and the financial burden resulted 
from ill health must play a major role. Similarly, the proportion of asthma in younger 
adults with HF is intriguing. The relationship with inhaled beta-agonists may have 
contributed as discussed in Chapter 5. Or younger adults who initially presented to primary 
care with breathlessness may have been mis-diagnosed as asthma initially. Further studies 
examining the relationship between HF and asthma or depression will be very informative.  
 
 Younger adults were more likely to receive HF medications in both CHARM and 
MAGGIC. Comparing to older patients, younger adults have more severe left ventricular 
dysfunction, and a greater proportion with HF-REF, mandating treatments with ACE 
inhibitor or ARB, beta-blocker, and spironolactone. Younger adults with better renal 
function may tolerate these medications better. However, patients recruited into clinical 
trials are closely monitored and medications optimally titrated. ‘Real-life’ populations are 
very different. In the CPRD, the prescription rates for ACE inhibitor or ARB, beta-blocker, 
and mineralocorticoid receptor antagonist in patient aged 20-29 years were the lowest at 1 
year after index HF diagnosis. Worse still, the initiations for these medications were slow 
in patients aged 20-29 years. Perhaps optimisation was limited by comorbidities such as 
the use of beta-blockers in patients with asthma. Alternatively, physicians managing 
younger adults with HF may be complacent and reassured by their better NYHA functional 
class and survival.  
 
This thesis advances our understanding of the reasons for HF hospitalisation and 
clinical presentation during decompensation in younger patients. The large datasets 
including a randomised trial and linked hospital, outpatient and emergency department 
administrative databases permit more detail examination of the circumstances leading to 
HF hospitalisations, and allow comparisons between age groups. In CHARM, younger 
adults were less likely to comply with medications, dietary restriction, and alcohol intake 
leading to their hospitalisation for HF. As discussed previously, younger adults with HF 
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were less likely to present with clinical pulmonary oedema or radiological signs of HF 
during decompensated HF. In the Alberta Ministry of Health database, by linking 
hospitalisation data with outpatient clinic or emergency department, the duration from the 
first diagnosis of HF at outpatient setting to the first HF hospitalisation can be determined. 
Compared to older patients, younger adults aged <40 years were admitted to hospital with 
HF much sooner after their first HF diagnosis at outpatients clinic or emergency 
department. It is plausible that younger adults with a new diagnosis of HF may be 
struggling to adhere to their medications and lifestyle restriction, leading to earlier 
hospitalisation with HF. Conversely, it could also be explained by the lower prescription 
rates of HF medications in younger adults aged 20-29 years as discussed in the CPRD 
analysis. In the Alberta database, younger adults <40 years were also more likely to present 
to the emergency department following their index HF hospitalisation. Intriguingly, this 
did not lead to a higher proportion of hospitalisation. 
 
Short and long-term mortality rates in younger adults are lower compared to older 
patients. In CHARM and MAGGIC, younger adults had lower 3-year mortality compared 
to older patients which was comparable between the two datasets. In the CPRD analysis, 
between 1988 and 2011, mortality rates in patients with HF have been improving. 
Mortality rates in younger men aged 20-29 and 30-39 years have reduced by almost 80%. 
Similarly, in the Alberta database, mortality rates in younger adults following first HF 
hospitalisation are lower compared to older patients. These findings concurred with a 
recent Swedish study examining mortality trends between 1987 and 2006, which showed 
decreasing case fatality in younger patients by more than 50%, but a plateau since 
2001.(17) In contrast, the CPRD followed up patients from 1988 to 2011 showing that the 
mortality continued to improve after 2006. This may reflect the wider use of 
mineralocorticoid receptor antagonist and cardiac resynchronisation therapy following 
publication of landmark trials in the last decade. Younger adults, although having lower 
mortality rates compared to older patients, are more likely to compare themselves to their 
peers. Calculating the standardised mortality ratio comparing the studied population (i.e. 
young adults with HF) to sex and age matched general population may be a better method 
to reflect the substantial risk of death in younger adults with HF comparing with their 
peers. 
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 Very little information exists regarding the incidence of HF in younger adults and 
even less so on its trend over time.(17;30) In the Alberta database, the incidence of first HF 
hospitalisation declined between 1999 and 2008 for all age groups. This is consistent with 
recent publications from Minnesota and Scotland.(67;214) However, a Swedish study 
utilising the national hospital discharge registry reported an increase in first HF 
hospitalisation by 50% and 43% between 1987 and 2006 in patients aged 18-34 and 35-44 
years, respectively.(17). The authors postulated that an increase in incidence of 
cardiomyopathy in younger patients might play a part, or that physicians were more likely 
to admit younger patients for further investigations. In the Alberta database, the majority 
(99%) of admissions were emergency. Therefore, the incidence of HF hospitalisation had 
fewer patients admitted for investigations. The study from Minnesota included only 
patients with validated HF using the Framingham Study criteria. The differences in 
incidence between these databases might partly be explained by the different inclusion of 
different cohort of patients with HF (emergency vs. emergency and elective admission and 
validated HF vs. coding).  
 
 The strength of this thesis is that it consists of 4 large databases representing 4 
different HF populations (a randomised clinical trial, a meta-analysis, a primary care 
database, and a secondary care database) allowing detailed examination of younger adults 
with HF from different perspectives. I was also able to substantiate findings from the UK 
with data from Alberta, Canada. Specific limitations have been discussed in each chapter, 
but some further general limitations warrant consideration. The primary and secondary 
care databases included in this thesis are from North America and the UK. These findings 
might not apply to other developed countries. Similarly, these findings might also be very 
different from younger adults with HF from other developing countries. Although all 4 
databases complimented each other in many ways, there also represent 4 very different HF 
populations including different variables limiting the ability to corroborate some of the 
finding across all the datasets.  
 
 Future research should focus on establishing the aetiology of HF in younger adults, 
especially those <40 years. Better understanding of the causes of HF in younger adults is 
key to early diagnosis and management. It might even help to further develop therapeutic 
options. The difference in symptoms and signs of HF and the circumstances leading to HF 
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hospitalisation in younger adults need to be validated in other cohorts. More 
epidemiological study using linked primary and secondary care datasets would provide 
greater definition of the incidence and prevalence of younger adults with HF in these 
populations, and also examine how younger adults interact with and transition between 
primary and secondary care. 
 
 Lastly, over the course of preparing this thesis, it is increasingly clear that the 
definition of young is fluid. Very young adults <40 years have different baseline 
characteristics as described above compared to older patients Mortality rate, however, did 
not differ much among young adults <60 years. Perhaps not surprisingly, with increasing 
age, the number of co-morbidities increases with higher mortality rate.  
 
 I hope this thesis has successfully summarised and extended our current 
understanding of young adults with HF. Some of the questions have been answered but 
many more are still to be addressed. This provides a basis for further research in young 
adults with HF. 
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